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3 
Principles and sources 
of laboratory information 
in the diagnostics of diseases 
Stages in early detection of disease 
Prevention I No prevention J 
Early pathological change 
Early detection No early detection 
Treatment j Developing pathological change j 
I 
(, Symptoms j 
! 
( Treatment j ( No treatment 
I 
I. Gross pathological change 
4 
2 
Nonpathological factors of variability of laboratory 
researches results 
1----- Considered factors _QJf ~ biolo2ical variation 
__ PhysjQ_logical facto!:_S _ _!~ctors of environment 
f- ---- Eth~c group __ _ _ _ ' --~o a hical factors 
I Gender (prc;gnancy, childbirth, Temperature, humidity 
I rnen~trual cycle. menopause , 
i ! - ~~o;.t~iti~1~~ _ -~-~- --1=~~--- Ti~-~-~-a-----l 
I 1 Physica l ,\l tiv1ty I Diet (water composition, soil 
_ ___ _ _, ___ ___£.Q__mposition) 
Nutrition Social and household 
environment 
- ----- -------- --- ----; 
_ _ ·- ·· ___ _ _B.esults of J.~~Q_~~Q_IT_ rese_a_r_c_h ______ --1 
Ethanol, caffeine, nicotine, 1 Food intake time, physical ac-
1 contraceptives, sedative sub- tivity, the body position, pre-
1 stance, psychotropic drugs, vious rest, stress during a test 
professional and household taking, stasis of blood during a 
' toxic substance, diagnostic test taking, preservatives, 
i and medical factors : ware, temperature, time keep-
l-12.~~d_ the~i!~!i~factorU: Conditions oftest takin 
3 
5 
Some uses of biochemical investigations and laborato-
ry tests in relation to diseases 
Use 
l. To reveal the fundamen-
I tat causes and mechanisms 
I of diseases 
2. To suggest rational treat-
ments of diseases based on 
item I above 
3. To assist in the diagnosis I of specific diseases 
j 4. To act as screening tests 
for the early diagnosis of 
certain diseases 
5. To assist in monitoring 
the progress (ie, recovery, 
worsening, remission, or re-
l~se) of certain diseases 
6. To assist in assessing the 
response of diseases to ther-
apy 
Example 
Demonstration of the nature of 
the genetic defects in cystic fi-
bros is 
A diet low in phenylalanine for 
treatment of phenylketonuria 
- -
Use of the plasma levels of tro-
ponin I or T in the diagnosis of 
myocardial infarction 
Use of measurement of blood 
thyroxine or thyroid-
stimulatin hormone (TSH in I g ) 
j the neonatal diagnosis of con-
' enital h oth roidism 
--- - j 
Use of the plasma enzyme ala-
nine aminotransferase (ALT) in 
monitoring the progress of in-
fectious hepati!is --1 
Use of measurement of blood i 
carcinoembryonic antigen i 
(CEA) in certain patients who I 
have been treated for cancer of 
the colon 
4 
6 
Why analytical results vary 
1. Inter-individual variation. 
a. Age. 
b. Sex. 
c. Race. 
d. Genetics. 
e. Long term health status. 
2. Pre-analytical variation. 
a. Transport. 
b. Exposure to UV light. 
c. Standing time before separation of cells. 
d. Centrifugation time. 
e. Storage conditions. 
3. Intra-individual variation. 
a. Diet. 
b. Exercise. 
c. Drugs. 
d. Sleep pattern. 
e. Posture. 
f. Time of venipucture. 
g. Length of time tourniquet is applied. 
4. Anal)1ical variation. 
a. Random errors. 
b. Systematic errors. 
5. Post-analytical. 
a. Transcriptions errors. 
b. Results reported to wrong patient. 
7 
s 
Medicine and Biochemistry 
BIOCHEl\USTRY 
Nucleic acids Proteins Lipids Carboh~·drates 
Genetic Sickle cell Athero- Diabetes 
diseases anemia sclerosis mellitus 
MEDICINE 
6 
Steps in the investigation of a patient 
I. Patient history. 
2. Physical examination. 
3. Laboratory tests. 
4. Imaging techniques. 
5. Diagnosis. 
6. Therapy. 
7. Evaluation. 
7 
8 
In troduction to Biochemistry 
I 
I L ____ __  
Biochemistry relations with other sciences 
Pharmacology, clinical disciplines, toxicological chemistry, 
pharmaceutical chemistry 
Molecular biology 
l 1 
8 
Genetics +------ Biochemistry Normal and 
pathologic physiology 
Bioorganic Morphology 
chemistrv l __ ~hY'ko~ <ollo;dal cbom;•try, b;ophy•kal <hom;.try 
9 
9 
Objects of biochemical researches 
l. Organism. 
2. Isolated perfused organs. 
3. Slices of organs. 
4. Homogenates of organs. 
5. Extracts from organs. 
6. Cells. 
7. Yeast, bacteria. 
8. Subcellular components: 
a. membranes; 
b. organoids; 
c. cytosol. 
9. Enzymes. 
l 0. Biological fluid. 
Content of biochemistry subject 
IO 
2. Composition, structure H chemical description of sub-
stances in living organism. 
3. Bioenergetics. 
4. Metabolism: catabolism- anabolism. 
5. Regulation of metabolism. 
6. Molecular basic of heredity and morphogenesis. 
7. Molecular mechanisms of specific physiological processes. 
8. Features of biochemical processes in organs and tissues. 
II 
10 
Methods 
I. Analytical procedures. 
2. Isotopic immunoassay. 
3. Colorimetry. 
4. Spectrometry. 
5. Chromatography. 
6. Electrophoresis. 
7. Centrifugation: 
a) differential velocity centrifugation, 
b) ultracentrifugation, 
c) equilibrium density-gradient centrifugation. 
8. Analysis of enzymatic activity. I 9. Photometry. 
I 0. Fluorometrv. ~- Nephelome(ry. 
12 
Aim of biochemistry 
Describe and explain all the chemical processes in living 
cells in terms of molecular, nature of the chemical constituents 
of living matter, their transformations in biological systems and 
the energy changes associated with these transformations. Such 
1 studies effort to understand how life originated. 
Aim of biochemistry is decided by: 
I. Descriptive biochemistry that concerns with the qualitative 
and quantitative characterization of the various cell com-
ponents and 
2. D:,. namic biochemistry that deals with the elucidation of 
the nature and the mechanism of the reactions involving 
these cell components. 
13 
11 
Major causes of disease 
l. Physical agents: mechanical trauma, temperature extremes, 
radiation, electric shock. 
2. Chemical agents: toxic compounds, drugs. 
3. Biologic agents: viruses, bacteria, fungi, parasites. 
4. Genetic disease: congenital, molecular. 
5. Oxygen lack: loss of blood, decreased oxygen-carrying ca-
pacity of blood, mitochondrial poisoning. 
6. Immunologic reactions: anaphylaxis, autoimmune disord-
ers, hypersensitivity. 
7. Nutritional imbalances: deficiencies, excesses. 
8. Endocrine imbalances: hormonal deficiencies/excesses. 
1 ~ 
Biochemistry makes possible to: 
1. Determine the etiology, diagnosis. and prognosis of dis-
ease. 
2. Explain the causes of disease and to design appropriate 
therapy. 
1
1 
3. Establish the diagnosis and monitoring of therapy results. 
! 
15 
12 
Structure and functions 
of proteins 
16 
lc~assifi~atio-=-~~ pr:teins based on the functions 
I I. Enzymes (ribonuclease, trypsin, DNA- and RNA-
polymerases) 
2. Protective proteins (immunoglobulin, complement, 
interferon) 
3. Contractile proteins (actin, myosin) 
4. Structural proteins (collagen, silk fibroin, keratin) 
5. Reserve proteins (casein, albumin) 
6. Antibiotics 
7. Toxins (botulinum toxin, diphtherial toxins) 
8. Transport proteins (hemoglobin, rnyoglobin, cytochrome c, 
membrane ATP-ase) 
9. Regulatory proteins (histones, initiation factors) 
10. Receptor proteins (rhodopsin, choline receptor) 
11. Hormones (insulin, growth hormone) 
17 
-------- - ------------' 
13 
Biological functions of peptides: 
I. Hormones ( oxytocin, andiuretic hormone, bradykinin, ga-
strin). 
2. Neuropeptides of brain ( enkephalin, endorphin). 
3. Alkaloid (ergotamine). 
4. Antibiotic (gramicidins A, B, C). 
5. Toxins and antitoxins. 
6. Regulatory peptides (releasing factors, camosme, anse-
rine). 
18 
~----------------------- --, 
Molecular mass of proteins 
l. 
2. 
3. 
4. 
5. t----+ _ _ _ _ _ _.....__ _ ____________ _ 
1-6 __ ·-1-- ~---~-~---J __ l_Q_OOOO _ 
7. 330 000 
t----+------~------+------ ---
8. 660 000 
--- - - - --
9. 4 000 000 
19 
Degree of protein a-spiralization 
--
1. Hemo~lobin 80% 
2. Insulin 46-60% i 
- -
3. Albumin 30-45% 
-
4. Pees in 20-30% 
5. Casein 10% 
~ 
I 
~ 
20 
14 
Functions of organs and protein metabolism 
~I Function in r Malfunction Change in protein 
! I pro~~~s';,,eta- 1 metabolism ~1 Sphttmg of --- Insufficient synthesis of 1 Protein starvation "I stmal tract i ~:.~enou~~o-_ ~1gestive enz~~es ---+-- - ---------1 1 Absorption of c.!!J1paired i!bso~tion Protein deficiency ~ I amino acids i Impainnent of intestin- Deficiency due to loss of __ u. _ ___ :__ ____________ :-al wall~rmeability protein _______ __, Endocrine Regulation of syn- Hyper- and hypofunc- I Increased anabolism or 
glands thesis and degra- tion catabolism 
dation f--------+-- - ·-
Li ver I Synthesis of al-
bumins and some 
. of globulins 
Detoxication of 
I 
: products of nitro- i,' 
! genous metabol-
1 
Hepatocyte dysfunction Hypoalbuminemia De-
creased formation of 
blood clotting factors 
Accumulation of nitro-
genous products, de-
creased urea formation 
I ism j ------·-- - - - r-- ·-------------1 Metabolism of Defects of enzymes Metabolic disorders 
I aini~~s- - -- +-- ----- --- --- ----+------------; I Synthesis of Reaction on Hyperfibrinogenemia 
fibrinogen inflammation ______ +------------1 
1
---- ____ _ ___ ~_a_t_o_m_a _ ___ ____ _ Pri:~~l!ce of a-fet~rotein 
Kidneys Regulation of_ ; Nephrosis Loss of albumin 
I 
_ _g~em excretion _ ' I Excretiou of l Impaired nitrogen ex- Accumulation of nitro-
genous products in blood 
1 
products of nitr- ! cretory function of 
I ous metabolism I ~lomerules 
I
, Impaired reabsoiji-u~-o-n- +-L-o_s_s -o..,.f-am-in_o_a-ci-ds----1 
in tubules 
>--- - ------- ·-+-----------1r--- - ·- -·------1 
: Connec- ! Synthesis ofy- Immune reactions Hypergammaglobuline-
~tive_!\;;~~1!obulins mia 
' Immune Immunodeficiency Hypogammaglobuline-
system syndrome -----.,.--1-rn_ia _ ___ -,--c-----1 
J Reaction on decreased Hypergammaglobuline-formation of albumin rnia ~ -----·------'--'-M~IYL·e~lo~m=cca _______ _._P_ara_~o•ro~t_e_in_e_m_i_a ___ _, 
21 
15 
The structure of the twenty amino acids found in proteins 
A ....... e(Ala) 
H,,N.CH.cocr 
- !tt.OH 
Serine (Ser) 
. 
H~.CH.coo-
?4-coo-
L11lne (Lp) 
l'hellJlalullM (Phe) 
Vdltoe (VII} 
H}i.ot.coo-
~H 
CH. 
Threonine (Thr) 
H}i. ~"'H. coo-
- ~ 
~ NH . 
I 
./c,._. 
NH0 NH 
Arplne(hz) 
H.N ·?4 .c:oo-
~· ~ 
H0N.~coo-
~ 
L.Mdne(t.e.) 
H.N-ir-coo-
CH,,SH 
C,stelM (CJS) 
H.N-cr·coo-
C?\ {H, 
coo-
Glutaonk: add (GIY) 
16 
H$i.cH.coo-
I 
~ 
I NH OCH 
H H 
Hll!Nlne (Mil) 
~~ 
H H 
Trypcioplml (T1'11) 
.._N.t .coo-
/'\. 
CJ\ 'r' 
CH• 
bo'-dn•(lle) 
lfwN.fH.coo-
r-
CH,,S.CH. 
Medllonine (Met) 
H,N.fH.coo- _ 
~Ha 
fW. 
CONH,, 
Gl-lne (Gin) 
H.N-~.coo-
H 
GIJdne (Gly) 
Prollne (Pro) 
22 
(a) (b) (c) 
r 
54J. 
l 
Secondary structure - a helix 23 
------------------------------' 
econdary structure - !}-pleated sheet 24 
17 
The structural hierarchy in proteins 
~--------
aU.lii 
25 
Oxygen dissociation curves of myoglobin and hemoglobin 
in whole blood 
1.0 ('C Myoglobin 
Pso• I torr 
0 10 20 30 40 50 
O, pressure <pO, in torrs} 
26 
18 
Modeling protein folding with Linus (George Rose) 
lual ;UV.I prcdklecl 
!0.TilctUn::!I of l.hrcx 
dunrA "" n( lot tina I 
fany m id hi ndinft 
prnrcm 
"':tn;;J amt pnc-<IKte<I 
uuc::rurts of ean 
O:·helii.~:d •lonuUn of 
cvto<:hmmc b~ 
AC:TUAL PIU!DICTW 
) ' 
./. I 
) 1~, --~ 
I 
{ 
I 
I 
19 
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Structural and functional advantages driving 
quaternary association 
1. Stability: reduction of surface to volume ratio. 
2. Genetic economy and efficiency. 
3. Bringing catalytic sites together. 
4. Cooperativity. 
28 
Chaperones 
• Most proteins fold spontaneously into their native conforma-
tion. 
• In the unfolded state, the apolar regions of the peptide chain 
tend to aggregate with other proteins or with each other to 
form insoluble products. In addition, unfolded proteins are 
susceptible to proteinases. To protect partly folded proteins, 
there are proteins called chaperones. 
• Chaperones are formed increasingly during temperature 
stress and are therefore also known as heat-shock proteins 
(hsp60 and hsp70). 
• Chaperones of the hsp70 type are common, as are type hsp60 
chaperon ins. 
• While small proteins can often reach their native conforma-
tion without any help (1 ), larger molecules require hsp70 pro-
teins for protection against aggregation (2) which bind as 
monomers and can dissociate again, (3). By contrast, type 
hsp60 chaperonins form large, barrel-shaped complexes with 
14 subunits in which proteins can fold independently while 
shielded from their environment (4). 
29 
20 
! 
i 
I 
Protein maturation by chaperones and chaperonins 
Folded 
protein 
I "A9gregati0n 1 L ·- ··--, , ~---' / 
',{ ,/(2'\ 
v " ,v 
\./) ' 
_J) 
CG~ 
Small 
protein 
/ 
1; 
1® t 
© ~ 
! ! Insoluble 
precipitate 
or degradation ~~ 
Folded protein 
30 
L__ __ 
21 
f I .. . :.. ~r: [~ ~r,'ine; 
Hemo&lobin 
Proteinpathies 
Mutation results in the b 
chain of HbA contains 
Val rather than Glu at 
position 6. RBC that 
contains large complex-
es of HbS molecules 
J 
l- ----1- .-- - - -- - - ~~--~--~-~----------...J 
' c~ f, ,;i ;! " 1( )' l•1 ·.; .l7:ymes 
n ~ · --- 1 , , ( rr. , ...., ~t..' nlism 
j1 Def i ~ ie":·cy , .; enzymes j Defects in fructo~ Seep 126 .~~~..:tose _! _let;:bo~i_:;m _ 1 1 1·: Lil _o_li_sn_._- _ _ ___,, ___ _ 
1
: G .. il:ictose-1 -;Jhe:;pnate r (}alactosemia 
Urt ·.~t~u.J•e ~ ... 
Dc1 1w•~•·~ } ._,, <.: L~) .Tlt.:> --- -;- L:::.urders of tyro- Seep 176 
Seep 127 
of·) , 0:>i1 .w ~r- ; 1c1.yl.ila- I !.iu ~ (phenylala-
L :i ' 1 . e ~ ..: _::• .. iJ'' ' :'...!:!_ _ 1 nine) metabolism_~-- -------' 
31 
. - . - -- -- . -- - ------------- --------' 
Polymorphism of proteins 
• Many proteins exist as polymorphisms (genetically determined varia-
tions in primary structure due to mutations in the genetic code). 
• Within the same individual, the primary structure of these proteins va-
ries with the stage of development and is present in fetal and adult iso-
forms, such as fetal and adult hemoglobin. The primary structure of 
SO!l'P. proteins, such as creatine kinase, can also vary between tissues 
(tic;sue-specific isozymes) or between intracellular locations in the 
same tissue. 
32 
22 
Enzymes. Structure and 
properties. Kinetics of 
enzymatic reactions 
33 
Similarities between enzymes and chemical catalysts 
1 . Do not alter the nature and quantity of the end products. 
2. Do not alter the chemical equilibrium point of a reversible 
reaction but only the speed of the reaction is changed. 
3. Catalyse the forward and reverse reactions proportionately. 
4. Increase the rate of a chemical reaction without being used 
up in the reaction and can be recovered chemically 
unchanged at the end of the reaction. 
5. Do not accelerate reaction that is not thermodynamically 
favorable. 
34 
23 
Differences between enzymes and chemical catalysts 
1. Enzymes are almost all proteins and. like proteins, they 
undergo denaturation. 
2. Enzyme catalyzed reactions usually take place under rela-
tively mild conditions (temperatures well below 100°C, 
atmospheric pressure, neutral pH). 
3. Enzymes are highly efficient, being formed in the living 
system as per their requirements. 
4. The activity of an enzyme is maximum, activity of en-
zymes is regulated. 
5. Activity of enzymes is regulated on genetic level, and by 
low molecular weight compounds - effectors (inhibitors 
and activators) . 
6. Enzymes are very specific in that they act either on a single 
or at the most on some structurally-related substrates. 
3 
Substrate specificity of enzymes 
1. Absolute substrate specificity - enzymes are capable of 
acting on only one substrate. For example, urease acts only 
on urea to produce ammonia and carbon dioxide. 
2. Relative substrate specificity - one enzyme acts on more 
than one substrate, having one type of bond. For example, 
lipase hydrolyzes fat to 3 fatty acids and glycerol acting on 
ester bond. 
3. Relative group substrate specificity - one enzyme acts on 
more than one substrate, having one type of bond, but ap-
pointed atomic groups forming this bond are required. For 
example, proteolytic enzymes (pepsin, trypsin, chymotryp-
sin) catalyze a different but related reaction, namely the 
hydrolysis of a peptide bond. 
4. Optical substrate specificity - enzyme reacts with only 
one of the two optical isomers. For example, L-oxidase acts 
only on L- amino acids and not on its D-isomer. 
36 
24 
I 
I 
I 
Reaction specificity of enzymes 
- same substrate can undergo different types of reactions, each cata-
lyzed by a separate enzyme 
H 
R-C-COOH 
I 
NH2 
.-\rnmo acid 
[OJ 
R-C-COOH + NH3 
II 
0 
a-Keto acid 
R-CHi +C02 
I 
NHi 
l _____________________ ___ A_n-1i_n_e _____ J_?~ 
~-- - ------ -- ------ -------------. 
Structure of enzyme 
Enzyme 
2~0 .. ·: Vit:.J 
Loosely attached to 
the enzyme 
Covalently tightly at-
tached to the enzyme 38 
- - -- - --------- - - ------------' 
25 
Active site of enzymes is formed: 
• Simple-protein enzymes: active site is a three-dimensional 
entity formed by functional groups of amino acid residues 
that can lie far apart in the linear polypeptide chain. 
• Complex-protein enzymes: active site of simple-protein 
enzymes + cofactor. 
Examples of functional groups of amino acid residues in ac-
tive sites: 
-NH2-Lys -OH-Ser 
-COOH - Glu, Asp -SH-Cys 
Parts of active sites: 
1. substrate binding site - for substrate fixation 
2. catalytic site - for catalysis of the specific reaction 
39 
Features of active site: 
I . It is the region that binds the substrate and converts it into product. 
2. It is a three-dimensional entity formed by side-chains of amino acid 
residues that can lie far apart in the primary structure. 
3. It is a relatively small part of the whole enzyme molecule and is of-
ten a cleft or crevice on the surface of the enzyme. 
4. The substrate(s) is bound in the active site by multiple weak forces 
(electrostatic bonds, hydrogen bonds, van der Waals' forces and I 
hydrophobic interactions) and in some cases by reversible covalent 
bonds. 
5. Substrate specificity applies to the nature of the substrates that are 
involved. The properties and spatial arrangement of the amino acid 
residues forming the active site of an enzyme will determine which 
molecules can bind and be substrates for that enzyme. 
40 
26 
~ssification of enzymes based on I the type of reaction catalyzed: 
i 
I 
I 
1. Oxidoreductases: Enzymes involved in oxidation-reduction 
reactions between two substrates. 
2. Transfernses: Enzymes catalyze the transfer of functional 
groups between two substrates. 
3. Hydrolases: Enzymes catalyze the hydrolysis of their sub-
strates by adding constituents of water across the bond they 
split. 
4. Lyases: Enzymes catalyze the removal of groups from sub-
strates by mechanisms other than hydrolysis, leaving double 
bonds. 
5. Isomerases: Enzymes catalyze interconversions of optical, 
geometric or positional isomers by intramolecular rear-
rangement of atoms or groups (isomerization reactions). 
6. Ligases: Enzymes catalyzing the linking together of two 
compounds, utilizing the energy of ATP or a similar com-
pound, fanning C-0, C-S, C-N and C-C bonds. 
41 
I 
L__. 
Units of enzyme activity 
• Katal (kat): One kat denotes the conversion of I mole sub-
strate per second (mol/sec). 
• Enzyme unit (U): One enzyme unit is that amount of en-
zyme, which will catalyze the transformation of 1 µmol of 
substrate per minute at 25°C under optimal conditions for 
that enzyme. 
1 µmol min = 1 U = 16.67 nanokat. 
42 
27 
Ways to increase rates of chemical reactions: 
1. Increase average energy of molecules, 
2. Decrease energy barrier of reactions. 
Energy barrier is the energy needed to transform the substrate 
molecules into the transition state. 
The Gibbs free energy of activation (AG:j:) is equal to the dif-
ference in free energy between the transition state and the sub-
strate. 
43 
Stages of enzyme catalysis 
E+S~ES EZ-EP-E+P 
I. E + S ~ES - formation of enzyme-substrate complex 
Two models have been proposed to explain how an en-
zyme binds its substrate: 
1. In the lock-and-key model proposed by Fischer, the shape of 
the substrate and the active site of the enzyme are thought to 
fit together like a key into its lock. Thus the active site of an 
enzyme is a rigid and pre-shaped template where only a spe-
cific substrate can bind. 
2. In the induced-fit model proposed by Koshland, the active 
site of the enzyme is not rigid and pre-shaped. The interac-
tion of the substrate with the enzyme induces a fit or a con-
formation change in the active site. Due to induced fit, the 
appropriate amino acids of the enzyme are repositioned to 
form the active site and bring about the catalysis. 
44 
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Reasons of the rate acceleration on the I stage: 
I. Substrate binding induces changes that bring reactive groups 
into proximity with one another at the active site of an en-
zyme. The particular proper orientation of the substrate 
sorbed at the active site, which favors interaction with the 
site' s catalyt ic s~gment; 
I 12. Thi> incrc.iscs the effective concentration of the substrate. 
L_____ _____ __ __ 45 
I 
I 
Stages of enzyme catalysis 
II. ES -+ EZ -+ EP - formation of intermediate state 
I 
I Enzyme works by lowering the activation energy of a 
1 reaction. 
Enzymes decrease the activation energy in 2 ways: 
I. The induced structural changes upon formation of the en-
zyme-substrate complex introduce strain in the substrate 
bonds, which allow it to attain the transition state more 
easily («rack» hypothesis); 
2. The reduction of activation energy increases the number of 
reactant molecules with enough energy to reach the activa-
tion energy and form the product. 
46 
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Energy diagram, comparing the nonenzymatic and 
enzymatic reactions, S ---+ P 
Transition stale (*) 
Reaction coordinate 
47 
Stages of enzyme catalysis 
III. EP - E + P - product is released 
48 
30 
Factors affecting reaction velocity 
1. Substrate concentration 
v 
c 
max ·-- ----------- --- ---- ·-------------
When S is low, the equation 
for rate is I st order with re-
spect to substrate (a); 
V~trL= When S is high the rate of reaction is independent of S, the equation for rate is 0-order (c). 
Km (SJ 
For part «a» - Michaelis-Menten equation: 
v ·[s] 
v= max 
ks +[s] 
V - measured velocity, 
Vm - maximum velocity, 
; [SJ - substrate concentration, 
v 
v= max 
1 +ks 
[s] 
I Ks - rlissociatton constant ofenzyme-substrnte complex. 
L 49 
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B rig and Haldane modify Michaelis-Menten equation for 
curve, entering Michaelis constant km 
v= 
vmax 
1 +fem 
[s] 
Km is equivalent to the substrate concen-
tration at which the velocity is equal to 
halfofVmax. 
vmax vmax V= -- = --
1+1 2 
31 
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Lineweaver-Burk double reciprocal plot 
I 
v 
' 
k
111 
] 
---'-"--- + --
'max · [s ] 
I 
[s] 
vmax 
Factors affecting reaction velocity 
2. Enzyme concentration 
51 
I~ 
In situations where the substrate concentration is sa~rating, a doubling of I 
the enzyme will lead to a doubling ofV0: V =k [Ej. 
3. Temperature 4.pH 
-
32 
I 
I 
General mechanisms that affect enzyme activity: 
I. Control of the overall quantities of enzyme. 
2. Factors that affect the rate of enzyme-catalyzed reactions 
(pH, t. r ), concentration of substrate and enzymes, availa-
bi I ity of activators, inhibitors. 
3. Alteration of the catalytic efficiency of the enzyme. 
L __ _ 53 
,---~~gulation of the enzyme levels 
I The amount of enzyme present is a balance between the 
rates of its syntht.:->is and degradation. 
There are two types of enzymes in a cell: 
I. Constitutive enzymes (house-keeping enzymes) - one pro-
duced constantly, irrespective of environmental conditions or 
demand, the levels of which are not controlled and remain 
fairly constant (e.g., lactate dehydrogenase, transaminases, 
acid and alkaline phosphatases, creatine phosphokinase). 
2. Adaptive enzymes - their concentrations increase or 
decrease as per body needs and are well-regulated (inducible 
and repressible enzymes). 
• Inducible enzyme one whose rate of production can be 
stimulated or accelerated by substrate of that enzyme. The 
inducible enzyme is used for the catabolism (process of 
degradation) in the cell. 
• Rcpressible enzyme one whose rate of production is · 
decreased as the concentration of certain substances, often 
a final product is increased. The repressible enzyme is used L for the anabolism (process of synthesis) in the cell. 
54 
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Activators of enzymes 
- any molecules which acts directly on an enzyme to increase its activ-
ity. 
Features of activators: 
I. Form the active site of enzyme (Co2\ Mg2~, Zn2·, Fe2+, Cui+). 
2. Facilitate formation of enzyme substrate complex (Mg2· , Mn2+). 
3. Stabilize native structure of enzyme. 
4. Protect functional groups of the active site from damage, for exam-
ple, restore SH-groups of the active site (glutathione, cysteine). 
5. Influence subunits of enzyme molecules (cAMP regulate enzyme 
protein kinase). 
Activators are usually cations, more rarely are anions (Cr activates 
pepsin, amylase). 
Inhibitors of enzymes 
- any molecules which acts directly on an enzyme to decrease its activ-
ity . 
Classification of inhibitors 
Enz)me inhibitors 
-----
Nonspecific inhibitors 
(Induce enz~me 
denaturation -
salts of hetl\)" metals, 
acids, bases) 
Specific inhibitors 
I \ 
h·renrsible Ren1'Sible 
/ 
C . / ompet1t1ve 
inhibitors 
34 
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No~~ompetitin 
inhibitors 
56 
Irreversible inhibitors 
- inhibitors bind irreversibly to active site of enzyme often form a co-
valent bond to an amino acid residue and permanently inactivate the 
enzyme 
I. Inhibitors that strongly change valency of Fe and Cu of metall-
containing enzymes of respiratory chain (e.g., cytochrome oxidase), 
preventing electron transfer to 0 2 - HCN, KCN, CO, NaN3 (respi-
ratory poisons). 
2. Alkylating reagents that combine with sulfhydryl (-SH) groups of 
cysteine at the active site of enzyme - Iodoacetate, substances of 
mercury and arsenic. 
3. Organophosphorus compounds that bind with enzymes containing 
OH-groups of serine at the active site (e.g., serine proteases, acetyl-
choline esterase)- Diisopropylphosphofluoridate (nerve gas). 
51 
I Reversible competitive inhibitors 
I 
- inhibitors have close structural similarities to the substrate there-
fore compete with the substrate to bind with the active site of enzyme 
+I ~EI~E+P 
E+s ~ES ~ E+P 
,. 
\"max= \'maxi 
Kml - Km 
there is no change 
in the Vmax and 
Km incre-dlleS 
[SJ' -lfKm -lfKml 
35 
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Example of competitive inhibition 
r r r Sin.mite ~ &n:inite rn OCil)'thigemse I +FAD <Xhy~ II II +FAa-li r '7 -N>reactim r rn I CXXJ 
an CXXJ l\tilmie 
Suriim: Fmmte 
Malonate is competitive inhibitor 
59 
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Reversible noncompetitive inhibitor:--1 
- inhibitors bind reversibly at a site other than the acthe site (i.e., at 
the allosteric site) and causes a change in the overall three-
dimensional shape of the enzyme 
slo-w{v 
E+ S+ I~ ESl--+E + P+ I Vmaxl<"\ 'n1ax 
KmJ=Km 
\' 
Vmax is deer-eased 
Km 1-emains constant 
[SJ 
36 
I/\' 
-I/Km ~ -1/Km I 
60 
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Antimetabolites 
- competitive inhibitors of enzymes, mimicking the structure of the 
native substrates. 
For example, sulfanilamides 
Paraamin•J 
bt•nz,1ir add E 
(PABA) 
H2N- (Q)-COOH 
Growth and 
Folk acid --)•reproduction 
ofbacte1ia 
l_______~~--------S-u_l_fa_n_i_la_nu_·_d_e _____ 6_1-J 
Regulation of enzyme activity 
- all alterations of enzyme activity at its constant quantity. 
Some methods to regulate enzyme activity are: 
1. Feedback regulation. 
2. Allosteric regulation. 
3. Reversible covalent modification. 
4. Formation ofmultienzyme systems. 
5. Proteolytic activation. 
fi2 
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Allosteric regulation 
Models for allosteric behavior 
l. Concerted or symmetry model (Monod, Wyman, Changeux) 
2. Simple sequential model (Koshland, Nemethy, Filmer). 
Concerted or Symmetry model: allosteric enzyme can exist in still 
two conformations, active and inactive. All subunits are in the active form 
or all are inactive. Binding of substrate to one of the subunits increases 1· 
the probability that both switch from the T to the R form. Allosteric inhi-
bitor shifts the R-+ T conformational equilibrium tow:i rd T. whereas an ! 
allosteric activator shifts it toward R. The result 1s that an alloskrk acti-
vator increases the binding of substrate to the enzyme, whereas an allos-
teric inhibitor decreases substrate binding. 
Quaternary structure: TT, RR, 
S+TT--+ RR 
Simple sequential model: allosteric enzyme can exist in only two 
conformational changes individually. Consider an allosteric enzyme con-
sisting of two identical subunits, each containing an active site. The T 
(tense) form has low affinity and the R (relaxed) form has high affinity 
for substrate. Binding of substrate to one of the subunits induces a T -+ R 
transition in that subunit but not in the other. The affinity of the other 
subunit for substrate is increased because the subunit interface has been 
altered by the binding of the first substrate molecule. 
Quaternary structure: TT, RR, TR 
S +TT --+ TR --+ RR(+) 
S +RR--+ TR--+ TT(-) 
63 
Formation of multienzyme systems 
• Complex enzyme systems are not independent molecules but occur as 
aggregates involving several different enzymes. 
• Fatty acid synthase is one such example. Each component of this 
complex enzyme is so arranged as to provide an efficient coupling of 
the individual reactions catalyzed by these enzymes. The product of 
the first enzyme becomes the substrate of the second and so on. 
64 
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Feedback regulation 
Control mechanism that uses the consequences of a process to 
regulate the rate at which the process occurs. 
Feedback inhibition 
(-) 
' E1 E2 E3 En 
A-+B-+C-+-+ Z 
(+) 
Feed-forward activation 
Feedback inhibition - negative feedback regulation. 
The enzyme catalyzing the first step (E1) is inhibited by the 
end product of the reaction (Z). Increased levels of Z wiII result 
in E1 decreased synthesis. Control of the enzyme which carries 
I out the committed step of a metabolic pathway conserves the 
metabolic energy supply of the organism, and prevents the 
build-up of large quantities of unwanted metabolic interrne-
i diates further along the pathway. 1 Feed-forward activation - the activation of an enzyme 
(En) by a precursor of the substrate (A). 
High concentration of an earlier reactant not involved in 
the continual chemical reactions of the pathway will help to 
catalyze final reactions down the pathway. The reactant which 
serves as the feed-forward activator is intrinsically linked to the 
final product it helps to catalyze. 
65 
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Proteolytic activation 
• Some enzymes are synthesized as larger inactive precur-
sors called proenzymes or zymogens. These are activated by 
the irreversible hydrolysis of one or more peptide bonds 
(proteolysis). 
• The pancreatic proteases trypsin, chymotrypsin and elastase 
are all derived from zymogen precursors (tty p ~; inogen, chy-
motrypsinogen and proelastase, respectively) hy protl'olytic 
activation. 
66 
Reversible covalent modification l 
I 
• Reversible covalent modification is the making and break-
ing of a covalent bond between a nonprotei n group and an 
enzyme molecule. 
• The most common modification is the addition and re-
moval of a phosphate group (phosphorylation and dephos-
phorylation, respectively). A phosphor} lated enzyme may 
be either more or less active than its deph osphorylated 
form. 
• For example, glycogen phosphorylase, an enzyme involved 
in glycogen breakdown, is active in its phosphorylated 
form, and glycogen synthase, involved in glycogen synthe-
sis, is most active in its unphosphol"}'lated fonn . I 
~ 
40 
I Enzyme _ __ ,! I diagnostics_ 
Medical 
enzymology 
I 
Enzyme 
therapy 
68 
------ ------ - _______________ ___. 
, ------ ---- --- -;-n-z~-,m-e--~iagnostics 
I 
- research of enzymes in biological medium of an organism with the 
diagnostic purpose. 
There are 4 groups of enzymes: 
1. Enzymes widely distributed in various organs and tissues. These are 
enzymes of the basic metabolic processes without which cell life is 
impossible (metabolism of proteins, fats, carbohydrates). Estimation 
of raised enzyme levels in blood due to cellular membrane damage is 
not used for the diagnosis of diseases. 
2. Tissue-specific enzymes are localized in certain organs. These en-
zymes are either totally absent or present at a low concentration in the 
cells of other tissues. Tissue-sp~cific enzymes are conveniently used 
as markers to detect the cellular damage which ultimately helps in the 
diagnosis of diseases. 
3. Isoenzymes. 
4. Enzymes are localized in organelles of the cells (oxidative-reductive 
enzymes in mitochondria, acid hydrolases in lysosomes). The en-
zymes when elevated in serum are markers of deep cellular damage. 
L____~~~-~~~~~~~69~ 
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Mechanisms of plasma enzyme activities alteration 
1. 
2. 
3. 
4. 
1. 
2. 
3. 
4. 
Increased plasma enzyme activities 
Increased enzyme ! Alkaline phosphatase 
synthesis j (ric_kets) ____ 
Increase of membrane- Creatine kinase (muscul ar 
permeability 1 dystrophy) 
Alanine transaminase. As-
ra l partate transaminase (vi 
; hepatitis) _ 
Necrosis of cells ! - . ! Aspartate transa minase. 
• Aldolase. Creat ine kma 
Decreased enzyme ex- fAfk; tine -phosphatase 
cretion _ __ _J _____ ___ 
se 
Decreased plasma enzyme activities _ 
Reduction of number of J Cholinesterase (cirrhosi 
cells, that secrete enzyme of I iver) 
s 
Pepsinogen (gastroecto-
- ----~l__ _ _ _ -- - -
Decreased enzyme Ceruloplasmin (Wilson' s 
synthesis disease) 
-
, Increased enzyme Ceruloplasmin (nephros 
secretion 
-- - -
Inhibition of enzyme ac- Trypsin (under intluenc 
tivity of antitl):psin) 
42 
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Isoenzymes 
- are different forms of an enzyme, which catalyze the same reac-
tion, but which exhibit different chemical, physical or kinetic prop-
erties (structure, isoelectric point, pH optimum, substrate affinity 
I or effect of inhibitors). 
I Creatine kinase (CK) or creatine phospbokinase (CPK) 
Creatine + ATP tt Creatine phosphate + ADP 
I 
1 Enzyme Creatine kinase is dimer of2 subunits, called B ("brain") and M 
("muscle"). 
Isoenzymes of Creatine kinase: 
1. BB (CK1) is found in brain, prostate, stomach, lungs, placenta, thyroid 
gland. 
2. MB (CK2) is found in cardiac muscle (25-46% of total CK) and in 
skeletal muscle (5%). 
3. MM (CK3) is found in skeletal muscle and cardiac muscle. 
71 
Lactate dehydrogenase (LDH) 
Lactate + NAD+ tt Pyruvate + NADH + W 
Enzyme Lactate dehydrogenase is a tetramer of two different types of 4 
subunits, called H ("heart") and M ("muscle"). 
lsoenzymes of Lactate dehydrogenase: 
1. Hi (LDH1) is found in heart and RBC. 
2. l·IJM (LDH2) is found in heart and RBC. 
3. H2M2 (LDH3) is found in lungs, brain and kidney. 
4. HM3 (LD~) is found in liver and skeletal muscle. 
5. M4 (LDH5) is found in skeletal muscle and liver. 
72 
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Applications of tissue-specific enzymes 
(isoenzymes) in the diagnosis 
Enzyme (isoenzyme) trgan damaged fr~ 
--~esar1s 
~which en] 
LDH l, 2 I Cardiac mus I 
LDH3 I Lungs 
LDH4,5 Liver, muse 
Amylase Pancreas 
Alanine transaminase (ALn Liver ~3 cle~--~ Aspartate transaminase (ASTI Cardiac mus 
Acid phosphatase Prostate ----- -~ 
Alkaline phosphatase Bone 
-
______ __ __J 
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Enzymopathology 
Hereditary enzymopathies - diseases related to inherited defects in en-
zymes. Changes can be of two types: 
I. associated with the formation of a substrate excess or its precursors in 
a reaction. For example, the accumulation and excretion of galactose 
due to the deficiency of the enzyme converted galactose to fructose -
galactosemia; 
2. associated with the inadequate formation of products of altered chem-
ical reaction. This type is accompanied by clinical manifestations. In 
this step, usually already too late to apply therapeutically effective 
measures. 
74 
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Immobilized enzymes 
- are physically immobilized by binding them to a solid, insoluble ma-
trix which will not affect the enzyme stability or its catalytic activity 
The bound enzymes c.in be preserved for long periods 
without loss of activ ity. 
I 
I i • 
I 
I 
I • 
I • 
I 
I 
i 
I 
I 
I 
Benefits of immobilizing an enzyme: 
Convenience: Mint•\culc amounts of protein dissolve in the 
rtac~ ion , so w0rlup can be much easier. Upon completion, 
reaction mixtu res typically contain only solvent and reaction 
rroduc:ts. 
Economy: The immobilized enzyme is easily removed from 
th ~ reaction mak ing it easy to recycle the biocatalyst. 
Stability: Immobilized enzymes typically have greater ther-
mal and operational stabi I ity than the soluble form of the en-
zyme. This can provid e increased resistance to changes m 
conditions such as pH or temperature. 
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Application of enzy 
concentrati 
mes as analytical reagents (for 
on estimation in blood) 
Application 
-
ase Glucose ~---Enzyme -------Glucose ox id 
i_Cholesterol ox idase Cholesterol 
Triacylglycerols 
-~ Urea I 
Lipase 
- - --- - --
1 lJ rease 
----
45 
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Enzyme therapy 
- is application of enzymes and regulators of their activity as medi-
cines 
Medicine Characteris~·c -lndicatio~s-T The purpose ~f I 
~plications 
Pepsin : Proteoytic enzyme -;;r· Insut1iciency oT I Replacement ther-
1 stomach I gastric digestion apy ~ 
1 _ (gastr~~ -- _ ___ _ 
Trypsin I Proteoytic enzyme of 1 a) Festering Spiitting ofnecrot-
1 
pancreas !. wound; b) in- , ic tissues and clots 
Aprotinin 
(trasylol) 
Fibrino-
lysin 
Inhibitor, of trypsin 
and related proteolyt-
ic enzymes 
Proteinase that dis-
: flammatory dis- I of blood 
; orders of res pi- : 
ratory tract ' 
Pancreatitis Prevention of pan- . 
Thrombosis of 
vessels 
creas autodigestion ! 
, by the trypsin, 
which is already 
' activated in the 
gland ducts at pan-
creatitis ---i 
Resorption of : 
formed trombuses 1 
1 
solves the fibrin of 
~--,-,---+-b_lo_o,.,_d.,..c_l_ots-,.------+----·-,----J------
lprazide Inhibitor of monoa- States of de- Stimulates the 
Hyaluro-
nidase 
Penicil-
line, 
cyclose-
rine 
mine oxidases, that 1 pression : mental sphere. 
inhibit catechola- i Eliminates states 
mines i of depression 
Glycosidase, an en- ' Scars after Breaking down the 
zyme that catalyzes bums and op- redundant connec-
the breakdown of erations, com- tive tissue 
hyaluronic acid in the missures 
body 
Iilhibitors of the en-! zymes that form the 
I components of the bacterial cell wall 
Bacterial 
infections 
Bacteriostatic and ' 
bactericidal action i 
I 
77 
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I 
I 
Biological membrane 
78 
l - --
Distribution of membrane components 
(structural asymmetry) 
• carbohydrates are located in the outer leaflet of membrane 
only: 
I • sphingomyelin and phosphatidylcholine are entially located 
in the outer leaflet of membrane; 
• phosphatidylethanolamine and phosphatidylserine are main-
ly located in the inner leaflet of membrane; 
• cholesterol is mainly located in the outer leaflet of mem-
brane. L _ _____ ____.7Q 
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Lipids of membrane 
- ----------------- -----1 
Lipids Hvdrof!_hobic ~t I __ _!!J!!}7:ophi!!f 1!!!_~!__ 1 
Glyceropho- two hydrocarbon fatty 1 phosphorylated alco~ 
spholipids acid chains I hots (choline, ethano-
!amine, glycerol, in-
1 
_ _ ositol or~erine) . _ ___ 
Sphingomyelins hydrocarbon fatty acidl phosphorylated cho-
chain and sphingosine ' line I 
backbone -~-- __ __ 
Glycolipids hydrocarbon fatty acid carbohydrate l 
chain and sphingosine L _ 1 
backbone 
Cholesterol fused ring system - OH al C-3 - -=-d 
80 
Membrane fluidity is regulated by degree of satura-
tion of fatty acids in phospholipids and cholesterol con-
tent. 
Increasing the length of the fatty acid chains or de- I 
creasing the number of unsaturated double bonds in the 
fatty acid chains and increasing the amount of cholesterol 
leads to a decrease in the fluidity of the membrane. 
81 
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I 
I 
I 
I 
I 
i 
Membrane proteins 
I 
a :b~~nd c arc integral membrane proteins 
d, e ant1 fare peripheral membrane proteins l ~ ---------- -~
Enzymatic markers of different membranes 
,- - M; mbra_n_e _ __ l+- Enzyme 1 
IPiasma membrane 1 5'-nucleotidase, adenylate cyclase, 
y-glutamyl transferase 
I ~ Endoplasm~-r~ticulum _ _ __ _ Glucose 6-phosphatase 
Goloi apparatus Galactosyl-transferase l1 -i-~ner ~1itochondri~l-r ATP- synthase membrane ------- --
--- -
83 
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I 
Fluid mosaic model of membrane structure according to I 
Jonathan Singer and Garth Nicholson ~
Structure of plasma membrane 
85 
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I 
Ttansmembrane transport 
Passive transport 
Simple diffusion 
Facilitated diffusion 
Osmosis 
Filtration 
Acth e transport 
Primary active 
transport 
Secondary acth•e 
trans ort 
~I -- -·----------------~86_..J 
Simple 
diffusion 
I 
I I I 
through lipid through through 
bilayer channels in the protein 
lipid bilayer channels 
87 
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Facilitated diffusion 
1'1tb mobile ca rrier with channel-forming 
ionophorcs ionopbore~ 
I 
Example, Valinomycin xomple. Grumicidio Forms channels adopted Forms complex with K .. and 
a lixed orientation in diffuses freely and rapid 
membrane. reating a 
across lipid membrane hole that pcnmts the 
transmembrane 
movement of mns 
88 
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Structure of the Na+/K+ - ATPase 
The Na+/K+-ATPase is an integral membrane protein, heterote-
tramer (a2pi), consisting of 110 kDa a and 55 kDa p subuniis. 
Binding sites on a subunits for: 
- ATP, Na+ (in the inner side of membrane) 
- K+, steroid inhibitors (in the outer side of membrane) 
89 
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I 
Mechanism of Na+ and IC transport 
Bind.illg ~IN• ion 
Release. ':\t ! 
Kt> the " ' 
inSLde of K' 
theC.U 
·The. Top ]S the Outte:r mr.mb?ftfl~ . 
•The 3 ottom ;, ilif..1.mte.r me.rLJltre1.t. (lnnde cfthe. Cell) 
D1.phosphorylocon .U 
•tructUrlll dlong& in prau.m. 
90 
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Secondary active transport system 
Cotransport - transport of a substance through the membrane 
is coupled to the spontaneous movement of another substance 
A A B 
II ._,_  _. 
l Antipo~ ----------------------------~ Symport 91 
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Metabolism. 
Biochemistry of nutrition 
and digestion 
91 I ,__~~~~~~~~~~~~~~-~---~~-J 
• Metabolism - entire spectrum of chemical ~nzymatic I 
reactions that convert nutrients into energy and the 
chemically complex products of cells, occurring in the 
living system. 
• Metabolic pathway - enzymatic chain of chemical 
reactio.ns. 
• Map of metabolism - set of metabolic pathways of 
all substances related to each other by common meta-
bolites. 
93 I 
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Metabolic homeostasis 
L._ _________ _ 94 
Catabolism 
The enzymatic degradative processes concerned with the 
breakdown of complex large organic nutrient molecules 
to smaller simpler compounds (e.g., C02, H20, NH3) 
with a concomitant release of chemical free energy, much 
of which is conserved in the form of energy-carrying mo- · 
lecule adenosine triphosphate (ATP). 
95 
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Catabolism occurs in three stages: 
I. Degradation of polymers to monomers: 
• starch, glycogen --+ glucose; 
• proteins --+ amino acids; 
• triacylglycerols --+ glycerol -r free fatty acids. 
II. Specific pathways of catabolism of monomers with 
formation of simple intermediates - pyruvate and acetyl 
CoA. 
Examples of specific pathways of catabolism: 
• oxidation of glucose to pyruvate, 2 ATP; 
• oxidative deamination of amino acids to ketoacids 
(pyruvate), acetyl CoA and NH3, 2-3 ATP; 
• ~-oxidation of fatty acids to acetyl CoA, 5 ATP. 
III. Common pathways of catabolism with formation of 
end products: 
• oxidative decarboxylation of pyruvate to acetyl CoA 
and C02, 3 ATP; 
1 
• oxidation of acetyl CoA via Krebs cycle (or citric 
acid cycle) to C02, H20, 12 ATP. / 
-~ 
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Anabolism 
The enzymatic biosynthetic reactions involving the for-
mation of complex organic molecules from simple pre-
cursors and require an input of chemical free energy 
which is furnished by the breakdown of ATP to ADP 
and phosphate. 
97 
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- - - ---- ----·- ----------------. 
Stages of anabolism 
I. Third stage of catabolism (amphibolic). 
II. Formation of monomers. 
The anabolic and catabolic pathways are not 
reversible and must be controlled by different 
I regulatory signals independently. 
I III. Synthesis of polymers from monomers. 
L 98 
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The central role of ATP in metabolism 
58 
Other 
cellular work 
Complex 
biomolecules 
Mechanical 
work 
Osm(;tlc 
work 
99 
Daily 
requirement , (average) 
9200~ (2200kral) 
'--· 
12f&~ 
~OOOIO) 
Essential components of diet 
Amino acids 
- Leu-Ile 
-Trp-Met 
- Thr-Val 
- Lys-Phe 
-Arg-His 
Fatty acids 
- Linoleic acid 
- Linolenic acid 
- Arachidonic acid 
100 
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Regulation of digestion by the hormones 
of the gastrointestinal tract 
~---~----~-------~ -- -·-- --- ---·· 
Stimulus I Effect 
ofsecre- I 
ti on l 1--------1f------+-p-ro_t_e-in_s _ __.._j _st-im_ u_late secrcti-;;-n of gastric . 
, (derived I HCI and pepsin by fundic I 
I• from food) cells of stomach I __ __. _ _____ o_r ~by~H_CI 
I
I fat (de"ri: j inhibits--gast~kHC~nd-) 
ved from j pepsin secretion possibly by 
Cholecys-
tokinin 
(pancreo-
zymin) 
Himodenin 
Entero-
crinin 
Villikinin 
' intestine 
--/!--
--!/--
I 
food) 1 blo~ki~g the activit~_gastrin I 
HCI pre- I stimulates the flow of I 
sent in the I pancreatic juice rich in 
: 
acid chyme I bicarbonate, water, and the 
~-
' flow of bile _!i)_~ht:_p_~ll~<:!eas 
oducts of stimulates the contraction of 
otein and I the gall bladder and release of ' pr 
pid bile into the intestim:. :ind thL I pr Ii 
I di 
I 
gestion release of pancreatic juice, I 
which is rich in digestive 
I enzymes and HC0 3. by the I 
___ _lP~I]CrC~--- _ ---~ 
I stimulates s;,·nth::si s and secre- I 
tion of chymotrypsin0gen by 
~ _ _____ _ __g_~e~creas_ _ ------~ I ~ti mulates se..::retion of the digestive g:!Jnds of the small 1 
intestine 
-II-
- - ---- -- -------I I stimulates movements of the I 
1
1 intestinal vi! E and intestinal 
absorption of digested food 
materials ! 
-- - - ---- ------- - -- -
102 
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Failures of nutrition today 
1 . High fat intake. 
2. Deficiency of polyunsaturated fatty acids. 
3. Deficiency of (animal) proteins. 
4. Deficiency of majority of vitamins. 
LS. Deficie:icy of macro- and microminerals - Ca, Fe, I, F, Se. 6. Defic1e11cy of dietary fibers. 103 
, ----·- -- -----
! N utraceuticals 
I 
- naturnl ingredients of food, such as vitamins or their pre-
cursors (e.g., p-carotins), polyunsaturated fatty acids of ome-
ga-3 family, sonie mono- and disaccharides, dietary fibres 
(cellulose, pectins) and so on. 
[ __________ . 104 
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Nutraceuticals with reported medicinal value: 
• Antioxidants: resveratrol from red grape products; flavo-
noids inside citrus, tea, wine, and dark chocolate foods; an-
thocyanins found in berries. 
• Reducing hypercholesterolemia: soluble dietary fiber 
products, such as psyllium seed husk. 
• Cancer prevention: broccoli (sulforaphane) fiddleheads 
(Matteuccia Struthiopteus). 
• Improved arterial health: soy or clover (isoflavonoids). 
wered risk of cardiovascular disease: alpha-linolenic 
d from flax or Chia seeds. 
105 
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Bioenergetics. 
Biological oxidation. 
Cellular respiration 
___ 1~ 
Laws of thermodynamics provide ------1 
the underlying principles to: 
1. Predict the direction of a reaction, whether from left to 
right or vice versa. 
2. Expl_ain why some reactions may occur while others do 
not. 
3. Understand the accomplishment of work, whether usdul 
or not, and whether the energy for driving a reaction 
must be delivered from an external source. I 
______ 1n7J 
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Thermodynamic principles 
Enthalpy (H) is a measure of the change in heat content of the 
reactants compared to products. 
Change in free energy (AG) is that portion of the total energy 
change in a system that is available for doing work; i.e., it is the 
useful energy. 
Entropy (S) represents the extent of disorder or randomness of 
the system and becomes maximum in a system as it approaches 
true equilibrium. 
AG= AH-TAS 
108 
[------·-- ---· 
I 
I 
Reaction: 
A--+B 
AG(+) 
if AG is positive, the reaction proceeds only if free energy can be 
gained; i.e., it is endergonic. 
2) GB <GA AG(-) 
If AG is negative, the reaction proceeds spontaneously with loss 
of free energy; i.e., it is exergonic. 
3) GB= GA AG= 0 
~ If AG is zero, the system is at equilibrium and no net change akes place. IOQ 
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-------- - - - ·-------, 
Adenosine triphosphate (ATP) 
11 0 
-- ----- ---
High-energy (or energy ~ich) compound:-, 
- are substances when hydrolyzed liberate more ene rgy than that of I 
ATP (30,5 kJ/mol) , 
There are 3 groups of high-energy compounds: 
1 ). High-energy phosphates: 
1. Anhydrides (e.g., 1,3-Bisphosphoglycerate, ATP. CTP, 
GTP); 
2. Enolphosphates (e.g., Phosphoenolpyruvate); 
3. Phosphoguanidines (e.g., Creatine phosphate). 
2). Energy-ricbed thiol esters involving coenzyme A (e.g., 
acetyl-CoA), acyl carrier protein (ACP), 5-adenosylmethionine 
(S-AM), UDP- glucose, 5-phosphoribosyl- l -pyrophosphate. 
3). NADPH2 as energy accumulator of electrons in C)1osol pro-
vides with electrons and protons the processes of reductive bio-
synthesis. 
Ill 
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Standard free energy of hydrolysis of some organophos-
phates of biochemical importance 
Compound 
KJ/mol 
-~--
Phosphoenolpyruvate 
C.:irbarnoy: ph0sphate 
1,3-Bisphosr·!ioglycerate I I 
Creatine phosphate _J_ 
r - -- -A~I~---+ 
i -- -----ADP-__ _ 
! Pyrophosphate 
I 01.JCOSt'- i-phosphate 
-61.9 
-51.4 
-49.3 
-43.1 
-30.5 
-27.6 
-27.6 
-20.9 
-13.8 I, I Glucose-6-phosphate , I -- - - ------ -1. 
- -- -
tJ G°' 
Kcal/mo/ 
-14.8 
-12.3 
-11.8 
-10.3 
-7.3 
-6.6 
-7.4 
-5.0 
-3.3 
I I'he intem1ediate position of ATP allows it to play an important role in 
L~~:r~!_:~~fer. _ __ _ _____ 112 
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Cycle ATP/ADP 
Endergonic reaction: 
Hexokinase 
. Glucose ~ Glucose-6-phosphate 
Excrgonic reaction: ~ 
ATP ADP + Pi 
Exergonic reaction: 
Phosphoglycerate kinase 
1,3-Bisphosphoglycerate · 3-phosphoglycerate 
Endergonic reaction: 
DP + Pi ATP 
113 
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ATP can be synthesized in 3 ways: 
1. Oxidative phosphorylation - ATP synthesis via transport of 
electrons produced by substrate oxidation through a respira-
tory chain and proton gradient in the inner mitochondrial 
membrane. I 
2. Substrate level phosphorylation - reactions, in which ATP 
is synthesized from the high-energy phosphates. 
3. Photosynthetic phosphorylation - ATP synthesis via light I 
energy during photosynthesis in the thylakoid membrane. i 
Conclusion: ATP is universal accumulator of energy. ! 
ADP+Pi -ATP 
ATP is universal source of energy. 
ATP is required mainly for the following 4 purposes: 
l. To synthesize macromolecules from simpler and smaller pre-
cursors. 
2. To transport molecules and ions across membranes against 
gradients (active transport). 
3. To perform mechanical work, as in the muscle contraction. 
4. To ensure fidelity of information transfer (nerve impulse con-1 
duction). 
11 5 
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Adenylate kinase 
ATP+AMP-+ 2ADP 
This reaction performs 3 main functions: 
1 . Permits the high energy phosphate of ADP to be used in the 
formation of ATP; 
2. It is a means by which AMP can be rephosphorylated to 
form ADP; 
3. Under stress of ATP depletion, AMP concentration increas-
es which acts as a metabolic signal to increase the rate of ca-
tabolic reactions so that more ATP molecules are regene-
rated. 
116 
Energy ~µH+ generated during electron transport is 
used for following biological purposes: 
I. To provide energy for the synthesis of ATP during oxidative 
phosphorylation (chemical work); 
2. For secondary active transport of substances through the 
membrane against concentration gradient (transport Ca2+ 
from the cytosol into the matrix of mitochondria) (osmotic 
work); 
3. To generate heat in order to maintain the body temperature; 
1 4. Rotation of bacterial flagella is also controlled by the proton 
IL gradient generated across the membrane (mechanical work). 
117 
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Biological oxidation 
- is the whole set of all oxidative processes proceeding in an organism 
with participation of 0 2 
Ways of substrate oxidation: 
I. By dehydrogenation (02 is acceptor of H~ ). 
1). H2 removed from substrate is transferred on 0 2 thr.)ug.h a 1 
number of carriers to produce H20 in mitochondria. Energy is 
released as ATP. 
SH2 + ... Yi02 ~ S + H20 +ATP (cellular respiration) 
2). H2 removed from substrate is transferred at once on 0 2, to 
fonn hydrogen peroxide in peroxisomes. Energy is released as 
heat. 
SH2 + 02 ~ S +H20 2 + Q (peroxidase oxidation) 
I 
I 
I II. By incorporation of 0 2 (oxygenase oxidation). 
1 ). Incorporation only one atom of oxygen into the 
(endoplasmic reticulum). 
substrate I 
S + Yi02 ~ S-OH (microsomal or hydroxy lase oxhJation) 
2. Incorporation both oxygen atoms into the substrate ( endop-
lasmic reticulum). 
S + 0 2 ~ 802 ( dioxygenase oxidation) 
3. Oxidation with participation of oxygen free radicals (active 
fonns of oxygen) (free radical oxidation). 
I 18 
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I 
i 
Purpose of biological oxidation: 
l) Recover energy from various compounds (cellular respira-
tion); 
2) Destruction or detoxication of xenobiotics (peroxidase, 
oxygenase oxidatien); 
i :') biO'->) nthesis (h) droxy!ase oxidation); 
I 4 \ l hange in n11.rr.bran1: permeability, oxidative modification l or' nwie.:ule (free radi.:al oxidation). !IQ 
------·------ - --------------~ 
I 
I 
l 
1) It is a part of biological oxidation where substrate is oxi-
dized by dehydrogenation and 0 2 is acceptor of hydrogen 
to produce H20 in mitochondria. 
2) Reducing equivalents (HT ore") are funneled into the respi-
ratory chain, where they are passed down a redox gradient 
of carriers to their final reaction with oxygen. 
3) 1 he flow of electrons through the respiratory chain gene-
rates ATP by the process of oxidative phosphorylation. 
120 
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Respiratory chains: 
Complete respiratory chain 
s n. m,NAD--?FMN , co-enzyme Q ,Cyt b ""Cyt C1-7 Cyt c,C)·t aa3, 'Ii o~ 
·I· 
Incomplete J 
respiratory chain j ' 
S 1 - -~ FAD 
. 
I j 
Types of oxygenated substrates (SH2) 
----1 
I 
1. S1 Hydrocarbons (succinate, acyl-CoA) are oxidized by 
FAD-linked dehydrogenases (incomplete respiratory 
chain). ~G = 150 kJ/mol. 
2. Su Alcohols (isocitrate, malate, lactate) are oxidized by 
NAD-linked dehydrogenases (complete respiratory chain). 
~G = 200 kJ/mol. 
3. Sm Aldehydes (glyceraldehyde-3-phosphate) are oxidized 
by NAD-linked dehydrogenases (complete respiratory 
chain). ~G = 250 kJ/mol. 
70 
1. NAO-linked dehydrogenases (coeflZ)me is NAO); 
2. NAOH dehydrogenases (or FMN-linked dehydrogenases) 
(prosthetic groups are FMN and FeS-centers); 
3. Ubiquinone (Q, co-enzyme Q); 
4. Cytochromes (prosthetic group is heme). 
LMM 
IMS 
Mechanism of cellular respiration 
NAl>-linked DH 
F'MN·lnlHDH 
(orNADH Dtfl 
+ 
~ 
s, F D-liaked DH 
+ + + 
' H,.-------H•---- H•--__, 
71 
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Nicotinamide adenine dinucleotide (NAD+) 
: ~r:;.::..:_ ~ -..{,-:--- Participates in 
•~-. Ji ' dectron transfer 
'..._t:J:i. __ Q_ - -- - ~ 
7 
O=P-0-
1 
0 :~ 
I OH OH 
O=P--0 NH, 
I <N=i:~ 0- C~O':J ~ 
~i-{H 
OH OH - NADP• contain$ a 
phosphate group 
in this position. 
I 
12s I ~-------------------- ·-------- '._J 
~------------------- - --
Mechanism of substrate oxidation by 
NAD-linked debydrogenases 
NAO• NADH 
72 
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Flavin mononucleotide (FMN) 
H H H OH 
I I I I 
CH -C-C-C-CH O-P=O 
I 
2 I I I 2 \ 
OH OH OH OH 
: N 
cH3-!f' ( · L~ l :r=o 
(ff,- --. s / '- rn h 4 NH 
·' -"' ' N ~O 
127 
'------ ------- ---·---- -----------' 
[ ------ -- -;lec-~ani~-m ~f NADH oxidation by 
I FMN-linked dehydrogenases 
128 
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Ubiquinone structure and mechanism of reduction 
Semiquinooc Hydroquioone 
I 
I 
_ _ 12~ 
~----------------· - -----·---
Heme in cytochrome b 
Iron protoporphyrio IX 
130 
'--------------------~----__J 
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r-;eme -is attached to ap~protein part of cytochromes 
by 5 and 6 coordination bonds of Fe 
I ~!'''~,~:;;,.~ [-· ·~···· · .. His - _£_ . ~ 
' ' His ' -ffet---\ 
I «C» i I ;ov~ent bond of vin,I L ou of heme with C s 
, 
1
- -- -«~-;;----- , - NH2-group oT , 02, HCN, CO 
I I . \ _ _ _____ J_ ~mmo ~ar __J 
I 131 
-- ----- ---------
r--
1 
I 
I 
Flavin adenine dinucleotide (FAD) 
132 
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- - - - - ------- -1 
Structural organization of electron transport chain 
----- - --- - ---- - ----
f--_ _ __ C_o_m~_l_ex ______ 1_ _ _ Composition ___ _ 
I 
NADH dehydr~enase ___ • __ FM_N_.:__feS - <:~nters _ 
II I 
Succinate deh drogenase __ L 
III I 
j QHi- dehydrogenase Cytochromes b, c1, 
lc Ft:S - centeis . I ytochro~e oxidase c-.yt-o~-h-r-o~-e-s a, ~~ . · · ,11 J, 
i I Cu2-~------------·__J_ ___ -_-_·_=___:_-~ ~J 
The electron transport chain, showing------, 
lnlennembrane 
the respiratory complexes I 
Fe-s-~e,.-.,_ _,,,=,,.-
~1b 1 
,m Ai 
Suooinat• ETF; 0 CylocOrt<Tle b-c1 
deh)<jrogtM&e a>ldomduciase complo• 
76 
1/2 0, + 11-1' H20 
Cytochrome c 
<Mdasa 
134 
I 
ADP+ Pi --ATP 
The process of synthesizing ATP from ADP and Pi 
coupled with the transport of electrons produced by substrate 
oxidation through a respiratory chain and creation of the proton 
gradient in the inner mitochondrial membrane is known as oxid-
ative phosphorylaiion . 
135 
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i----------
PIO ratio 
1
. P/O ratio refers to the number of inorganic phosphate mole-
cule~ utilized for ATP generation for every atom of oxygen 
I con <: umed. 
• P/O ratio represents the number of molecules of ATP synthe-
sized per pair of electrons carried through electron transport 
chain. 
l __  _ 136 
,--
1 
Sites of oxidative phosphorylation in 
electron transport chain 
I. Oxidation of FMNH2 by coenzyme Q (complex I); 
2. Oxidation of cytochrome b by cytochrome c1 (complex III); 
3. Cytochrome oxidase reaction (complex IV). 
137 
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Coupling e- transport and oxidative phosphorylation 
lnlet'membrane 
space 
+W 
NADH 
dehydrogenasa 
Complex l 
Cytochrome 
b-c, 
Complex llf 
Cy!Oellrome 
oxldsse 
Complex l\ 
nw 
I 
l ADP ATP i 
.. P, ! I 
ATP I 
S)'Olhase I 
I 
I 
rn I ~~~~~~~~~~~--~~~~~~~-----~- .'--.J 
- - ---- - - , 
Efficiency coefficient of complete respiratOl'y chain [ 
Substrate oxidation energy - 220 kJ/mol 
ATP synthesis: 30,5 * 3 = 91,5 kJ/mol 
30,5 k.Jlmol-synthesis of I ATP; 
3 - number of synthesized ATP via complete respiratory chain 
Efficiency 
coefficient = 
91,5 l 100 
-----~41% j 
220 
-------
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~o~heses of mechanisms of oxidative 
1
1 
r·h
4
, .. •~ni r phosphorylation 
1 
1. Che1111cal Coupling Hypothesis (E. Slater, A.L. Lehninger) proposes 
I 
that electron transport is coupled to ATP synthesis by a sequence of 
censecutive reactions in which a high-energy covalent intermediate is 
I 
formed by electron transport and subsequently is cleaved and donates 
its energy to make ATP. These reactions are believed to be analogous I lo the substrate level phosphorylation. 
I NADH + FMN- FMN H2 + NAD+ 
NADH + X-> NAD + XH2 
XH2 + H3P04->X·H2·H3P04 
X·H2·H3P04 + FMN -> FMN H2+X-H3P04 
X-H3P04 + ADP-+X +ATP 
2. Mechanochemical or conformational hypothesis (P. Boyer) is envi-
saged that the energy released in the transport of electrons along the 
respiratory rhain causes the conformational changes in the inner mito-
chondrial membrane and that this energy-rich condensed structure, in 
J tum, is utilized for ATP synthesis. 
13. Chemiosmotic theory according to Peter Mitchell. 
I I. lhc them) postulates that oxidation of substrates in the respiratory 
I 
chain generates protons (W) driven by the respiratory chain com-
plexes I, III, and IV, each of which acts as a proton pump, which are 
I ejected from the inside to the intermembrane space of membrane in 
I 
the mitochondrion. 
2. Inner membrane is impermeable to protons, which accumulate in-
1 
termembrane space, creating an electrochemical potential difference 
(~~1H+) across the membrane composed of the membrane potential 
and the proton gradient. 
3. The transmembrane flow of protons to the matrix down their concen-
tration gradient through specific protein channels provides the free 
energy for synthesis of ATP. This is performed by a membrane ATP 
synthase that couples proton flow to phosphorylation of ADP. 
140 
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Chemiosmotic theory 
Transport of electrons through electron transport chain from 
substrate to 0 2 (cellular respiration) 
Protons are pumped from the mitochondrial matrix to the 
intermembrane space and generation an electrochemical gradient 
l 
Proton influx from the intermembrane space to the mitochondrial 
matrix through the ATP synthase pore generates ATP 
141 
Chemiosmotic theory 
142 
80 
I 
I 
u-
I l _______ _ 143 
r·-----· 
Role of ff~ I ATP synthase: 
I . F 0 serves as a channel for protons flowing back into the 
matrix from intermembrane space. 
I 2. F1 is an enzyme that hydrolyses ATP to ADP and Pi. 
l 3. F0 - F1 complex generates ATP. ----~ 144 
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For the synthesis of ATP during cellular respira-
tion following are required: 
l. Substrates of oxidation; 
2. 02; 
3. Substrates of phosphorylation (ADP and Pi) . 
Respiratory control 
145 
- alteration of respiration rate in mitochondria with the alteration of 
ADP concentration 
States of respiratory control 
-- -
Conditions limiting_ the rate oL resp_iration ___ ·--------~ 
State 1 I Availability of ADP and substrate : I State 2 Availability of substrate only 
State 3 The capacity of the respiratory chain itself, when all sub- I 
i strates and components are present in saturating · 
amounts. Availability of ADP only 
State 4 Availability of ADP only ; 
State 5 Availability of oxygen only __ _ _____ _ j 
146 
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Uncouplers 
Some chemicals valinomycin, 2,4-dinitrophenol, rotenone, 
H2S, cyanide, azidc and CO, oligomycin, barbiturates (amobar-
bital), dimercaprol, antimycin A, carboxin, malonate uncouple 
mitochondria by carrying H ions across the inner mitochondrial 
membrane and hence dissipate the proton gradient. More than 
60% of oxidation energy derived from uncoupled electron trans-
port is released as heat ~ hyperthermia. 
There are endogenous uncouplers phenols, unsaturated fat-
ty acids, and their peroxides. 
Uncoupling of oxidation with phosphorylation is at ex-
1 treme temperature, radiation. 
_I ___ _ _ ______ ______________ 1_4_1~ 
Hypoenergetic conditions: 
I) No substrates of oxidation (starvation); 
2) Low levels of oxygen (hypoxia): 
• lack of oxygen in the air; 
• failure of oxygen supply to cardiovascular and respira-
tory systems due to their damage; 
• anemias of different origin. 
3) Mitochondrial damage (or uncouplers). 
4) Different types of hypovitaminosis - deficiency of vita-
mins PP, B2, B1. 
148 
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Primary uncoupling respiratory systems 
Peroxidase oxidation: 
Oxidases catalyze the removal of hydrogen from a substrate 
using oxygen as a hydrogen acceptor. They form hydrogen perox-
ide (H20 2) as a reaction product. Substrates are aldehydes. amines, 
D- and L- amino acids, purines. 
SH2 + 02 ~ S + H20~ + Q 
Oxygenase oxidation: 
Oxygenases may be divided into 2 subgroups: 
1. Dioxygenases (Oxygen transferascs, True oxygenases) 
incorporate both oxygen atoms (02) into the substrate. 
S+ 02 ~ S02 
Examples of this type include enz~ mes that contain iron 
such as homogentisate dioxygenase and 3-hydrox~ anthranilatc 
dioxygenase from the supernatant fraction of the liver, and en-
zymes utilizing heme such as L-tl)·ptophan dioxygenase from the 
liver. 
2. Monooxygenases (Mixed-function oxidases, Hydrox-
ylases) incorporate only one atom of oxygen into the substrate. 
The other oxygen atom is reduced to water, an additional electron 
donor or cosubstrate being necessary for this purpose. Substrates I 
are benzpyrene, aminopyrine, aniline, morphine, and benzphe-
tamine and endogenous substances such as steroid hormones. 
S-H + 02 + ZH2 ~ S-011 + H20 + Z, 
Z is cosubstrate 
84 
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Main components of microsomal oxidation are: 
I) Apolar compounds containing aliphatic or aromatic rings; 
2) Cytochrome P-450; 
I 3) 01: 
I 4) NADPH:. 
L_ ______ ---- ------
P-450 
I 
Fe ' ' 
Microsomal oxidation 
Substrate A-H 
j Product A-OH 
150 
L _________________________ 1s_1__. 
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Reaction mechanism of microsomal oxidation 
1. In the resting state, in cytochrome P-450 the heme 
has F e3+. The substrate binds near the heme group. 
2. Transfer of a first e from NADPH2 reduces Fe3+to 
Fe2+ that is able to bind an 02. 
3. Transfer of a second e reduces the bound 0 2 to the 
superoxide anion 0 2 •• 
4. Uptake of H+ gives rise to H20. 
5. The activated oxygen atom inserts itself into a C--H 
bond in the substrate, thereby fonning an 01 I group. r 
6. Dissociation of the product returns the enzyme to its 
initial state. 
Functions of microsomal oxidation: 
1. Hydroxylation of many drugs as the 1-st step of xe-
nobiotic detoxication. 
2. Synthesis of bile acids and steroid hormones from 
cholesterol and eicosanoids as well as the formation 
of unsaturated fatty acids. 
86 
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Free radical oxidation 
Oxygen is a potentially toxic substance is due to the involvement of oxy-
gen free radical~: 
Oz+ e ~ 02- (superoxide) 
Oi°'' + W ~ H02° (peroxide) 
0 1- + H02° + H+~ 02 + H202 (hydrogen peroxide) 
·1 02 .... is formed during oxidations m the respiratory chain: 
EnzH1 + 0 2 ~ EnzH + 0 2· • + tt• 
' O, .... is especially dangerous. It does not itself react readily with cellular 
constituents. but it will combine with peroxides to fonn hydroxyl radicals 
(OH0 ), which arc reactive: 
0 2 - + H20. ~ 0 2 + Off + OH" (hydroxyl radical) 
F~+ fe1+ 
H20 2 and 0 2· • arc toxic to cells as they attack the unsaturated fatty acid 
components of membrane lipids, thus damaging the membrane structure. 
H20 2 + Fe2+ ~ OH- +OH" + Fe3+ 
0 2·• can reduce oxidized C)'1 c: 
0 2·• + Cyt C (Fe3+) ~ 02 + Cyt C (Fe2+) 
154 
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Free radicals and diseases 
1 
I 
I 
• Atherosclerosis. 
• Diabetes mellitus and diabetic angiopathy. 
• Respiratory diseases (chronic obstructive bronchitis, bronchial 
asthma, emphysema, lung edema). 
• Rheumatico- inflammatory and moronic diseases of joints (rheuma-
toid arthritis). 
• Cataract. 
• Cancer. 
• Aging. 
• Intoxications. 
• Intlamm itory disorders - chronic glomerulonephritis and ulcerative 
colitis. 
• Other diseases - Parkinson's disease, Alzheimer's disease, multiple 
sclerosis, liver cirrhosis, muscular dystrophy, toxemia of pregnan-
cy. 
155 
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Antioxidative system (AOS) 
- system of organism protection against toxic action of oxygen. AOS 
includes enzymatic and non-enzymatic antioxidants 
Enzymatic antioxidants: enzymes superoxide dismutase, 
peroxidase, catalase. 
Superoxide dismutase i 
Superoxide dismutase is a high active specific cnz) me; protect I 
aerobic organisms against the potential deleterious effects of supe- , 
roxide. The dismutase is present in all major aerobic tissues. 
Hydroperoxidases (peroxidases and catalase) protect tbe 
against harmful hydrogen peroxides. 
I 
I 
I 
body / 
i 
! 
Glutathione peroxidase I 
Peroxidases are found in leukocytes, erythrocytes, and other tis- I 
sues involved in eicosanoid metabolism. 
1 
H 20 2 + 2HS-Glutathione ~ 1120 + G-SS-G 
The pentose phosphate pathway supplies NADPH+H+. which is 
needed to regenerate glutathione. The oxidized glutathione can I 
be reduced by the enzyme glutathione reductase: 
NADPH2 + G-SS-G ~ 2 GSH + NADP+ 
Catalase 
Catalase is a hemoprotein containing 4 heme groups. It is found in 
blood, bone marrow, mucous membranes, kidney, and liver. 
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I 
Non-enzymatic antioxidants 
l) Vitamin E (Tocopherol) is fat soluble vitamin. It is an anti-
oxidant present in all cellular membranes, and protects 
against lipid peroxidation. ct-Tocopherol can directly act on 
oxyradicals (e.g., 0 2 -, OH j, and thus serves as an impor-
tant chain breaking antioxidant. 
2) V itamir. C i Ascorbic acid) is water-soluble antioxidant. It 
is cnic1 .:ntiy scavan ges fn:e radicals, and inhibits lipid pe-
roxidation. ft .ilso promotes the regeneration of a.-
Tocopherol (from c.-!.ocopheroxyl radical produced during 
scnvengmg of free radicals); Uric acid is powerful scaven-
ger of singlet oxygen (102) and OH radicals. 
3) Bioregulators - thyroxin, steroid hormones. 
4) Compounds containing SH-group - glutathione, cysteine. 
5) Fe binding complexons. 
Antioxidants according to lipid peroxidation: 
I) Preventive antioxidants that will block the initial produc-
tion of free radicals, e.g. catalase, glutathione peroxidase. 
I I 2) Chain breaking antioxidants that inhibit the propagative 
l phase of lipid peroxidation. e.g. superoxide dismutase, vi-tamins E, C, uric acid. 158 
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Lipid peroxidation in membrane can have effects 
I. Increased membrane rigidity. 
2. Decreased activity of membrane-bound enzymes (e.g. So-
dium pumps). 
3. Altered activity of membrane receptors. I 
,,,I 4. Altered permeability. 
_ _ _ _ __________ _J 
Nutrient antioxidants and their dietary sources 
r------~------------------ - I 
1---A_n_t_io_xi.d__a_n_t_+-____ _ ___ D_ie_ta~urce I 
Vitamin C ' Cherry, papaya, orange. grapes, waterme- I 
(ascorbic acid) Ions, melons, grapefruit, kiwi fruit, straw-
berry, gooseberry (amla), guava, cauliflow-
er, cabbage, spinach 
Vitamin E 
( a-tocopherol) 
Cotton seed oil, sunflower seed oil, peanut 
oil, whole grains, legumes, almonds, hazel- J 
I nut, leafy vegetables mayonnaise, egg yolk, i 
1 butter , t--- ------+-- ----- ------ - - -·--·--- -·-
Dark green and yellow-orange vegetables i 
and fruits: carrots, insipid potato, tomato, i 
spinach, pumpkin, watermelon,. papaya, I 
apricot, spinach, tumiQ_ _______ _______ _J I 
~ 
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Common pathways of catabolism 
161 
.----------- ----------------~ 
Oxidativt~ decarboxylation of pyruvate 
?Ii 
C=o 
I COOH 
Pyr11vate 
+NAD+ 
+ SHCoA 
\ \. 
CH3 
c=0 
~ 
SCoA 
COz NADH+H+ AcetylCoA 
I NAD++H2 0+3ATP 
The NADH produced by the pyruvate decarboxylation is reox-
idized and the energy released is used to synthesize 3 ATP by 
oxidative phosphorylation. 
Pyruvate dehydrogenase complex consists of 
the 3 enzymes: 
162 
I. Pyruvate dehydrogenase ( coenzyrne is thiamin diphosphate ); 
2. Dihydrolipoyl transacetylase (cofactors are coenzyme A and 
lipoic acid); 
3. Dihydrolipoyl dehydrogenase (cofactors are FAD and 
NAO+). 
163 
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Thiamin diphosphate (TDP) 
Pyrimidine Thhuole 
164 
Coenzyme A (HSCoA) 
Pantoic acid 
~ IJ-Ahlnine Thioethanolamine 
CH -C-<-"11-C-NB-Cllz·CUz-C-NH-CUi-Cllz-SH 
I 2 I I II II 
o cepeo NH o I 2 
0 ,.-oe ~N 
0 <Z~ 
0 f-o-1'!;<>-;j j 
OB °l--{° 
0 OH ~s OH 
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I 
!..ipoic acid (LA) I 
I 
1 1 I 
CH2-CH2-CH-CH2-CH,-CH , -CH2-COOH __ ,,J 
,----- -- - -- - - - --1 
I Mrcha.nism of the pyruvate decarbo~· iatiun I 
ru_ ~~·-·· -N:!.-C-CH, 
~ ,.. - !I n -+~f +Rt~--aiJ ___ .,_.110 'cc·~/;;---~ --\; -
I HC' l,.'-ffz Uf"'~ • ( ~ • 
COOll ''fl ---:J'-- tn, >fl 
TDP C'ar!Joxydh~-1-Tl.>i' 
en.,. 
1-n 
C -··· ,-s .. 
/ L i 
HS 
Hydroxy~thyl -TDP 
CH'4 CH3 1-o '-o + c.::s + SH-CoA- c..:::s, _ 
)1A Co.A. 
HS Ace~·l-C'o.-\. 
Acet)-1-S-lipoate 
At . t~·l-S-lipm1te 
HS )L< 
:ns · 
Lipoic ~1cid 
"\ s 
ulLA +FAD -- v LA+ FADH2 
F.ADH2 + NAD+ --.... _ FAD+ NADH+ H+ 
93 
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Citric acid cycle I 
CH3 OJOB l~o + b 
c_s 1 
'CoA CBz 
Acetyl C'oA toon 
Citrate OJOB 
sr11tflase I 
·+ H .O CJli Aco11itase 
.:~ ~ 
~ 
Oxalo;1cet"te 
coon 
&2 
-t-coou 
&. 
I COOR 
Cis-aconitate 
Citrate 
lsootrate coon 
Aco11itase I Dehydrnge11ase 
+ H10 Cn2 + ~,.1.0• 
Ht-C~NA~'ti+tt• 
no--& 
tooe Nc\D+H?0+3ATP 
lsocitrate 
a-Ketoglutarate 
coon ~OOH de/Jydrogenasecomplex tu CH 2 {TDP, LA, CoA, FAD, NAD) 
---12 ~I ., e~ -coon co
2 
~H2 )o
1 
'\ 
tooe tooe c=o c=o lNADH+W 
Oxsalosuccinate a-Ketoglutarate NAD+HiO+lAif 
coon 
I 
?Dz 
Clli 
l_o 
c-
l 
SCoA 
Succinyl CoA 
Succinyl CoA 
synthetase 
+GDP+Pi 
+ 
ADP 
i 
A'.[f+GDP 
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! 
coon 
I 
Cn2 
- - - 1 
CH2 
i 
coon 
Succimtte 
Citric acid cycle 
(continuation) 
S11cci11ate 
Del1ydroge11ase 
+FAD 
\ 
F.-\DH, 
1 
FAD+H10+2ATP 
Jlalate 
COOH 
I 
CH 
11 
CH 
I 
COOH 
Fum.u-ate 
COOH dellydroge11a.Ye COOH 
I +N.-\D+ I 
HCOH c=o I ~~--..,--~~--- I 
CH2 \ CH2 
I N.-\DH+H+ I 
COOH COOH 
F11111ar11.tte 
+H20 
I _  _ 
l\Ialnte NAD+H,0+3ATP Oxaloacetate 
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Regulation of citric acid cycle 
I Three enzymes regulate citric acid cycle: 
l. Citrate synthase is activated by substrate, and inhibited by ATP 
andNADH. 
2. Isocitrate dehydrogenase is activated by ADP, and inhibited by 
ATP and NADH. 
3. Succinate dehydrogenase is activated by substrate (succinate), 
phosphate, and inhibited by oxaloacetate. 
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Functions of citric acid cycle (CAC) 
1. CAC is the common pathway of acetylCoA oxida-
tion that is the product of carbohydrate, lipid and 
protein degradation by successive decarboxy lations 
and dehydrogenations. 
2. CAC is the generator of protons and electrons to 
respiratory chains: 11 ATP molecules produced 
from the reoxidation of the 3 NADH (3 ATPx3 
NADH) and 1 F ADH2 (2 A TPx 1 FADH2) by oxida-
tive phosphorylation. 
3. Energetic function: I ATP molecule is produced di-
rectly from the cycle by substrate-level phosphory-
lation. 
4. Amphibolic function: CAC is the third stage of ca-
tabolism and is the first stage of anabolism. 
5. Integrative function: CAC unifies the catabolic 
pathways of carbohydrates. lipids and proteins. 
96 
Metabolism of carbohydrates 
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Biological role of fiber 
l. Helps to maintain the normal motility of gastrointestinal tract 
and prevents constipation. 
2. Adsorbs large quantities of water and also the toxic com-
pounds produced by intestinal bacteria that lead to increased 
fecal mass and its easier expulsion. 
3. The lower incidence of cancers of gastrointestinal tract (e.g., 
colon and rectum). 
4. Improves glucose tolerance by the body. This is mainly done 
by a diminished rate of glucose absorption from the intestine. 
I 
5. Decreases the absorption of dietary cholesterol from the intes-
tine. Fiber binds with the bile salts and reduces their entero-
1 hepatic circulation. This causes increased degradation of cho-
. Adds to the weight of the foodstuff ingested and gives a sen-
sation of stomachfullness. L 
lesterol to bile salts and its disposal from the body . 
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Glucose transport through biological membranes 
1. Transport of glucose through the apical membrane 
of intestinal, choroid plexus and kidney epithelial cells 
depends on the presence of secondary active Na+/glucose 
symporters, which concentrate glucose inside the cells, using 
the energy provided by cotransport of Na' ions down their 
electrochemical gradient 
2. Facilitated diffusion of glucose through the cellu lar 
membrane is otherwise catalyzed by glucose carrier,<, (GLUT), 
Molecule movement by such transporter proteins oc .. :urs by 
facilitated diffusion. I 
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Digestion of carbohydrates I 
Sourc~of/ Enzyme Substra~T E11~ ~~d .. ct J secretion ! 
Salivary Salivary Starch, I Maltose plus l :6 i 
glands amylase I glycogen I glycosides 
' 
I (oligosac-charides) 
I 
! plus malto-triose_ p .---r-Pancreas ancreat1c Starch, Maltose plus I :6 
amylase glycogen glycosides 
( oligosac-charides) 
I plus malto-trios~ 
Small in- I Sucrase Sucrose Fructos~uCO§~ 
testine Maltase Maltose Glucose 
--
Lactase Lactose Glucose, galactose ~ 
Trehalase Trehalose ____ Gluco~ __ ; 
·---
lsomaltase or 1:6 Glucose 
:I I :6 glucosidase glucoside~ ___ _ 
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Types of GLUT 
Five glucose transporters in the cell membranes have been iden-
1 tified. They exhibit ti ssue specificity. 
GLUT-I is ubiquitously expressed and transport glucose in most cells. 
Responsible for the low-level of basal glucose uptake required to sustain 
respiration in all cells. It is found at highest levels in erythrocytes and also 
in the protective membrane of the blood vessels in the brain (blood-brain 
barrier) and in fetal tissues. 
GLUT-2 is expressed by renal tubular cells and small intestinal epithelial 
cells that transport glucose, liver cells and pancreatic P cells. GLUT-2 has 
a lower affinity for glucose than GLUT-1. GLUT-2 is most active when 
high levels of glucose are present, such as after food. Bidirectionality is 
. required in liver cells to uptake glucose for glycolysis, and release of glu-
[ cose during gluconeogenesis. In pancreatic P-cells, free flowing glucose is 
1
1 required so that the intracellular environment of these cells can accurately 
gauge the scrum glucose levels. Gucose is transported from the intestinal 
I mucosa! cell into the portal circulation by GLUT-2. 
GLliT-3 is the primary glucose carrier for neurons. It is also the main 
transporter in the placenta and testes. 
· GLUT-4 is abundant in striated muscle (skeletal muscle and cardiac mus-
cle) and adipose tissue. GLUT-4 is an insulin-regulated glucose transpor-
ter that has a high affinity for glucose. Adipocyte cells and the skeletal 
system both require insulin as well as a glucose transporter to absorb glu-
cose molecules from the bloodstream. Insulin is released from the pan-
creas which then attaches to receptors on the adipocyte and skeletal cell 
membranes. As GLUT-4 is an insulin responsive protein, it is alerted to 
the presence of the insulin bound to the receptors on the cell membrane. 
The GLliT-4 molecule is then able to transport the glucose molecule 
across the cell membrane and into the cell. 
GLUT-5 transports fructose in intestine and testis. 
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All carbohydrates of tissues are divided into 2 groups: 
1). Carbohydrates with mainly energetic function: 
1. I molecule of glucose oxidation gives 38 molecules of 
ATP. From glucose all other carbohydrates of organism are 
formed, except ascorbic acid. 
2. Polysaccharides (starch in plants, glycogen in animal 
cells). Glycogen, a large polymer of glucose residues, pro-
vides an important energy reserve for the body. 
2). Carbohydrates with mainly structural function: 
1. Glycolipids and glycoproteins are abundant in the plasma 
membrane of eukaryotic cells but are also involved in spe-
cific interactions (for example, they are receptors). 
2. Glycosaminoglycans are a part of a connective tissue. 
Some of them (e.g., heparin) perform regulatory function. 
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Sources and utilization of blood glucos:-1 
Sources of blood glucose: 11 
I. Dietary carbohydrates. 
2. Degradation of glycogen in liver (glycogenolysis). I 
3. The synthesis of glucose from noncarbohydrate precursors 
such as glucogenic amino acids, lactate, glycerol in liver 
and kidney (gluconeogenesis). 
Utilization of blood glucose: 
I. Generation of energy at aerobic and anaerobic glucose 
oxidation. 
2. Synthesis of other monosaccharides. 1 
3. Synthesis of glycogen and heteropolysaccharides. :J 
4. Synthesis of fat, some amino acids and other compounds. 
17!! 
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Catabolism of carbohydrates 
I stage - degradation of polymers to monomers, in-
cluding digestion of carbohydrates in gastrointestinal 
tract and lireakJown of glycogen in the cells of organs. 
II stage - specific pathway of glucose catabolism to 
pyn:vatc under aerobic condition and to lactate under 
' ana~ro i1i c condition. 
I 
HI stage - common pathways of catabolism: 
- oxidative decarhoxylation of pyruvate; 
- citric acid cycle. 
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Glucose catabolism under aerobic conditions 
1. Specific pathway of glucose catabolism to pyruvate 
(glycolysis ). 
2. Common pathways of catabolism: 
- oxidative decarboxylation of pyruvate to acetyl-
CoA; 
- oxidation of acetyl-CoA via citric acid cycle to C02 
and H20. 
3. Malate-oxaloacetate shuttle of NADH from cytop-
lasm to mitochondria. 
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Specific pathway of glucose catabolism 
Glycolysis takes place in all cells of the body in the cytoplasm. 
I. Glucose is phosphorylated to glucose 6-phosphate by hexoki-
nase (all the tissues) or glucokinase (in liver). This is an irrevers-
ible reaction, dependent on ATP and Mg1+ or Mn1+. Hexokinase 
has low Km= 10-5M (high substrate affinity) therefore acts even 
at low concentration of glucose and is inhibited by glucose 6-
phosphate. Glucokinase has high Km = Io-3M (low substrate af- I 
finity) therefore acts only at higher levels of glucose i.e., after a 
meal when blood glucose concentration is above I 00 mg/di and 
is not inhibited by glucose 6-phosphate. Glucose-6-phosphate is 
impermeable to the cell membrane; therefore it is a central mo-
lecule with a variety of metabolic pathways. I 
Glucose Glucose-6-phosphate 
2. Glucose-6-phosphate is converted to fructose-6-phosphate by 
phosphoglucose isomerase. This is a reversible reaction. 
Glucose -6-phosphate Fructose-6-phosphate 
181 
102 
I 
I 
I 
I 
3. Fructose-6-phosphate is phosphorylated to fructose-1,6-
bisphosphate by phosphofructokinase. This is an irreversible 
reaction, dependent on ATP and Mg2+ and a regulatory step in 
glycolysis. 
CH20P03H2 CH20H PtlOSphofructol.- ~ffi20P9Jfll CH20PO:JH2 
+ATP,Mr/'" 
u 
.Arif' 
H OH I OH 
00 H 
Fructose-6-phospbate Fructose-1,6-bispbosphate 
4. Aldolase splits fructose-1,6-bisphosphate glycolysis to two 
three-carbon compounds, glyceraldehyde-3-phosphate and dihy-
droxyacctone phosphate. 
I ~ ~OPOA I~ Ho ~ ~ 
00 H 
C--0 + H COO 
ffizoo ~ I 
I
I Fructose-1,6-bisphosphate - Dihydroxyacetone- Glyceraldehyde-
phosphate -3- phosphate 
5. Dihydroxyacetone phosphate formed can rapidly be converted 
to glyceraldchyde-3-phosphate by triose phosphate isomerase as 
glyceraldehyde-3-phosphate is used by the rest of glycolysis. 
Thus, for each molecule of fructose-1,6-bisphosphate that is 
cleaved, two molecules of glyceraldehyde 3-phosphate continue 
down the pathway. 
Tric:m Ji'lti!IJJ IE 
lsu1aase ~ C=O ~~~~~---
l Dih=acetone-phospbate 
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"c-° 
I 
HCOH 
I 
CH20P03"2 
Glyceraldehyde -
-3-phosphate 
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6. Glyceraldehyde-3-phosphate is converted to 1,3-
bisphosphoglycerate. The reaction is catalyzed by glyceralde-
hyde-3-phosphate dehydrogenase and uses Pi and NAD+. The 
other product is NADH2. The energy for creating this high- I 
energy phosphate bond comes from oxidation of the aldehyde 
group of the glyceraldehyde-3-phosphate. 
q 
'C-O~IOJli 
I 
2 H~OI 
~ I I 
Glyceraldehyde-3-phosphate 1,3-Bisphosphoglycerate I 
7. The newly created high-energy phosphate bond of 1,3-
bisphosphoglycerate is now used to synthesize ATP. Phosphog-
lycerate kinase catalyzes the transfer of the phosphoryl group 
from the 1,3-bisphosphoglycerate to ADP, generating ATP and 
3-phosphoglycerate. This step is example of substrate level 
phosphorylation. 
q 
C-O-fC¥12 
2 HCOH 
I 
CHi0~2 
1,3-Bisphosphoglycerate 
Phosphoglycerate 
Kinase 
+2ADP 
-2ATP 
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3-Pho•phoglymate I 
\Rl 
8. 3-Phosphoglycerate is converted to 2-phosphoglycerate by 
phosphoglycerate mutase. This is an isomerization reaction. 
Thus the reaction is a movement of the phosphate group to a 
different carbon atom within the same molecule. 
(OOH 
2 H C OH 
I ).,()[ 
3-Phusphoglycerate 
... 
COOH 
I 
2~-0-~ 
CffiOH 
2-phospboglycerate 
9. Enolase catalyzes the dehydration of 2-phosphoglycerate to 
I
, fo rm phosphoenolpyruvatt: (PEP). This reaction converts the 
low-energy phosphate ester bond of 2-phosphoglycerate into the 
I high-energy phosphate hond of PEP, dependent on Mn2+ or 
Mg2·. 
CXXIJ 
I 
2HC-O--~ 
I 
CHzOtl 
Eillase CDOH 
---........ 2C--o-PQA 
.. -HP ffiz 
2-Phosphoglycerate Phospboenolpyruvate 
I 0. Pyruvate kinase catalyzes the transfer of the phosphoryl 
group from PEP to ADP to form ATP and pyruvate. This step 
also is a substrate level phosphorylation. Pyruvate kinase re-
quires K ~ and either Mn2+ or Mg2+. Reaction is irreversible. 
-2AlP 
Phosphoenolpyruvate 
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<fOOH 
2 c=o 
I 
CH3 
Pyruvate 
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Energy yield of glucose catabolism 
under aerobic conditions 
1) Specific pathway of glucose catabolism to pyruvate (glycoly-
sis) in cytoplasm. 
Glucose -- 2 Pyruvate + 2 NADH2 + 2 ATP 1 
(4 ATP (by substrate-level-phosphorylation) - 2 ATP (used in i 
• I 1-st and 3-rd reactions). · 
2) Common pathways of catabolism in mito,;hondria. I 
- Oxidative decarboxylation of pyruvate: I 
2 Pyruvate-- 2AcetylCoA+2C02+2NADl-l2 (2 x3 "" 6 ATP) 
- Citric acid cycle: 2 Acetyl-CoA -- 4 CO~ -+ 2xJ NADH2 
(6x3= 18ATP)+2xl FADH2 (2x2=4ATP) + 2x l ATP. 
3) Malate-oxaloacetate shuttle of NADH2 from Cj1oplasm to mi- I 
tochondria: 2 NADH2 (2x3 = 6 ATP). I 
In summary = 38 ATP I 
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Malate-oxaloacetate shuttle of NADH2 from cytop-
lasm to mitochondria 
.\fa/ate 
Dthydrogellast Cytoplasm lllitocbondrion 
.lla/att 
COOHf + l'UDy;] COO} COOB D11r,.,1ro:mn" COOB 
I I I +NAD· I 
c =o HCOH IJ c 0 B ------- c =o I . I I I ~~ ~H Io~ b[ri.\Ji~ ) ~~ 
Oxalo:icetale 
01aloacelate l\lalale l\Ialate _:~~~~io::_J Al!] 
The NADH produced is reoxidized and the energy released is I 
used to synthesize 3 ATP by oxidative phosphorylation. 
'--~~~~~~~~~~~~~~~~~~~~~~~s~j 
106 
Anaerobic glycolysis 
1) Specific pathway of glucose catabolism to pyruvate (glycoly-
~is). 
2) Pyruvate is converted to lactate by lactate dehydrogenase. 
Reoxidation of NADH formed from oxidation of the glyce-
raldehyde-3-phosphate. 
CH3 I 
c=o 
I 
COOH 
L;.u:to,te 
~hy\lroi~n•w CB, 
I 
_+_ro;_AD_ H_ • _11_· - CBOH 
-N.-\D+ I 
COOR 
Pyruvate Lactate 
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Energy yield of glucose catabolism 
under anaerobic conditions 
Specific pathway of glucose catabolism to pyruvate (glyco-
lysis) in cytoplasm. 
Glucose 2 Pyruvate + 2 NADH 
+ 4 ATP (by substrate-level-phosphorylation) 
- 2 ATP (for phosphorylation in I and 3 reactions) 
2 Pyruvate 2 Lactate 
In summary = 2 ATP 
At glycogenolysis (anaerobic degradation of glycogen) one 
more ATP is generated. This is because no ATP is consumed for 
the activation of glucose (glycogen directly produces glucose-1-
phosphate which forms glucose-6-phosphate). Thus, 3 ATP are I produced from glycogen deg,-adation. 
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All tissues may be divided into 3 groups accord-1 
ing to a role of glucose oxidation: 
I. Anaerobic glycolysis is a major pathway for ATP synthesis in i 
tissues with few or no mitochondria, such as the medulla of 
the kidney, mature erythrocytes, leukocytes, and cells of the 
lens, cornea, and testes. The occurrenr;e of uninkrrnpt~d gly-1 
colysis is very essential in skeletal muscle during strenuous 
intensive short-term exercise where oxygen supply is very li- 1' 
mited. 
2. Aerobic glycolysis is very essential for brain. retina. skin, ! 
renal medulla and gastrointestinal tract which are denendent j 
on glucose for energy. I 
3. ~eu~o~lial_ cells, hepatocytes, lipocytes. These cells synthes-1 
tze hp1ds if necessary. Therefore products of glucose ox1da-1· 
tion usually are used to synthesize fatly acids and glycerol. 
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Alcoholic fermentation 
·---, 
In yeast and some other microorganisms under anaerobic 
conditions, pyruvate fom1ed from glucose is transformed into 
ethanol and C02, a process called alcoholic fermentation . 
?' 
c=o 
I COOH 
PjTlll'tlle 
decarboxyla.ve 
+TDP 
. llcolwl 
de/11 ·dr11ge11t1.'e Cl\ . 
I _,. ___ ~fl\ 
C::O + NADH+H' Cit.OH I o· .oz 
H 
~-P_,_··_~_,·_at_e _______ A_ce-t-al-d-el_~_·d_e-----~ E<h•nol
0 
I 
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Metabolism of ethanol 
1. Ethanol is detoxified by the cytoplasmic alcohol dehy-
drogenase (ADH). The normal function of ADH is the oxidation 
of the small amounts of various alcohols produced by microbial 
fermentation processes that occur within the intestine. 
II 
I 
CH20H 
E tha n• I 
-Vcu/10/ 
J>elryJrogenas<! 
' NAD• 
---------~-
" DH+H• 
CB I 3 
c=o 
I 
0 Acetnl<lehyde 
I 2. \\-hen the rnncent rat ion of ethanol in hepatocytes be-
! comes high, it is also detoxified by the microsomal ethanol-
I 
I 
oxidizing .\J'Sfem (.M EOS). 
.\/EUS 
+ K \VPH+tt·+-02 
.. 
N,-\DI-'' 
CH3 I 
c=o +2 H 20 I 
H . 
3. Less important mechanism for ethanol detoxification in-
volves catalase, an enzyme found within peroxisomes. 
CH I 3 
CB20H 
Cntnlttse 
+ H202 
CB3 
I 
C=O +2 H 20 I 
B 
Acetaldehyde is converted to acetate by aldehyde dehy-
drogenase which is located within the mitochondrial matrix. 
Acetate is metabolized in other tissues, such as cardiac and ske-
letal muscles. 
J>e'1J·drog1..~1uu·e 
+ NAD ' 
N.\.I>H+H· 
+ HSCo.A+ATP 
CD3 I 
COOR 
. .\..cet.•te 
C H 1 
-""''I---....... ·- I -:::;.O 
Al\lP PPi C- SJ:,'oA 
Acet;o.-ICoA 
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Gluconeogenesis 
Gluconeogenesis is glucose biosynthesis from noncarbohydrate 
precursors in the liver and kidneys. 
I. During starvation the formation of glucose particularly uses amino ac-
ids produced by the protein breakdown and glycerol by fat break-
down. 
2. During exercise the blood glucose levels required for brain and skelet-
al muscle function are maintained by gluconeogenesis using lactate 
produced by the glycolysis and glycerol by fat breakdmvn. 
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Glucose biosynthesis fro:;actate--1 
Gluconeogenesis resembles the reversed pathway of glycolysis. The 7 
(out of 10) reactions are common for both glycolysis and gluconeogene-
sis. Essentially, 3 reactions of glycolysis are irreversible catalyzed by the 
enzymes, namely hexokinase, phosphofrnctokinase and pyruvate kinast!. 
These three steps have to be reversed in gluconeogenesis by using other 
enzymes: 
l. Conversion of pyruvate to phosphoenolpyruvate: Lactate is con-
verted to pyruvate by the lactate dehydrogenase in cytoplasm. Pyruvate 
formed is transported into the mitochondria and converted to oxaloacetatc 
using the enzyme pyruvate carboxvlase that is located in the mitochondri-
al matrix. Since the inner mitochondrial membrane is impermeable to 
oxaloacetate, it is converted to malate inside the mitochondria by mito-
chondrial ma/ate dehydrogenase. The malate is transported through the 
mitochondrial membrane and then converted back to oxaloacetate in the 
cytosol by cytoplasmic ma/ate dehydrogenase. The oxaloacetate is acted 
on by ohofohoenolvvruvate carboxvkinase which converts it to phos-
phoenolpyruvate. 
2. Conversion of fructose 1,6-bisphosphate to fructose-6-phospbate: 
Phosphoenolpyruvate undergoes the reversal of glycolysis until fructose-
1,6-bisphosphate is produced. The enzyme fructose-1.6-bisohosohatase 
converts fructose- 1 ,6-bisphosphate to fructose-6-phosphate. 
3. Conversion of glucose-6-phosphate to glucose: G/ucose-6-
Dhosphatase catalyses the conversion of glucose-6-phosphate to glucose. 
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I Conversion of pyruvate to phosphoenolpy~vate 
CH 3 Lactate CH 3 I Dchydrogenase I 
CHOH +NAD+ c=o 
I -.. I 
COOH - NADH + u+ COOH 
Lactate Pyruvate 
cytoplasm mitochondrion 
mitochondrioo 
cytosol 
PyrU\'&te COOH 
CH3 Carboxylase I I +col + ATP c=o 
c=o ---- I 
I ADP-Pi CH2 
COOH I 
COOH 
Pyru' ate Oxaloacetate 
Ma late 
Debydrogeoase 
COOH COOE 
Ma late COOH Dehydrogeoase I 
+NADH+B+ CH2 
\ • I HC-OH 
AD• I 
COOH 
'.Vlalate 
Pbospboenol 
pyruvate 
Carboxykioase rJ.f_ Cllz +SAD+ CJ\ 
I I 
HC-OH C'=O 
+GIP iru:z 
----· ~-0-PO.Jlli 
I - 'ADU+H' I 
COOH COOE 
COOH 
-GDP-C01 
Malate Oxaloacetate Pbospboeoolpyruvate 
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Cori cycle 
LIVER MUSCLE 
~ Gjucose 
t ~ 
GkJconeogenesis i 
t 
t G'ycotysis 
t ~ 
Pyruva\e BLOOD I Pyruva\q I I I NA:>t1 • ..,. , """' t NAl>h H' "'"' r I dehpoger.ase dehydrogenase 
NAO. NAO• 
I 
I 
' ''"a'e I Lactate L..C'.'l ...... ' 
L___._ I '-----------------·--~-5 _I 
- - - ------i 
Pasteur effect - inhibition of anaerobic glycolysis by I 
oxygen (aerobic condition) 
Mechanism of effect: 
1. In the aerobic condition, the levels of glycolytic interme-
diates from fructose-1,6-bisphosphate onwards decrease 
while the earlier intermediates accumulate. This clearly indi-
cates that Pasteur effect is due to the inhibition of the enzyme 
phosphofructokinase. · 
2. The inhibitory effect of citrate and ATP (produced m the I 
presence of oxygen) on phosphofructokinme explains the 
Pasteur effect. I 
~ 
11 2 
Reciprocal regulation of glycolysis and gluconeogenesis 
If glycolysis and gluconeogenesis operated simultaneously, the 
net effect would be a futile cycle resulting in the hydrolysis of two ATP 
and two GTP molecules. 
This is prevented by reciprocal regulation at the enzyme steps that 
are distinct in each pathway. AMP activates phosphofructokinase (glyco-
lysis) but inhibits ji-uctose-1,6-hisphosphatase (gluconeogenesis). ATP 
and citrate inh ibit phosphofructokinase but citrate stimulates fructose-
/ , O-bisµJ, GiphafL ~S :' . 
! 1 hus gl) cu lysis is inr.ibitcd in times when ATP and biosyn-
1 tb et1c mknw-,1i.itt:s arc in excess whilst gluconeogenesis is inhibited in 
te~ v. i1cn the A i P lc·;cl b low. 197 
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Pentose phosphate pathway 
Patlmay takes place in the cytosol and is particularly important in 
tissues such as liver, adipose tissue, adrenal gland, erythrocytes, testes and 
lactating mammary gland. Most of these tissues are involved in the bio-
synthesis of fatty acids and steroids which are dependent on the supply of 
I NADPH. 'I he sequence of reactions of pentose phosphate pathway is divided 
! into two phases-oxidative and non-oxidative. 
I 
A. Oxidative phase: Pentoses formation includes 2 dehydrogena-
tion reactions. The coenzyme of dehydrogenases is NADP+, which is re-
i duced to NADPH~ . Pentoses are formed as a result of oxidative decarbox-
1 
ylation reactions. 
B. Non-oxidative phase: The non-oxidative reactions are con-
cerned with the interconversion of three, four, five and seven carbon mo-
nosaccharides Hexoses are converted into pentoses, the most important 
being ribose-5-phosphate. 
The overall reaction may be represented as: 
6 Glucosc-6-phosphate + 12 NADP- + 6 H20 
--- 5 Glucose-6-phosphate + 6 C02 + 12 NADPH + 12 H'". 
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Pentose phosphate pathway 
Enzymes ---- - , 
tion reaction. 
Glucose-6-phosphate 
dehydrogenase 
2. Lactonase 
3. 6-phosphogluconme 
dchydrogenase 
Non-oxidative phase of pentoses for- ; j 
II mation: I 
Overall reaction: 1 
5 Fructose-6-phosphate B 5 Ribose-5- 1 / . Transketolase j 
phosphate 2. Transa/do/ase I I 
Non-oxidative phase includes intercon- 3 Transketo/ase 
I version of three, four, five and seven car- , ./. Phosphopentose I I 
boo mono•occl>ruidos. J _ ;"'-~'-°"'--- ~- ;.,- j 
Functions of pentose phosphate pathw=~--1 
The two major products of the pathway are reduced nicotinamide ade- 1
1 
nine dinucleotide phosphate (NADPH2) and ribose-5-phosphate. 
I . NADPH is required for the reductive biosynthesis of fatty acids, cho-1 
lesterol and certain amino acids. 
2. Ribose-5-phosphate or its derivatives are useful for the synthesis of 'I 
nucleic acids (RNA and DNA) and many nucleotides such as ATP, 
NAD+, FAD and CoA. 
3. Microsomal cytochrome P450 system (in liver) brings about the de-
toxification of drugs and xenobiotics by reactions involving NADPH. 
4. lnterconversions ofmonosaccharides from C3 to C7• 
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Oxidative reactions of 
pentose phosphate pathway 
OH Glucose-6-phosphate <;? 
H\ ; Dehvdrogenase . y~ Lactonase COOH 
6 Hc-oul + 6 NADP' 6 HC-OH + 6 H 0 I I 2 
- I 
6 HC-OH 
I 
HO-CH 0 HO-CH 0 --- HO-CH -I 
HC-mII -61'iAl>PH + w HC-OHI I , I 
UC--' HC 
HC-OH 
I 
HC-OH 
I I 
CH20P03H2 CH20P03H2 
I 
CH20POj112 
Glucose-6-phosphate 
6-phosphogluconate 
Jehydrogenase 
+ 6 NADP' 
6-Phosphoglucono- 6-Phosphogluconate 
-0-lactone 
H //0 
ls om erase H~-OH 
6 1 
H 20H __-::::::::=- ut- ou Ribose--S-
c=o :;:::::::;--- 2 I phosphate 
-,,,.-~--- --- Ht-ou ~ HC-OH 
6 NADPH + H' 6 C02 u t-OH ~pimerase tu20P03H2 
t H20P03H2 ~ + ~ CH20H 
Ribulose-5-phosphate 
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I 
c=o 
I 4 HO-CH 
I 
HC-OH 
I 
Xylulose--5-
phosphate 
CH20P03H2 
Non-oxidative reactions of 
pentose phosphate pathway 
,----,JI 0 
CH20H y Transketolase I . I 2 ~=<>j HC-OH + TDP 
u1 · + 2 I 
CH20lf 
2 t=o l __ 11 , /p 
I C 
HO-CH j I ----
._,,o-?I HC-OH 
HC-OH I 
I HC-OH 
--1-- - -+ 2 HC-OH 
H~:-on ~ H20P0 1"2 
CH20P03H2 I 
CH20P03H2 Xylulose-5-phosphate 
H~·-011 G lyceraldeh)des-
HC-OH 3- ph'lsphate 
Ribose-5-phosphatc 
I 
CH2<W03H2 
Transaldolase 
2 
H, -/0 
c 
! 
Sedoheptulos~-7-
phosphate 
HC-OH 
i 
HC-OH 
I 
CHzOl'O:JH~ 
Frudose-4-pbosphak Er)·throse-4-phosphatc 
1 P\OH Cl\O !\ /.0 Transketolsse , •1 0 I ---....: c' c=o ' " '/ 2 
f=O J I + TDP 2 , C !J~tH + 2 Hf-OH _ ___ _ llO-~ II + 2 H~-011 
ut-ou HC-OH u~ :-OH "·~Offi:il lz 
t l\OIO:iffi tl\OR>.JHz up-011 Gl~·cc ralilehvdes-
CJl-Oin..Hz -J-1ihospbate 
Erythrose-- 4- phosphate 'Z • '-'3 
Xylulose-S-phosphate Fruct1••t-r.-phosphatc 
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Metabolism of glycogen 
Importance of glycogen «branching» 
I. The glycogen molecule branches like a tree and has many 
nonreducing ends at which addition and release of glucose 
re ~,i d ue s occ ur dming synthesis and degradation, respective-
ly. 
2. Brnnc!•ing improves solubility of glycogen. 
The cell is not capable to deposit free glucose 
for following reasons: 
I. Glycogen is high-molecu lar substance and, unlike glucose, 
influences osmot ic pressure in a cell not very much. Accu-
mulation of free glucose would lead to increase of osmotic 
pressure and, as result, to edema of a cell. 
2. G ly~~ogen is more stable molecule than glucose. 
I 
u - 1 . -'~lyc~ldk bonds 
I _______ _ 203 
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Glycogen synthesis 
The two main storage sites of glycogen are the liver and ske-
letal muscle. 
Glycogen synthesis consists of 3 stages: 
1. Formation of the UDP-glucose. 
Hexokinase Cll,OPO 11 , 
. J--. 3 - l' ' 1 e 
_':_ATP ~- ':'__ 
-ADP OH I OH 
Glucose 
CH20H 
I OH 
Glucose -6-phosphate 
UDP-glucose 
p;•rophosphorylase 
+UTP Mutase .. ~~~~i 
6~ OP03H2 - H4P20 7 
OH I +H20 
---·----
Glucose-I-phosphate 2 H PO 
CH20H ~ 3 4 ro, I HN I 
--+ .,;i OH OH l I 
o o-fi-o-fi-okf.--8"--J,,, 
OH O 0 1 r-i':'_I 
. UDP- glucose OH OH 
(active form of glucose) 
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Glycogen synthesis 
2. Glycogen synthesis by glycogen synthase: Glycogen syn-
thase now transfers the glucosyl-residue from UDP-glucose to 
the C4-0H group at the nonreducing end of a glycogen mole-
cule, forming an a-1,4-glycosidic bond. 
+.UDP 
0 
3. Formation of branches in glycogen: After a number of glu-
cose units (usually about 1 1) have been joined as a chain with a- . 
1,4-linkages, branching enzyme breaks one of the a-1,4- glyco-1 
sidic bonds and transfers a block of residues (usually about 7) to 
1 
a more interior site in the glycogen molecule, reattaching these 
by creating~ j 
c.- 1 12 C1 . 
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Glycogen degradation is in 2 ways~ 
egradation of glycogen occurs by acid ma/lase or a-1,4-
glucosidase that is a lysosomal enzyme. This enzyme conti-
nuously degrades a small quantity of glycogen to free glucose 
molecules. 
2. Phosphorolysis: The a-1,4-glycosidic bonds (from the non-
reducing ends) are cleaved sequentially by the enzyme glycogen 
phosphorylase to yield glucose-I-phosphate. 
l CH20H -, CII20H 
I ~o. + H3Po, Phosphorytme k'r0 ""'-. I + 
-O oo I ~l J OH r-J .. O-P03H2 1 on o OH 
Glycogen Glucose-1-phosphate 
[ ~~ J + +~O
OH n-1 
Glycogen (n-1) 
Glucose-1-phospha te Glucose-6-phosphate Glucose 
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Mechanism of glycogen degradation 
1. Glycogen phosphorylase removes glucose units (that are 
more than fi\ e residues from a branchpoint) sequentially from 
I 
the nonreducing ends of a glycogen molecule, forming glucose-
1-phosphate and continues until four glucose residues remain on 
I either side of branching point ( a-1,6-glycosidic bond). 
I 
2. Oligo-a-1,4-+l,6-glucantransferase removes a frag-
ment of three glucose residues attached at a branch and transfers 
them to another chain. 
3. Debranching enzyme or amylo-a-1,6-glucosidase breaks 
the LX-1 .6-glycosidic bond at the branch with a single glucose re-
sidu~ and releases a free glucose. 
Glurose 
Glucose-1-
phosphate 
'-! 
Glycogen phos-
phorylase 
- - - Glycogen phosphorylase 
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The characteristics of the enzymes participating i-:1 
regulation of glycogen metabolism I 
1. Protein kinase A consists of two regulatory subunits (R) and I 
two catalytic subunits (C), making a complex R2C2 that is 
normally inactive. The binding of two molecules of cAMP to 
each of the R subunits leads to dissociation of the complex 
into a 2R complex and 2C subunits that are now catalytically 
active. Ca2~ ions activate protein kinase in muscle. 
2. Phosphorylase splits glycogen. Phosphorylase exists in 1 
phosphorylated active "a" form (tetramer) and dephosphory-
lated inactive "b" form (dimer). Phosphorylase ''b" is con-
verted into phosphorylase "a" by phosphorylaticm by the en- 11 
zyme phosphorylase kinase. Phosphorylase kinase in turn is 
activated by protein kinase A. The process can be reversed I 
and phosphorylase "a" inactivated by removal of the phos-
1 phate group by protein phosphatase. 
3. Glycogen synthase synthesizes glycogen, forming an a-1,4-
glycosidic bond. Glycogen synthase exists as dephosphory-
lated active glycogen synthase "a" (tetramer) and phospho-
rylated inactive glycogen synthase "b" (tetramer). Glycogen 
synthase "a" is converted into glycogen synthase "b" by 
phosphorylation by the enzyme protein kinase A. The I 
process can be reversed and glycogen synthase ''a" activated 
by removal of the phosphate group by protein phosphatase. 
4. Adenylate cyclase converts ATP to 3'5' cyclic AMP (cAMP) 
(activated by epinephrine and glucagon, inhibited by insulin). 
5. Phosphodiesterase acts on cAMP which is converted to 
5'AMP (activated by insulin). 
208 
122 
Scheme of regulation of glycogen synthesis and de-
gradation in muscle and liver 
i\erve impulse 
l 
release Gf ('a !~ 
Insulin 
Phosphodiesterase I@ Epinephrine <D Glucagon Qlnsulin 
Adenylate 
"' (Phosphor~ hhe kinase I 0 
E I \ 3'5'c.\l\fP 
.f; -H,ro~ , -rATP 1 
~ PROTEIN KINASE 
c 
C:: Phosphoryl:ist kinase \ 
cyclase ATP 
+.I.UP, lg!· GI 1 +4ATP Mg2+ ~ r-ph~::;1:1-te-~Gly~gen 
Phosphorylase Phosphorylase l'np 1 s~nthase sn1thase 
\ 
·u -a ucose · • b a "' I D ~ Glycogen/ ~
Protein phosphatase Protein phosphatase 
LI 209 
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Features of glycogen degradation in liver and muscle 
Liver Muscle 
- - -- - · ----- - - - - - -1 
Th·- :• rocess 
II scheme 
11 
Glycogen 
J. 
G lucose-1-phosphate 
Glycogen 
-1. 
Glucose- I-phosphate 
l '' c" 
i 
J. 
G lucose-6-phosphate 
..!-H3P04 
Glucose 
J, 
into the bloodstream ; 
-1. 
Glucose-6-phosphate 
-1. 
Aerobic or anaerobic 
glycolysis 
- --- ----- --+--- ---·- --- - -
1 -,·er contains the en- · Muscle does not con-
L~ rne glucose-6-
piw sphatase, which 
. or1verts the glucose-
6-ph . 1sphate to glu-
tain glucost.:-6-
phosphatase 
_ 1_ co2 e _ ___ --~- ----- · --- ___ _ 
• • · • , l !_. ,,_~ose-6-phosohate 
1t\·crts to glucose, 
.. ;; i1..h then diffuses 
u ...i L into the blood-
st:-eam and so main-
t:- ins the blood glu-
cose concentration. It 
enables the blood glu-
cose level to be main-
tained between meals 
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In muscle the main 
aim is to produce 
energy quickly and so 
the i?:lucose-6-
phosphate is metabo-
lized via glycolysis 
and is oxidized to yield ' 
energy for muscle con-
traction 
2 10 
vcogenosises - glycogen storage diseases caused by in- ! 
ited defects of one or more enzymes involved in glyco 
gen synthesis or degradation 
I 
I 
------;-- - - 1 -0-,.gans T Deficiency of ·I S t ! 
___ !!~_J_J!!yofred / enzym~ ymp oms 1 I 
IT (E. von I Liver I Glucose-6-~ypoglycemia. 1 
J Gierke's I I phosphatase I j;~toacidosis, I 
~j~eas~----- __ I - ----k----__J_ hepatomegaly __ _ J 
I II (l.C. I Heart. I Lysosomal(l ,4) I Muscular , , 
i Pompe's dis- I Liver, I glycosidase I weakness, heart 
I eas~) _ _ __ __lMus~_J_ ____ -~~!1rophy__ -1 
, 1II (Cori' .s I Liver, 
1
1 Debranching JjHypoglycernia, 1 1 ~~as~--- . Muscle ___ en~e _ __ _ h__9 •atomega1y 
I IV l Liver I Branching en- ,. Hypoglyct " an. (Anderson's : zyme hepatomeg.,:: ~sease) I --h tr 
Iv (B. Mac / Muscle I Phosphorylase Cirrh0sis. mi' 
I Ardle's dis- i I cular c ..... liaust1c11 
I ease) I : after loading 
~(Her;,- - : Liver I PhosPhorylas~+w.;:i~!~i~1~ 
ldisea~L _ _l _____________ I ____ _ __ ' 1 
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Metabolism of fructose 
1. In liver fructose is metabolized by the fructose- I -phosphate 
pathway. 
Fructou 
<(H20H 
C=O 
I 
+ 
CH20P03"2 
Fruclo••-1-p~osphat• 
HO 
Trios~ k;mue c I 
~Ollj 
CllzOH +ATP 
Dlh•·dro:<•·ac•lon• j\ 
pho~phat~ j '\ Gl)·ceraldeb)·de Gl)·<•r~ld•b)·d•-3-phosph•t• 
Gluconeo- Gl~·rol~·"is under aerobic 
and anaerobic conditions 
2. In muscle and adipose tissue, fructose can be phosphorylated 
by hexokinase to form fructose-6-phosphate, which then enters 
glycolysis. 
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Defects in fructose metabolism 
Fructokinase Aldolase 
Fructose Fructose-I-phosphate 
1 2 
1. Essential fructosuria. Due to the deficiency of the enzyme he-
patic fructokinase, fructose is not converted to fructose-I-phosphate. This 
is an asymptomatic condition with excretion of fructose in urine. Treat-
ment involves the restriction of dietary fructose. 
2. Hereditary fructose intolerance. This is due to the absence of 
the enzyme aldolase. Hereditary fructose intolerance causes intracellular 
accumulation of fructose-I-phosphate, severe hypoglycemia, vomiting, 
hepatic failure and jaundice. Fructose- I-phosphate inhibits liver glycogen 
phosphorylase and blocks glycogen degradation leading to hypoglycemia. 
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Metabolism of galactose 
O ! 011 .\ T p : 11,r,11 
OU ,.._:__C •' OfVf - -fl. !I 
'· .. JlH 'i , -- - . - - < Hu 11 
!I '·-·--· ' l \ I IF' I 1----" \ll'I , Cl • 
II <HI M (Ill 
Galactose-1-
phosphate 
uridylyl 
CH20H transferase 
II ~0, H 
k - ~H H .'::I 9 0 c'_,~6;:-<>H ~ 
H OH 0 HN 1 
Galan•fe Ga!acto . .:-1 ·phosphate Ob~-CH2 od...__ Ji 
Cfl10H 
oJJ!.---o 11 
K Hu 11 ... ...: <? 
__ 1'1 ~ O-P- OH 
II OH 9 
0 )( __ 
HN II o=( / 
O=P-O-C~H, O fJH --
UDP-galactose H ; H 
I 
OH IT 
UDP-galactose-
• 4-cpuncrase. 
UDP-glucose 
I I 
OH 0 
UDP-glucose 
~P~H, 
+ A OH 
Glucose- I -phosphate 
I 
Phosphogluco-
rnutase 
G lucose-6-phosphate 
I 
Glycolysis 
Galactose m~·tabolism is impaired leading to increased galactose levels in 
circulation (galactosemia) and urine (galactosuria). Galactosemia is due to 
the deficiency of the enzyme galactose-1-plwsphate uridyltransferase. It 
is a rare congenital disease in infants, inherited as an autosomal recessive 
disorder. The clinical symptoms of galactosemia are loss of weight (in in-
fants) , mental retardation, cataract, hepatosplenomegaly etc. The accumu-
lation of galactose-1-phosphate in various tissues like liver, nervous tis-
sue, lens and kidney leads to impairment in their function. The therapy 
includes the supply of diet deprived of galactose and lactose. 
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Metabolism of lipids. 
Eicosanoids 
215 
Lipids are biological substances that are insoluble in water 
but soluble in organic solvents such as chloroform and me-
thanol. 
Functions of lipids: 
1. Food material. Lipids are source of energy which is stored 
in the adipose tissues. lg oflipid produces 9.3 kcal of heat. 
2. Structural component. Lipids are an important constitu-
ent of the cell membrane. 
3. Heat Insulation. Lipids are characterized for their high in-
sulating capacity. 
4. Hormone synthesis. The sex hormones, adrenocorticoids, 
vitamin D are all synthesized from cholesterol. 
5. Vitamin carriers. Lipids act as carriers of fat-soluble vi-
tamins such as vitamin A, D and E. 
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Biosynthesis of eicosanoids 
Epinephrine, I Membnm;.-sj 
hrad)·kinin. 1 
rhromhin. . osp~~pids I 
an::!iotensin. "'-. \ 
lipuperoxidt"s(+> Plwspfw- ''-
• lipauA2 
I Di~ta~~· linoll.'k -acidl 
~Meat, Jh-~-12.__J 
1· 
- \ · I ----- -, 
Gluc0t·; rticoids L Arac~ydonate I 
~-!_ CJ'dooxy- / Lipo>.yge11ase 
Aspirm ge11a.<e rf' 
- ·--- ----- - -1 J~ostaglandin H2 i 
/ \\ 
r't __ ,_J _ __ ~·'i;:\ 
~ I Other 1 ·~----~I 1 Prostacwlins l. 1 1. i Thl"Omboxanes , -- ----·-- prnstag anc ms __J 
---------- -·-
217 
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Ar8ctlldonlc acid 
OH 
~ 
The structures of arachidonic acid and prostaglandin PGE2 
218 
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Biochemical actions of prostagl~ 
Arachidonic acid 
Cyclooxy- / 
ge11ase-l / 
Cycfooxy-
ge11ase-2 
Prostaglandins -
membet"s of ph~·siologirnl 
Pt"ostaghmdins -
members of inflammator~· 
pt"ocesses processes 
I •lowering of blood pressure (PG-E, PG-A);--1 I PG El -IPC E.,-, 
I 
•inhibition of gastric HCI secretion (PG-E); I~_ am ·:..=_'.'.._i 
•decrease in immunological response (PG-E); I 
•induction of labor (PG-E2 and PG-Fl); I 
•platelet aggregation: promotion b~· PG-El and 1 
thromboxanA2, inhibition by prostacyclins 12; 
I •promotion of fever and pain (PG-E2); 
1 ·PG-Eis a bronchodilator, PG-Fis a constrictor 
I 
of bronchial smooth muscles; 
•increasing ofglomerular filtration nte (PG-E) 
219 
~--------------------- ------
I 11. Stimu Ian ts of allergic -r~:tion:. - - ---
' 
I 2. Implicated in :isthma. inflammatory reac- 1 
Leukotrienes / tions, hypersensitivity (allergy) and heart I 
attacks. 
13, Cause contraction of smooth muscles, J 
I bronchoconstriction, and vasoconstriction, I L I adhesion of \vhite blood cells and release I of l)'Sosomal enzvmes. I • I 
_ __J_ ·----- --- - - -
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Dietary lipids and digestion 
Food lipids Hydrolase 
enzymes 
I 
Triacylglycerols ': Pancreatic lipase, 
lingual and gastric 
Ii pases 
I Phosph-;;-lipid" ·r Phospholipases 
I ! A,, A2 , c. D. 
.::sters I 
Products of digestion 
Glycerol, fatty acids, 
mono- and diacylglycerols 
Fatty acids, glycerol, 
mono- and diacylglycerols, 
H3P04, alcohols (choline, 
ethanolamine, glycerol, 
inositol or serine) 
Fatty acids, cholesterol l Cholesterc.11 . l(.-.: i ioles;~I esterase - --- _ __ . _j _ ________ ---~----------~ 
221 
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,------ - Hydrolysis of phospholipids 
Pho"Phohpaoe A\ y 
H2C-O-C-R1 
0 
HC-o-!-R2 
" 
Q Phosphohpase A2 
II 
H2C-0-P-O-X 
Ph••ph•lip•Z 6- ~•ph•"'"" n 
222 
··--- ------------------' 
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Absorption of lipid digestion products 
I Hydrophilic products: I Hydrophobic product;;'i 
;;.. Glycerol 
;;.. Fatty acids (C<12) 
;;.. Choline 
;;.. Serine 
)l> Ethanolamine 
Cholesterol 
Fatty acids (C>12) 
Mono - and 
diacylglycerols 
Bile acids . ;i 
Micelles 
r1 
.J ..._ D Enterocytes 
223 
Role of bile acids in lipid digestion ----1 
1. Emulsification of dietary lipids. 
2. Incr~ase the effectiveness of pancreatic lipases. 
3. Make PH optimum for lipase action. 
4. Promote micelle formation for absorption of hy-1 
I 
drophobic products of lipid digestion. I 
224 
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-Li po proteins 
, p proteins are globular particles consisting of: 
I 
I 
i 
I 
I 
1. Hydrophobic core of triacylglycerols and cholesterol 
esters. 
2. Amphipathic coat of protein, phospholipid and free 
cholesterol. 
The protein components of lipoproteins are called apo-
lipoproteins (or apoproteins ). 
Lipoproteins function as transport vehicles for lipids in 
blood plasma. 
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Structure of lipoprotein 
Pbo•pholipid 
226 
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Characteristics of lipoproteins (LP) 
Chylo- i Largest LP. Synthesi-zed by M , 
microns CM 1 gut after a meal. Main carrier B-48, 
(CM) of die~~ tri~_y_!g~er~ls _ _ C-11, E _j 
Sy~thesized in the liver. B-l 00 i 
YLDLs pre-j3-LP Mam earner of '!ndogenous!y , C-ll E . 
roduced_tnacx !_gl)cero!?_ -r-- ··  -I 
I Formed from VLDL in the ---i LDLs 13-LP ~irculation Main carrier of , B-100 I 
cholesterol I , 
- - Sm-;llest LP. - Takes ~h~les- : ~~~ A-;-! HD P terol from extraht:pr:tic tis- ; 1: E . , L_ _ __ _ __ sues_to th t:__U_y_er for ~xcre!i_o!_l _ _ · '~ --
227 
~------------------- ----- - ---- -
Lipid transpor~-- -, 
228 
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I 
I 
Fatty acid oxidation consists of 3 stages: 
1. Activation of fatty acids and transport into mitochondria; 
2. P-Oxidation pathway; 
3. Acetyl-CoA oxidation via the citric acid cycle. 
229 
I --- ---------· 
I Activation of fatty acid in the cytosol 
'° ?i R-COOH+ATP- R- - O- P- O 
Fatty acid iY 
Acyladenylate 
Acy I CoA synthase 
+HSCoA 
.9 
R-C-S CoA +AMP 
Acyl CoA 230 
--- - -------------·------------·----" 
~ransport of acyl CoA into mitochondria 
lntei-1n.,mbro1J1~ 
spnc• 
Innermitochondrinlmembrane 
..\~ylCoA f Carnitine 
Wi C o..\ ~ _;c)·lrnrnlUne 
<!) Carnitine J~)·Uransf~n1se l 
(D C'arnitin1: a"·yltr.an .. fe r :ise II 
Carnitine 
A~lcur11lllne 
Matrix 
...._~ AcylCoA 
~HSCoA 
231 
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fl-Oxidation pathway 
0 
// 
R-CH2-CH2-CH2-C- SCoA Acyl CoA 
Acyl CoA dehyd•ogenase l -FADH, 
+FAD H 0 
I II 
R-CUi-C- C- C- SCoA Enovl CoA 
I 
H 
Enoyl CoA hydratase 
OH H 0 
I I // 
R-CH -c-c-c~ SCoA 2 I I H H 
Hydroxyacyl-
CoA 
I 
I 
Hydroxyacyl CoA dehydrogena1e ! 
+ NAO - NADH1 I 
o o I 
II II I R-CH2- C-CH2-C-SK0A 
11 3-Ketoacyl CoA 
P·Ketothiolase I 
+ HSCoA I 
0 0 
II • II I 
R-CH2-c--SKoA+ CH3-C- SKoA 1 
Acyl CoA Acetyl CoA I 
_d 
136 
,-
1 
I 
Calculation of the ATP yield of 
fatty acid oxidation: 
[5 · (n/2-1) + n/2 · 12) - 1, where 
I • 5 - number of ATP produced by oxidation of NADH (3 ATP) 
I and FADH2 (2 ATP) in each round of oxidation; • I n/2-1) - number of oxidation rounds; 
1
1 
• n/2 - number of acetyl CoA; 
I 
, • 12 - number of ATP produced by acetyl CoA oxidation in the 
citric acid cycle; 
• number of ATP used for the fatty acid activation. 
233 I __ _ ___ . 
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' Fatty acids oxidation 
I l1aYing an odd number of carbon atoms 
i 
I 
I Propionyl-CoA 
0 
It 
Propionyl-CoA carboxylase 
+ C02 +ATP+ Biotin 
-ADP -Pi 
--~cHr<fH-C- SCoA 
Mutase 
Vit 8 12 
COOH 
I MethylmalonylCoA 0 
I --~HOOC-CH2-CH2-~-SC0A-+ CAC 
SuccinylCoA L 234 
---------' 
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Glycerol oxidation 
Sources of glycerol: 
I) Dietary triacylglycerols (Tg) hydrolysis by pancreatic li-
pase. 
2) Tg hydrolysis in chylomicrons and VLDL by lipoprotein I 
lipase in capillaries of adipose tissue and muscle. 
3) Tg hydrolysis in IDL by hepatic TG lipase in blood stream. ! 
4) Tg hydrolysis in adipose tissue by i111race/11~<~~:·'es. 
235 
i 
Energy yield of glycerol oxidation 
to C02 and H20 
I. Glycerol activation -1 ATP 
2. G/ycerolphosphate gehydrogenase -2 ATP 
3. Catabolism of glyceraldehyde-3-pho.,phatc to pyruvate: 
Substrate-level-phosphorylation 
NADH + H+ malate-oxaloacetate shuttle 
4. Oxidative decarboxylation of pyruvate 
5. AcetylCoA oxidation via CAC 
~2ATP 
+ 3ATP 
+ 3 ATP 
+ 12 ATP 
In summary: 21 ATP 
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I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
l 
I 
I 
Glycerol oxidation 
Intestine, kidney, liver 
<Flycerol 
CII20H kin"·' ·: 
I + ATP 
CHOH - ----
! · A DP 
ClbC H 
C H20H 
I 
CHOH 
I 
CH20POlH2 tt-
Cl~c~1ol G lyccl'Ol-3-phosph ntt' 
2. l\.litochondrion 
Glycerolphosphate 
gehycJrogenase 
CH20H +FAD 
I ---------~ CHOR 
phospha te 
- FADH2 j+ Oz 
1+ 2ADP 
/+ HJPO~ 
I 
Dihydro:i:y11cetonl' 
phosphntt' 
FAD+ 2ATP+ H20 
3. Cytosol 
Trloso phosphate H-C=O CHzOH I 
c - o 
isomerase I 
--------u--- C- OH 
I 
CH.zOP~ 
Dihydroxyacetone 
phosphate 
I 
CllzOP~ 
Glyceraldehyde-
3-phosphate 
L _______________________ 2_3_7 ..... 
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Control of lipolysis in adipose tissue 
I Ad9IPJl&t& c~ 
j 
, __ ,_ .:r-- " 
ATP, I 
', I 
Protetn v 
•inase j 
/I 
ADP~ , 
1iocnone sen&1t:ve 
TGlipB$<>b~ 
, / !inactl'lfl) ',, 
ru:r ·r,:i~ ~:.(j -" :.·•-.1 -.· e 
T'G l!;J ..1; . .;;:1 • 
Tr1a~tgtvc err,. _...,. 1 - ' 0.Sr.)•-J y;;~ro i 
• 
F·e" •Ir; a.:<I 1- 4 FFI\ 
MOOOACP,Jl'-1.:-.err.I 
I 
'------------- ---~ 
Acetyl-CoA sources 
I. f3-0xidation of fatty acids. 
2. Catabolism of ketogenic amino acids. 
3. Oxidative decarboxylation of pyruvate. 
Use of Acetyl-CoA 
1. Oxidation via CAC to C02 and H20 with loss of energy. 
2. Ketone bodies synthesis. 
3. Cholesterol synthesis. 
4. Fatty acids synthesis. 
239 
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I-Ket~ne bod-ies synthesis (mitochondria of liver) Acetrl Co.--t-0 acetrllransferase 0 0 
I 2CH3 - ~· - SCo.~ CH3- ~I. - CI-Ii- ~I'. - SCoA + HSCoA 
I Acetyl CoA Acetoacetyl CoA 
3-l~rdro.\i·-3-mi:1hyl­
f.'lut11ryl Co-4 vyntlwse 
OH 
0 
II Acetyl CoA 
+ CH3- C - SCo .. \ 
0 
II 
COOH - CH,- C -CH2-C- SCoA 
HMG coA ! - I 3-Hydroxy-3-methyl-
/yase H3 glutal'yl CoA (HMG CoA) 
141 
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Use of ketone bodies ---1 
Heart muscle, kidnev cortex. sceletal muscle. brain 
0 
II 
CH3 - C - CH2 - COOH + succinyl-CoA 
l Succiurl Co.-t-Acetoacetate llcetoacet11te-tr1111s.fer11se ff . ft (It is not r•·esent in a lh·er) 
CH3 - C -CH2 - C - SCoA + succinate 
AcetoacetylCoA l Tylllttse 
O +HS Co.\ 
II 
2 CH3 -C - SCoA CAC 
Acetyl CoA 
..----------·------- ------· 
Biosynthesis of cholesterol 
Liver - 80 % 
Intestine - I 0 % 
Skin - 5 % 
Other tissues - 5 % 
800 ml! dailv. 
142 
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I 
I 
I 
I 
Biosynthesis of cholesterol 
1- st stage- fo1n1ation of isopentenyl pyrophosphate 
C O OH - < H , C - <._ H 2 - · l ' ll : O H + HS-Co..\+ 2 N..\DP 
2 Xl'P 
OH 0 
II 
0 
II 
COOH - C H 2 - C- CH 2 - CH 2 - O-P-0- P-011 
i I 
'-.. 
"-. "-- C 0 2 
""'- H
2
0 
OH OH 
5-pyropbospho-
mevalonate 
0 0 
Hi(' :-.. 11 11 
·, Isopenten~·I 
/ C - CHz- CH1 - 0- P- 0- P- OH p~·1"0phosphate 
isomeriz11t ion OH OH 
0 0 DimethYlalM 
H e ] II II . . l '"- p~1"0phosph11te 
[ ·c = CH - CH 2 O-P-0-P-OH _ . / _ I I (::-{atoms, 
H,C OH OH isoprene unit) 
L_~-~~~~~~~~~~~--~~~~~~~~~~~-2_4_3__, 
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Biosyntbesis of cholesterol (continuation) 
2-nd stage. The CS isoprene units in isopentenyl pyrophos-
phate are then condensed to form the C30 compound squa-
lene 
Condensation 
3 C 5 units ----• Farnesyl (15 C atoms) 
Condtnsotion 
2 Farnesyl Squalene (JO C atoms) 
Squaleoe ----- Lanosterol (30 C atoms) 
Lanosterol ----- Cholesterol (27 C atoms) 
Regulation of HMG CoA reductase activity 
AA&in'in · Inhibition: 
Radiation aclion Starvation 
Insulin introduction • Thyroidcctomy 
Introduction or glucagon Introduction or 
thyroid hormones 
Hypophyseclomy 
Introduction of J:lucocortkoids . 
Introduction of the nicotinic I 
! 
..-------- ·--
;'lnc~u. ol cholesterol 
1
• synthesis .,~) 
acid large doses 
___ l _ _j' ; Inhibition uf chn1uterol ' 
syntbt"is 
-------
~-- - :'44 
Cholesterol 
OH 245 
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I 
Fatty acid synthesis 
Co11sists of 3 stages: 
I. Acetyl CoA transport into the cytosol; 
2. Formation ofmalonyl CoA; 
3. The elongation steps of fatty acid synthesis. 
I stage: A ce~rl CoA M:rc-.:.1~ 
tramport 
i11to the cyto.wl Acr-i CuA 
\ 
L_ _ __ _ 
2-nd stage: Formation ofmalony/CoA 
~ Acetyl CoA carboxylase Biotin 
CH3 - C - SCoA + C02 + ATP 
Acetyl CoA 
0 
II 
COOH-CH2 -C-SCoA +ADP+ Pi 
Malonyl CoA 
145 
ICommitted step J l~-·-- -· ------- 247 
,-----------------------
CD-SH+ 
@ 
I 
SH 
Reactions of 3-d stage 
COOH CH3 
I I 
cH
1 
+ c = 0 Transacy/ase 
I z 
C = O SCoA - 2HS CoA 
l 
SCoA 
MalonvlCoA 
Acetyl CoA 
0 
ii ---i (i)-S --C- CHl [ ----+ 
(2) 0 -----~ l 
I II l ! I ' ~ l ~ C-CH2-COOH I 
Ketoacylsynt/1a~e ~ - SH (J)- SH II 
- 'f -NADPH. ~ ~:tydrt~::::_ Ii 
-C02 S-T1-CH2-~-CH3 ---N-AD_P __ • s-C-CH.-CllOH-CH 0 0 11 • - 11:0 J I 
IJ-Ketoacyl-ACP ~-;·drox;. ~cyl-ACP I 
(Acetoacetyl-ACP) rHydrox;b•1t) ryl-ACP) 
$-SH 
~ I +NADPH2 (j) -- SH 
s-cll -CH=CH-CH3 @-S ·-C --CH.-CH -CH 
- NADP II . 2 J 
O o Ac~'l-ACP 
Enoylacyl-ACP . e,sV;'o.se (Butyryl-ACP) 
(Crotonyl-ACP) 1\\'0 co~ p 
r."\ )( ~t; (t)- S-~- CHz-CH 2 - CH3 
w-SH M\ 
@-SH i? 1.6;.. S-fi- CH 2 -COOH 
ACoS- C-CH2 -CH2 -CH3 0 
Designations: The cycle now repeats with malonvl-
(D. SH- Peripheral SH-group ACP adding two-carbon units in e;ch 
@-SH-Central SH-group cycle to the lengthening ac) 1-ACP 
,__ _________ ....J chain. This continues until the 16-
carbon palmitoyl-ACP is formed. 
248 
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Palmitate synthase complex 
...----_ I ,,---- -
.-. ;1<etoacyl~ / ttydra- \ .- -~,~ ·· , _.-- \ reduct~se fase (. - · • • .. ns-~ 1 Enoyl- \ acylase etoacyl-) - · - - / eductasEI_ synthase I · / --·,....._ 
-:-:--.--:-• • ... • ~s , 1 ---1 Th lo-}_ 
{;.s,:;-' ~?.~·:: .... ~~::(~p I 
1 A · i> "( • .. • • •• • • ! stq·. 
- .i Tiu - '. • •. SH - - .: ~stt""1·a~e/ , I • •••••••••••• • • 
" Fno I- I k_,.'cys t~ 
,. ' ctu< tas• I e toacyl - Tl 
• · ~yntha e »c:;) 
- • }tydra - 1/kPtoacyl- ,__ __ / -
~ r.... . i~·e1! uctasc:J .... __.,., 
249 
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,--Syn-rJ.)-;sis -:-r~on~- chain f~~; acids from palmitate 
I . Furthl'r, chain elongation can take place by separate mechan-
isms: 
I
I 1. Mitochondrial. Palmitoyl CoA is carried by camitine into 
mitochondria matrix where the fatty acid chain elongation is al-
most a reversal of B-oxidation of fatty acids. Acetyl CoA mole-
cules are successively added to fatty acid to lengthen the chain. 
The reducing equivalents are derived from NADPH. 
2. Microsomal. The microsomal chain elongation is more 
predominant and involves successive additions of malonyl CoA 
with the participation of NADPH in endoplasmic reticulum (mi-
crosomes). These reactions are similar to that catalyzed by pal-
mitate synthase complex. A specific group of enzymes, namely 
elongases, bring about fatty acid chain elongation. 
Synthesis of unsaturated fatty acids 
Reaction is catalyzed by a membrane-bound complex of three 
enzymes: NADPH-cytochrome b5 reductase, cytochrome b5 and 
desaturas~ in the SER. The reaction may be repeated to intro-
duce more than one double bond into a fatty acid. 
Saturated fatty i.cyl CoA + NADPH2 + 0 2 
----+ Mono-unsaturated acylCoA + 2H20 + NADP 
250 
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Synthesis of triacylglycerols 
G(t1cerol activation 
1. Intestine, kidnev, live1·. 
+ATP 
Glycerol 
kinase 
CH20H 
I 
CHOH +ADP 
I 
CH20P03 111 
Glyceml Gly cerol -3-phospha tt' 
2. Adinose tissue. muscle. liYCr: 
CJL O H 
+NADH+H+ !H~H 
!u1 0P03 H 2 
Dihychuxyacetone 
phosphate 
GI.' cer ol 3-phosphat<" 
0 
II 
CH20-C - R1 
I o 
-2HSCoA II 
CH20H 0 
I 11 
CHOH + 2R- C - SCoA ---CHO- C - R2 
I 
CH20P03H2 
Glycerol 3-phosphate 
I 
CH20P03H2 
Phosphatidic acid 
0 
II 
CH20-C-R1 0 0 
11 I II 
P'1ol71/wta.fe 
-H3PO~ 
+R3-C-SCoA-- CHO- C-R2 +HSCoA 
Diac;,-iglycerol 
148 
I ~ 
CH20-C-R3 
Triac~·Igl~·cerol 
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Glycerophospholipids synthesis 
Lh e1~ intestine, spenmuies, mamnuu·y gland 
1? 
CH20 - C - R 1 
I 11 
CHO-C-R2 + CTP 
I 
CH20P03H 2 
Phosphatidic 
;1cid 
0 
CH20-~-R1 
I ff 
C HO - C-R2 
~H20 -~ - 0 - C H 2 - CH~ 
-co,, 1 ~- r!rn2 
Phosphatidylseline 
0 
I I 
CH20-C - R, I fj Phosphatidylethanolamine 
CHO - C - R 2 I 0 NH, 
c u,o -f- 0 - CH, - c1n, K 3 S-adenos;o1methionine 
o- ft 3 S-adenos:-·lhomoc;'l"Stelne 
C"H20-C-R1 
I ft Phosphatidylcholine 
CHO- C-R2 
0 II fH, 
CH20 - P - 0 - C:H2 - CH2 - N+ -CH, I I 
o - CH, 
149 
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·-- ---·----- -1 
I 
' 
Cholesterol metabolisrn. 
Biochemistry of atherosclerosis 
I 
-- ----· -- --~~J 
--·····----·--·--·-· - -
Cholesterol functions 
1. It is a major component of animal plasm~ mem-
branes; 
2. It is a metabolic precursor for the synthesi3 of: 
1. Bile acids 
2. Corticosteroids 
3. Sex hormones 
4. Vitamin D I I 
~--------~-----~-- -~ 
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Three pools of cholesterol (Cb) 
Every day 
Ch synthesized - 0,8 g 
l 
30 g 
Liver, blood plasma, 
intestine wall . 
50 g 
Slowly eir.change 
I 
I 
Quickly exchange~, 
1 9 per day 
I 
I ! 
I
. The steroid 
hormones 
I 0,1 g 
"-,, 
Secr~tion of 
sebaceous gland 
0,1 g 
I ___ ____ _ 
The bile 
acids 
0,5 g 
Diet Ch - 0,4 g 
-
c 
60g 
Brain, $:Onnective 
tissue 
Very slowly exchange, 
for years 
Sterines of 
excrements 
0,5g 
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Cholesterol transport 
Direct 
r-_. ..... •ch 
Reverse 
LCAT • Cb 
L ____________________________ 25_6___. 
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Receptor-mediated endocytosis of LDL 
LDL 
Stages of LDL receptor-mediated endocytosis 
l. Apoprotein B-100 on the surface of an LDL particle binds 
to a specific receptor protein on the plasma membrane of 
nonliver cells. 
2. LDL - receptor complex is taken up by cell through endo-
cytosis. 
3. Once in the lysosomes, the LDLs are digested by lysosom-
al enzymes, with the cholesterol esters being hydrolyzed 
by a lysosomal lipase to release the free cholesterol and 
protein component being hydrolyzed to free amino acids. 
4. The LDL receptor itself returns unscathed to the plasma 
membrane. 
258 
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I 
I 
I 
Receptor-mediated endocytosis protects cell from 
excess of cholesterol: 
I} Any excess of cholesterol is re-esterified for storage by 
acyl CoA cholesterol acyltransferase (ACAT). 
2) To prevent the build up of cholesterol and its ester deriva-
tives in the cell, high levels of cholesterol: 
decrease the synthesis of the LDL receptor, thereby reduc-
ing the rate of uptake of cholesterol by receptor-mediated 
endocytosis; 
2. inhibit the cellular biosynthesis of cholesterol through in-
hibition of HMG CoA reductase. 
[ ____ _ 259 
lunregul~ted pathways of cellular cholesterol uptake 
I 1. Nonspecific endoc11osis of LDL by "scavenger" receptors 
on macrophages. 
2. Receptor-mediated pathway (through receptors not having 
high specificity to certain apoproteins). 
3. Pathway of physico-chemical exchange of cholesterol be-
hveen cellular membrane and LDL. 
These pathways of cholesterol transport can lead to choles-
terol accumulation in a cell. 
2Afl 
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Reverse cholesterol transport mediated by HDL 
1. The plasma enzyme lecithin-cholesterol acyl-trans.ferase 
(LCA T) catalyses the transfer of fatty acid from the second 
position of phosphatidylcholine (lecithin) to the hydroxyl 
group of cholesterol present in the extrahepatic tissues and 
transfers to the HDL. 
2. Apoprotein A promotes the activity of LCAT. 
3. Due to the addition of cholesterol, HDL partic les become 
spherical. 
4. The HDLs are then either taken up directly by the liver. 
5. The liver is the only organ that cvn dispose of significant I 
quantities of cholesterol, primarily in the fum1 of bile salts. 
I 
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Frederickson's classification of hyperlipidemias 
! Increased -T 1 ----l 
I __ plasma ' Triacylglycerols I Cholesterol i 
l---I---~%f1~~i- -_ t1 ~ - =-: N (t) -=I 
Ila LDL N "' l---1-lb----+- -;-~D-LL -r·---i ----, --~ -I 
III - ---1--
Type 
IV 
,__ _ _  v __ ~l_C_h~y_lo __ m_i_cr_o_~ __ _ ____ l _ _ _ _ J 
2tJ2 
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The factors influencing HDL level 
Increased HDL Decreased HDL I 
Fish rotein) ; Vegetarianism, carboh drate diet 
- Ethanol - -i - -------No ethanol 
1 Th.£Pt.Y'.'.i.:a l ~~L~!~Y l -- Physical i!?-activi , obesi 
Estr~gcns __ -~ ___ _____J2_()~stins, andro ens 
H-. £Oth\1 oid ism : Effective treatment 
j Efti.:c-tiw ln:aLrncnt Djabetes m_e_ll_itu_ s __ ~ 
' _ _ _ $moki11g_ _ _ ___. 
L_ - - -
- - - - - - - -- ·--------------' 
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[ - - - --------- ------ -------The factors influencing LDL level 
- . ------ -
~ _ _ _!ncre"sed [.,DL ___ Decreased LDL 
i ~f:~~ ini~k~ of sa1Uratecf-1 ~~=~:take of polyunsatu-
! fattv ac td s rate.:....d:.....;:.:fa:t.o.ttv:"'--'ac:c:c-=-id:::..;s=----------1 
I High c: h~es-terol fat_di~t ~-==~+Low c_~olesterol fat diet 
I : Low fiher diet High fiber diet 
I 
IAJ£oht;L~~~~se -=~=- -_-=:::-:=- ~ f\1oderat;-al_c_o_h_ol_c_o _ s_u_m_p_t_io-n----l 
~r~gQ_<UH.:J _ _ ___ _ __ I Labor -- - -------1 
I ~g~:~~~~ ~~ITitu~-_ ·==-=--==-!-Weigh_t loss 
I 
l'.Potl~yroit_!lsm ----- -i 
ushing's s 1ndrome , Ef:c _ 
- ~-- -------- -----: 1ect1ve treatment ! J Jraem1a_____ _ _____ -~ 
I I Nephrosis i I 1 FamiiGTh- eriinldac~ia~ ---L- -- =- - - -- --=--=----- ___ 264__. 
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Lipid atherogenity index 
The index of atherogenity (IA) is the ratio between cho-
lesterol of atherogenic lipoprotein classes to cholesterol of an-
tiatherogenic lipoprotein classes: 
IA= (Chciotal> - Ch-HDL) I Ch-HDL (absolute units) 
The index of atherogenity is used for estimation of athe-
rosclerosis risk degree. 
Norm-up to 3 
Low risk - from 3 to 4 
Moderate risk - from 4 to 5 
High risk - greater than 5. I 
'------------------------ ----~) 
~--------------------- - --
Blood lipid levels at atherogenic types of 
hyperlipidaemias 
Phenotype LDL-C/1, mm_o//I T: ---- 1 g, mmol/l , 
- < 2,2s -i Ila > 5,05 I 
' I lib > 5,05 
_j_ 
IV < 5,05 
VLDL-Ch = (Tg • 2,29)/5 mmol/l 
VLDL-Ch = Tg/5 mg/di 
I 
> 2,25 -j 
- ;-2-25 ---1 
LDL-Ch = Chtotal - (HDL-Ch + Ch - VLDL) 
156 
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I Primary hyperlipidaemias 
I 
I 
l 
I 
I 
I 
I 
I 
·--- --.---- - - -- - - - -- -, 
_!:he1!_otype .__ ______!!_~>ba~le metabolic defect -1 I I I Familial lipoprotein lipase deficiency, 
_ _ __ -- ~ E!'~ ilial ap_?-C-II ~_e_fi_1c_ie_n_c_y _ _ ___ __, 
I 2a, ~b J_~am~ial hyperchol~_t_e __ ro_l_ae_m_ ia _ ___ -i 
I 3 I Familial abetalipoproteinaemia 
-- I ---- - ------ --------
1 -~ I·amilial hypertriglyceridaemia, 
l Familial combined hyperlipidaemia 
- -- ·----------- - ----- -------< ) Familial apo-C-11 deficiency, 
Familial hypertriglyceridaemia, 
_ _ _I Familial combined hyperlipidaemia 
L 267 
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r------
Secondary hyperlipidaemia 
r- - - --·- ~ 
~_!~en~IJJ1e +- Disease, syndrome 
I 2a Hypothyroidism, Cushing's syndrome, porphyria, 
• glucocorticoids, nonselective P-blockers, nephrot-
! ic syndrome 
•-- -ib --1 Cush.ing's syndrome, glucocorticoids, nonselec-
tive P-blockers, thiazide diuretics, nephrotic syn-
I drome 
,--T- 1 Diabetes mellitus, acromegaly, gout, oral contra-
ceptives, alcohol abuse, thiazide diuretics, urae-
l I mia, acute hepatitis, stress 
268 
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~---c __ •_a_ssification of serum lipid~e~el•_ ___ I 
Indication c; Values, mmol// ~ 
a/Ch~· - LDL-cl11 - Tg- . I 
--- --- -- - 1-- - - - -1- - ---- -
Optimal ; 3.56-5.2 I 1.91-2.6 0.5-1.8 
Desirable __ ,____ > 6.5 - - > 3.4 --r > i.25 - -
Borderline high j >_7.3 ___ 1·· > ~-.0~ --~ t= ->-5~1 
I High i >7.3 ___ 1 _~ 5.05 -- ->~-~'--
I 
_ _____ 26~ 
Optimal and desirable seru: lipi~ levels--, 
~j-r- LDL~clwle~·ter~l I ! 
/IL · mgldl mmo//L I 
--
Classification Total cholester 
of level 
mgldL mmo 
--9 _j <100 - <2.6 1 
--+--- ---·--- - I s.1 I 100-129 2.6-3.3 I 
-6.2 I I 3()- I 59 . 3.4-4:1 . I 
2- i ->C60 ~-~ I 
~-----~ -,~I 
I 
-
Optimal <150 <3. 
-
I Desirable 150-199 3.9-
- ---· 
Borderline 200-239 5.2 
high 
High >240 >6. 
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Risk factors for development of atherosclerosis 
and coronary heart disease 
~ Traditional risk factors creasing age amily history of hypertension I moking tol>arrn OtJI cholest.:rol, lq•J1 plasma level I LIJI cJ. ,> lt~ ; !ero l. high serum level 
, l ll~l _ ci·oksterol 101' scrup1 le,·el 
Novel risk factors 
Antioxidants, low intake 
Fibrinogen, high serum level 
Homocysteine, high plasma level 
, Dimethylarginine, high plasma level 
Lipoprotein (a), high serum level 
Fami ly i· ;•,t•'ry ofrr.:·,_1.: .rdi:il mforction 
rrlaC) !g .~ H f\\ high ~~ll!m level 
i Physical inactivity J ' i Trans fatty acids, high intake 
--- -----·-· 
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r·--·-- -~lis~ -f:H't:~.-s fo~·::velopmcut of coronary heart disease 
I r ';:,'.:~.~;~,, ''""' _____ ----
1
1 h ),·eme1ght-- - -----
T''"'"'''~ ,, "" ""'"'" ·="'· Waist circumference: 
males > I 02 cm, 
I females > 88 c~t 
i Body mass index (BM!) = weight (in kilo-
! 
~A.rtenal hypertens10n ---- - -
t[ams) I height (in meters2) = 30 and> i > 140/90 mmHg 
Antihypertensive drugs 
Arterial hn~ertension oscillation for young 
Less than I 0 hours per week of physical E''· -m"'""'-------- act1vi.!Y__<!_uring leisure time - Fasting glucose> 6,5 mmol/I 025 ml?ldl) 
i Earlv oii'set~f Cl'ron~h-:artdisease 
in the 1mmed1ate family 
Hyperd10 I ~stero kmia 
Hypcrtn.icylglyccrolemia. low HDL-
Ch 
males > 45 years old 
~ales >~ears old or earlv menopause I Myocardial infarction 
males < 55 years old 
_ ~males < 65 years old 
Total cholesterol> 5 mmol/I (150 mg/di) 
LDL-Ch > 3,0 mmol/I (115 mg/di) 
• TG ;::: l,7 mmol/I (150 mg/di) 
I HDL-Ch < I mmol/I ( 40 mg/di) 
272 
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Metabolism of proteins 
Digestion of proteins --- ·- ----1 
1,.....S_e_c_r_e-ti_o_n-.- -C-o_n_t_e_~-t-of _ ___ I___ Fu11ctiom-:- - --·
1
. I 
secretion 
1 
Hydrochloric aci~f I Denaturation of proteins and - \ Gastric 
juice 
Pancreatic 
juice 
I (HCl) j ~illing of certain microorgan-
1 
. 
. isms 
I Pepsin Fati_on of _reptide-;-and--;- - ·1 
' few ammo acids 
·------ ---
Rennin (chymosin) . Coagulation of milk (protein 
I casein conversion to calcium 
aracase!n_a_t_e )~-
f-----"-L-----
r--~-~~--~ 
1------ ---l 
Formation of free amino acids 
and small peptides (2-8 amino 
acids) 
e tidase I ~ 
Intestinal Aminopeptidase Formation of free amino acids 
1---------+' _an_d_ s __ m_a_ll_e~r p~tide _ _ _J juice 
Dipeptidase 1 Formation of free amino acids 1 
~---~~~------------- - - ·-------· 
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Oxidative deamination 
- removal of amino group from the amino acids as NH3 
coupled with oxidation 
;Enzymes I L-amin~ acid D-amino acid Glutamate de-
---____ { ____ ox_i_d_a_se_ --t _ _ o_x_id_as_e ___ 1--__ h"--dr_o....__en_ase---i 
~cifici!l'_ i Optical Optic~_ Absolute 
ubstra!~~, L-~noaci~ p_-a_m_i~a~d_s--+ __ G_l __ u_ta_m_a~te---1 
. Cofactors FMN FAD NAD C Iization 7eroxisomes Microsomes -+-_M_ito_c_h_on_dri_· a---i 
c!!_y_!!y_J Low ( l 0%) !::!!.g!!_ _ _l_ _ __:H.:.:i=-----1 
R I Enzyme ~ + Hp R 
HC-NH2 --~ C NH - --t=o 
I -2H I I COOH COOH - NH, COOH 
Amino acid I mine a-Keto acid 
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Transamination 
- transfer of amino group from amino acid to a-keto acid 
(pyruvate, oxaloacetate, a-ketoglutarate) to form corres-
ponding amino acid and a-keto acid 
The enzymes that catalyze these reactions are called trans-
aminases (or aminotransferases). 
The coenzyme of transaminases is pyridoxal phosphate de-
rived from pyridoxine (vitamin B6). 
Pyridosine 
(BJ 
Pyridoxal phosphate Pyrldoxamlne phosphate 
161 
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Transamination 
'!°°" BC -NR1 I [
B AsplUtaU 
ami11otransfovu,; f (ASA.T) =o 
+ + 
I l 
Stag~ 1 
CH 1 
6,oe 
Asp 
=o COOB tooe 
G-Ketoelutarate O:uloacetate 
Mechanism oftransamination: 
COOH COOR 
I I 
~ 0 cu, 
I 11 -a,o I -
HC-NH2 +C-pp = HC-N=CH--PP ~ 
I I +ILO I 
COOH H Pyrido-..1 - COOH Sdlltrbue I 
AID 
COOH 
I 
pb-hak 
Cllz 
I •a,o 
;!' <.:=N·CH 2-pp ;::=: tooa -e.o 
Sddll'.._ n O:uloautate 
s-~2cooe coon 
I I 
?~ 11-Kdochannte ~ 
p~ ~llz 
C=O+ H2N-CH2-PP ::=:~=N-CH2-PP~ 
I P)'rtc1uaaa.e COOH Sc1111r- n 
COOH ,_,."'" 
COOH COOH 
. ~ ~llz 
~~ ~llz ft 
H~-N=CH-PP H~-NH2 +~-pp 
COOH Sc111tr-1 COOH H Pyrtdea1 
phoplaate 
Glu 
162 
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Role of the transamination 
1. Synthesis of the nonessential amino acids. 
2. The first stage of the indirect deamination of amino 
acids. 
3. Unifies the catabolic pathways of carbohydrates, li-
pids and proteins. L_ 278 
Indirect deamination of amino acids 
1. Deamination of the most amino acids proceeds by indirect 
pathway. 
2. Glutamate serves as a collection centre for amino groups from 
amino acids. 
+ a-Ketoglutarate 
Aminoacid + Pyruvate - a-Ketoacid +Ala Pyruvate + Glu 
+ a-Ketoglutarate 
Aminoacid + Oxaloacetate - a-Ketoacid + Asp -+ Oxaloacetate + Glu 
Aminoacid - u.-Ketoglutarate - a-Ketoacid + Glu 
Glutamate 
dehydrogenase 
l i lu ----+ a-Ketoglutarate + NH3 
163 
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Decarboxylation of amino acids 
-removal of carboxylic group from the amino acids as C02 
to form the biogenic amines 
The enzymes that catalyze these reactions are called decarbox-
ylases which are dependent on pyridoxal phosphate. 
~COOH ~j~Cli CQCij-Cfi-Nij 10J \' Thryp~e has blood pressure 
NH elevatmg property 
TJwnllMlin• 
Tyramine bas blood pressure ele-
vating property 
.-attOOK "°IJJ~Clf4il1Serotonin is ~portant in nerve~-
- I pulse tnmsm.1s111on (neurottansuut-
\.q ter). It regulates sleep, behaviour, 
111 
NH temperature, blood pressure, pain 
......_..,,..,._ ........., perception etc 
tJ~-r \ 
... CQ 
... 
F°" 
~ 
r 
ffiN-CH- COOH 
Glu 
CH2 - SH I 
H2N- CH-COOH 
Cys 
Histamine is a vasodilator and low-
ers blood pressure. It stimulllles 
gastric HCI secretion and is in-
volved in inflammation and allergic 
reaction 
COOH GABA ac1S as an inhibitory neuro-
I transmitter in die nervous system ~ 
• Tawine conjugates with bile acids to 
~ increase their bydrophilism 
0\-Nf\ 
y-Amlnobutyrlc •ckl 
(GABA) 
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Decarboxylation of amino acids 
'jll2-NH2 
fH2 
CH2 "'\ 
I C02 
HzN-CH- COOH 
Tyr 
?H1-NH2 
fH2 
TH2 
CH2-NH2 
DOPA 
Putrescine is converted 
to spennine and spenni-
dine 
DOPAMINE 
Dopamine is 
utiliz.od in the 
brain as excita-
tory neuro-
transmitter 
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Detoxification of biogenic amines 
Biogenic amines are metabolized to less active degradation prod-
ucts. This detoxification system includes specific enzymes: monoamine 
oxidases (MAO) and diamine axidase (DAO) are complex enzymes loca· 
liz.ed in mitochondria. Prosthetic group of MAO is FAD; prosthetic 
groups of DAO are pyridoxal phosphate and Cul+. 
Amines are inactivated by oxidative deamination: 
~ +FAD bu=-NB +~O b- o+NB, 
~ FAf_~ i +o2 
FAD+H102 
The formed aldehydes are oxidized further to fatty acids which are 
oxidized to end products. 
Certain drugs (e.g., MAO-inhibitors) decrease the activity of MAO, 
for example iproniazid. 
282 
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Detoxication of ammonia 
Sources of ammonia: 
1. Deamination of the amino acids. 
2. Deamination of the glutamate. 
3. Deamination ofbiogenic amines. 
4. Deamination of purines and pyrimidines. 
5. Ammonia generated by enteric bacteria. 
283 
Local detoxication of ammonia 1 
Mechanisms: 
1. Human tissues (brain, muscle, retina, kidney, liver) initially 
detoxify NH3 formed by conversion to glutamine from glutamate 
for transport to the liver. 
Glutamlne synthetase 
~OOH 
Cffz +NH,+ ATP 
&1 
I ADP+H,P04 
'r8-NH1 
COOH 
0 
ii 
C-NJ\ 
I 
CJ\ 
I 
Cl\ I 
Cit-NI\ 
toou 
Glu Glutamlne 
2. Detoxication of NI-h in tissues by amidation of glutamate re-
sidues in proteins. 
284 
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Local detoxication of ammonia 
3. Reductive amination of a-ketoglutarate in muscle (glucose-
alanine cycle). 
NH3 +1a-KG NADPH+ff+ Glutillmm dah)'drogenase l.U MUSCLE 
GLUCOSE PYRWATE + JALAT 
····························r········ ······· ··········· ·· ····· ·· ·········~·-····~.___························-~~G +CJ~ 
UVER Al.AT 
Iii.UC PYRUVA GLU 
OKALOACETATE + ~ " Asl. ---------- m~G 
ALAT- alanine amiMJrrmsferase 
ASA T- asparJare amlMtransferase 
l UREA 
General detoxication of ammonia 
Mechanisms: 
2l!'i 
1. Ammonium salts are synthesized in the kidneys from ammo-
nia derived from hydrolysis of glutamine by glutaminase. 
NH3 +Ir - NII/ 
NH.++ Po/·, sol, er, c~:z-
Ammonium salts are normally excreted in 1 - 1.2 g per day by 
urine. 
Formation and secretion of ammonium salts maintain acid-base 
balance. 
286 
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General detoxication of ammonia 
2. Urea is synthesized in liver from ammonia derived from hy-
drolysis of glutamine by glutaminase. 
Carbamoyl phosphatP 
NH3+ C02+ 2A TP + H 20 synfhetasu 
0 
II 
H2N-C-O -PO:iff2 + 2ADP + H3P04 
Carbamoyl phosphate 
0 NH 2 Ornfthlne trans-l I I carbamoy/ase H • 
H 2N-C-O- P03H 2 +CH 1 I 
Carbamoyl CH 1 
phosphate tu 
I z 
HC-NH1 
I 
COOH 
Omlthlne 
"'H Arglnlno-'~ succlnate 
{I -OH+ lliN~~OH_::r~;~se 
NH , 
I CH . 1 • +H,P,o, (<[H zh COOH i+tt,o 
- AMP 
I -
c=o 
I 
l\H 
( ~H 2lJ 
I 
HCI - NH 1 
COOH 
Citrulllne 
NH COOH 
II I 
C-HN-CH 
I J-.-
NH CH ,.; I I 2 
tCH zh COOH 
I HC -NH 2H,Pn, 
I z HC-:'>H Asp 
COOH I COOH 
Cltrulllne Arglnlnosucclnate 
NH 2 
Argfn/nosucc/nase I C=NH 
I 
COOH 
I 
NH 2 I 
(CH2h I + 
HC-NH2 
I 
COOH 
Al'fllnase NH 
+HO I r __ .:c __ (CH ) 
I I l J 
HC -NH 2 
NH 2 I 
c=o 
\ 
NH 2 
I 
COOH 
Arginine 
Omithine Urea 
168 
.,. CH 
II 
CH 
I 
COOH 
Fumarate 
287 
Metabolism and functions of 
individual amino acids 
288 
,--------------
! I Methylation 
! 
- is iutrodurtion of methyl groups into substrate molecule 
Functions of methylation: 
1 . Formation of low-molecular compounds - choline, 
adrenaline, creatine, thymidine nucleotides. 
2. lnactivMion of biologically active substances - cate-
cholamines, hormones. 
3. Neutralization of xenobiotics. 
4. Maturation of DNA, RNA. 
289 
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Transmethylation 
- is transport of methyl groups from a source of methyl groups to a 
substrate of methylation with aid of donors (or carriers) of methyl 
groups 
Sources of methyl groups are serine, choline, betaine. 
Donors (or carriers) of methyl groups for substrates are active 
form of folic acid - tetrahydrofolic acid (THFA) and active form of me-
thionine - S-adenosyl methionine (S-AM). I 
------- --~' 
Scheme of transmethvlatio_: _ --- , 
• I 
Ser TIIH TIIR' ';S-. "!"II""'""" 
Gly x Moth> len• + 2H ~i.thyl " S-AI,~ mOOt•·•" 
TH:FA -..THFA Cll3 
I 
I 
I 
I 
l 
I 
! 
I 
choline. betaine i 
'---------------------------~ 
Folic acid 
OH 
N)cr· /~~JIC9H -: -NH~Co·:-NH-CH-CH -CH -COOH 12 I ' z ' ~-v r ; I z 2 ~I .~ I I COOH 
H2N N N I I 
Pteridine 
I I 
I 
Para-aminobenzaic acid, 
PAB(A) 
170 
L- Glutamate 
292 
5,6,7,8 -Tetrahydrofolic acid (THFA) 
OH H ~:u:/t'J';i H-R 1; I ;1 /~N -~/ H 
H214' I 
H 
The methyl group is transferred in 5u,-position - 5-methyl THF A. 
But THF A can fonn other derivatives: 
N5N10 methylene THF A (-CH2- ); 
N5 N 10 inethenyl THFA (-CH=), etc. 
The activated methyl cycle 
coo· 
I + H - C-NHj 
tHz 
i; 
171 
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Formation of S-adenosyl methionine 
NH~ 
H2'f -CH-COOH I ~ 
U...U-CH-COOH I Nx 
""2". I + ATP '~.HW .(" I N 
(CH?b ···-·-- +s H.,c \ ..-;: I 
I I I , 0 , N N?" 
S-CH3 CH3 r ~ ~ 3H~4 
Methionine . n 
00 OH 
S-.\ :\ r 
S-AM + substrate \ktln I S-AH + substratc'-C'll, 
Transferas<: 
' 
I 
~-------------------·---
2:J 
---·---------·--1 
Regeneration of methionine 
Nitz +H,0 
H:tN-cH-COOH _x-----""-r-~ f Jl J . ad<n"'"" 
~-c;:H-COOH 
I 
(CH2)z 
I 
SH 
Homoc~·steine 
I 
I ~· B12 I+ 5-meth~·I THFA 
OHOH 
S-adenosyl 
homocysteine 
(S-AH) 
172 
I 
Methionine + THFA 
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Examples of methylation reactions 
I. There are 2 stages of creatine synthesis: 
1) Guanidoacetate is formed in kidneys and pancreas 
r~· NH., NJ\ f2 i -
' 
c~=twH CH2 - <?f\>3 I ! + C==NH Nt-i + COOH CH-Nfii I ! NH (yH2h G I~ I I COOH 
CH NH2 CJ\ I I 
COOH Omitbine COOH 
L-Arg Guanidoacetate 
i 2) Synthesis of creatine is completed by methylation 
[ of guanidoacetate in the liver: 
I 
I 
I 
I 
I 
I 
I 
,Hi> 
C=NH 
I 
NH 
I 
CH~ 
I ' 
COOH 
+. -Al\ I 
(lin1·) 
- S-.-\ H 
+ ..\TP I 
crratillt' W11<1st' ' 
(mu~de) 
~ 
C=NH 
i 
N-CH:, 
I 
C"2 
I ""'°.· c~
Muscle 
~H-P0,"2 
j 
C=HH 
l'r C=NH ~-CH:J - Prine 
! t14i 
l_bo 
Crei•tinine 
I 
~-CH3 _.__./' -B,PO, I 
Cffi 
I . COOH C1-eatme phosphate 
L 297 
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Examples of methylation reactions 
II. Epinephrine is synthesized by methylation of 
norepinephrine in the adrenal medulla. 
Norepinephrine Epilwphrine 
III. Synthesis of phosphatidylcholine 
~0-~ +JS-Al\I %--0--~ 
I ,;:O - ·- - -+ I ,-:0 + j S-AH ctt-0--C~ CH-0-CLRz 
I Pit I OH 
Clfi-O-P-0-CHz-Clfi-NHz Cf\-0-P-<r Ct\-CHz-tf(Q\b 
II 11 
0 0 
Phosphatidylethanolamine PhosphatidykhoJine 
298 
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~~tabolism of phenylalanine and tyrosine 
~ I +-a-KG a· L iJc~ff-COOff -Glu . 7 lf-c~-cr-cmtt 
~· O ~ Phe Ht\ Mela nine 
lfrini ' ',, PbenvlpYrUYate , -Phe~yl '1·hen'."I . - CY i· ~~:ylalaninehydrox_llase r 
G. ~~ CJ\-(:H-CCX>H r'5' DOPA ac~tllte lacfale 
i 
Phl'~~-Iau~lyl 
ghn::minr 
Peroxidase I I I ~ 
T3, T4 -- ~ 'I)T N~ T~·rot\~ 
Cu 
Tran'3mina Hydroxylase 
+a-KG +o, 
01r - -<Hrfi - COOH :n--~ CHz-~H-COOH ~ JJ 0 ::::,..., I NH 0 1 p-hydroxyphenytpyruvate 2 
_,,.j DOPA · 
CO ..--i Hydroxylase C0¥ .J, Dopa decarboxylase 
' -
2 Vl!C Cu2+ 0 (~) • o,' '1~cH2-~2 ~1oo 0 ..,,-'01 •2 0 CH2-coOH I DOPAmlne 
Homogentisate + 02 
' 0 "dase 
! + Oz, C, cu2• 
( 4)1 Homogentisate CH--C11z 
__, . oxidase I I 
Fe'~ OH N11z 
Ol-r Norepinephrlne i Fumarylacetoac~tate --8-AM 
I Fuma'rate Acet~a~etate ~/ 
I c~c 2 acetylCo: ket~ne L~ S-AH bodies ~
I CAC ~ ;n£i~ 
L 299 
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I 
Disorders of tyrosine (phenylalanine) metabolism I 
I Me~~~al : Defective TDefective enzyme 1 -!J)mptoms a7.d effeds- / 
I conuttion I process J ____ _____ i _ j 
.... , -A-lb_i_n-is-m- -~, -l'v-1e-l_a_n-in_s_yn- I Tyrosinase I Hypnpigmentat~on t_ha~- . I 
thesis from ! caus;;s white hair, ptr.k I i 
>---------+--"ty~r_o_s_in_e _ _ _ ~-- : ski~ hl ,1e etes etc. : I 
Alkaptonuria Tyrosine .
1 
Homogentisatc i Dark pigment i i~ urrnc 1 1 
d d . "d I -I I . I . : I egra at1on ; ox1 ase i , ~te ·JeYc opmg art mt1s, I 
I alironcs:s._ .--------j 
Phenylketonuria I Conve~sion - vh~~ylala~i~~ by:- I ?\e,inatal '"··m1t1r.g, I 
I
, o'. phenylala-
1 
droxylase I mental rttarJation. fail - ,. 
nme to tyro- I ure t 0 waik or tali-;, fail- 1 
1
1 
/ sine I ' un.: of gro-wth, seizures i ~ ! and t •<0mor _J I 
1-Ri-.c-hn_e_r_- --+-,I -T-y-rosine d; Tyro~ine tr:i~s- - Skin (J~rn~atitis) anl- , 
Hanhart syn- j gradation I aminase i eye lesions nnd, mental :,!: / 
drome (Tyrosi- ' ret:1rdation. 
nemia type II) b 1 ,_N_e_o_n_a~ta~l~t-yr-o~--+,-T_y_r_os_i_n._e ___ · p-hydroxyphenyl- j Chroni(· degen~rative - 1 
sinemia degradation / pyruvate dioxyge- i changes in liver and j 
F I nase • kiJn~ . Tyrosinosis or Tyrosine Fumaryliceto_::--- I Li~er fai !d;:;. ricketS,"" -·1 tyrosinemia degradation / acetatehydrox) lase , renal tubular dysfunc- / type I and/or maley- ' t i011 :md pol) neuropa-
1 I lacctoacetatc i~,J- j th). 
Parkinson's dis- Dopamine ~-;-e hyd~x: -: '\ luscula; rii.? idit v, tre:-- -! 
ease synthesis I ;1~·s~~·DOPA- I mors, akinc~ia. ~xpres- 'I 
from tyrosine j decarboxyla~t" 1 :-. wnless far ". lethargy, ~-----~------- _ ; ___ _______ : i nvolur~ta~~ movc'!1~nt~I, 
~------------ ·-··----_:J 
176 
Metabolism of nucleic acids 
:- ------~itr:genous bases 
I 
I 
J~~ N b 
Pyrim:dinP 
P11ri ne 
0 0 "~ H-N~ ~/CH3 H-N J 
cflN) ~N o~N) I I I H H H 
Uracil (lJ) Thymine (T) Cytosine (C} 
RNA only DNA only both DNA and RNA 
"~(N> l / N "-"~(") ~/ N 
N I 
H 
Adenine (A) 
H,N I 
H 
Guanlne(G} 
301 
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Degradation of purine nucleotides 
I 
I 
I 
303j 
~----------------------·---------
p 
OH 
a-D-Ribose-5-phosphate 5-Phosphoribosyl 
a-pyrophosphate ~ 
?Pi ~Nrj ( • -~H 
r--4 ~l~H20~03H2 Nl.!i.__ _ -- - ck~~o~ 1-1'-~ 
Gia GIL I I l/l 
I H 1 I 
OH OH OH OH 
11-5-Pbosphoribosylamiae 
PPP- pentose phosphate pathway 
PRP P- Phosphoribosyl pyrophosphate 
178 
laosiae moaophosphate 
or iaosinic acid (IMP) 
304 
l'••r:.,. of individual atoms in purine rin; 
I C02 
Glycine 
Aspartatc 
N 10-formyl-THF 
~ c\l 
J N. 
' . m1yl-THF ~,, 
Glutamine (amide-N) 
10~ 
I Synthesis of AMP and GMP 
I 
I 
I 
I 
Adeoybucd nate NADJ' ll) 
~ D 
0 0 
,::{NH >. {; ~:Ix 
I ~Ao P I N Nllz 
H + p, ..,._._, 
Ribc~e-5-P CMP 
Xaathosine monophosphare 
179 
RJbot....S.P 
AMP 
(I) Adenylsuccinate 
synthetase 
(2) Adenylsuccinase 
(3) IMP dehydrogenase 
306 
Degradation of pyrimidine nucleotide 
NJ:: Cvtosine HN~CH O~NJ o·A :-; ) Ti1vmine 
V. °<_r H, I'\ \DPH 1 
~ '>ADP-.'~~ 
JO J: C H3 HN , Uracil HN'~t-H Di hydro-~ j COOll ~ 1hpnine 
0 e:, ..... , i"'~' 0 ~  ·~ 
I o"""')~· o-c .. , •.• ,,., r "",' NADP+/~0 H / )/ :1,.:: ,..,,,,,, ,H,ll~ °;~' 
, co, r f' r 
HN -H H,o ~HJ ~ ,,,-n 'I 
I Nlh-CH -CH.1-COOH 0 " 1 1-1 ~:-; '" ;f-Alanme I. N-Carbamoyl-Jl- I 
0 II H II, ammo-isobutyrate I 
Dihvdrouracil / 1 JJ O,+:-.H, 
NH, - Clk·CH-COOH 
- . I 
1:1-A~~'i>isobutyratc 
I 
_:j 
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I 
Biosynthesis of pyrimidine nucleotide 
( ' 0 0 0 
[i "iAJI' ~ .\IHI , LI PRPP P, ll C02 ll 
... t l N . . ~~tnf'' ~~-') 4H~ ,,.. )li1 (6)~ . 1j " ) 
o~·~' · "; coo· ,~ ...... ·.; oo- o-:7'- · - oo· if/'N 
H I I 
U rotate Ribose-5-P Ribose-5-P H l li ~ .. r:1. 01> rotntt: 
Orotidinc mono- UMP 
pbospb11te (OMP) 
.! (7) 
dl ' l\tP UDP (IO) UDP 
(1 l) ~/-N5,1" 10-Methylene-THFA 
HFA (lJ)THFA) 
\...~ 
I (8) 
+Gin U~P 
+AT~ (9) 
0 
H~CU, 
0 A N)dTMP 
J dRibose-5-P 
( / ) C 'arbamoyl phosphate synthetase 
(2) ilspartate trw1scarbumoylase 
(3 J !JihyJroorotase 
(4) Difrrdroorotafe dehydrogenase 
(5) Ornule phosphorihosyltramrerase 
(6) (),\ / : de~arbo."Cylase 
ur) CTP~N I Ribose-5-P 
(7) Nucleoside phosphate kinase 
(8) Nucleoside diphosphate kinase 
(9) CTP synthetase 
( J(I) Ribonuc/eoside diphosphate 
reductase 
rJ /) Thymidy/ate synthetase 
308 
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Disorders of nucleotide metabolism 
-
Medical 
condition 
Gout 
Xanthinuria 
Lesch-Nyhan 
syndrome 
I I Enzymes Sympt 
I deficiency 
oms and effects 
Disorders of purine metaboli sm 
PRPP synthetase 
PRPP glutamyla-
midotransferase 
I 
I 
I 
' 
Hyperuric-. ~mia, deposition of 
ate crystals in the sodium ur 
joints (top. 
I the joints r 
hi). inflammation in 1 
esulting in a pain-
' ful gouty a 1 hri;j, rreci pita-
tion of s•Jd 
uric acid i1 
iw~1. urare and/or I 
i ters tlrnt r" 
__ -----~ge imd stc 
, Xanthine oxidase I High cone 
l l<wnevs and ure-sult~ i; renal dam- l 
•ne formation 
- - -- ---- -
er.trations of xan-
1 
• thine in bl ood and urine, 
I 
; 
~ypoxru>thin<-
, guanine phosphori-
bosyltransferase 
i 
i 
I 
I 
which can kad to health prob-
as renal failure and I !ems such· 
I xanthine ki 
' the rarest types of kidney 
dnoy >lm>0>, ono of I 
stones. 
Hyperurice mia, neurological 
abnormal it ies such as mental 
retardation , aggressive beha-
, vior, learni I The patient ng disability etc. s have an irresisti-
bite their fingers 
using self-J:"'geto d lips, ca 
tilation 
--------- ____ J 
Disorders of ~yrimidine metab olism I 
of orotic acid in l Orotic aciduria I Orotate phosphori- 1 Excretion 
ho•yl trmfrm~ u•in<, "" 
· , OMP decarboxylase tarded gro\ 
Reye's syn- Ornithine transcar- Accumulati 
drome bamoylase phosphate. 
(secondary i and excreti 
re anemia and re- i 
vth I 
- - - - -- --- - - j 
on of carbamoyl I 
Increased synthesis 
on of orotic acid ' 
orotic aciduria) _J_ __ _ __ ___J 
309 
182 
,----
1 
Primary structure of DNA 
Secondary structure of DNA 
2. Dot>I* strand 
183 
310 
311 
Tertiary structure of DNA 
Tlle 
9019nolU i
-
,_ 
312 J 
---------
-------- ---- - ------- --------· 
Replication 
- is a process in which DNA copies itself to produce identical daugh-
ter molecules of DNA 
I 
Components required for the I stages ofreplication: 
1
1. Initiation step: initiation 
proteins, single-strand binding 
; protein (SSB), helicase, gi·-
1 rase, primase, nucleoside tri-
1 phosphates; 
: 2. Elongation step: deoxynuc-
1
. leoside triphosphates, DNA 
polymerase Ill, primer, DNA 
1 polymerase I; 
j 3. Termination step: DNA 
1 ligase. 
Nidb)· 
D~A8}Ule 
I 
5' 
I' 
--Ol.wk1frjf'1Klli(p!I\ 
of die laWnf MIW) 
'~-4 .. '+--SSB~ 
_ ,J 
184 
Transcription 
- is a process of RNA synthesis directed by a DNA template 
Components required for the stages of transcription: 
1. Initiation step: RNA polymerase, template strand of DNA. 
2. Elongation step: nucleoside triphosphates. 
3. Tcrmin:ltion step: termination sequence. 
upstr~a•r )t"'t':lWtam 
.. __ - --"T' 
I 
··an 
S•i 
I 
· l () . 1. O = ft::""~I Slllild )cJ#M-_ __ · ·-·-----~ 
~ T~ SlilWI 
.RNA P~rase ' .! 
T llll\SUJbH : 
OW. T Slrarwi 
314 
~----------------------------' 
------------------------~ 
Processing of mRNA 
l•<"IC'Jl:tit' T·mlati " 
,i,;t ~an(A Cl 
Q Exon Q '1tron 
I ii I ill 
315 
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Protein synthesis (or translation) 
Cellular components required for the stages of protein synthesis: 
I. Activation of amino acids: 20 proteinogenous amino acids 
(L type), tRNAs, aminoacyl-tRNA synthetases, ATP, H20, 
M 2+ 
2. Infti~tion step: Initiation factors (IF-I, IF-2, IF-3), small I 
(30S) and large (50S) ribosomal subunits, N- I 
formylmethionyl-tRNA (= initiator tRN;\), mRNA. initia- I 
tion codonsin mRNA (AUG, GUG). G'T f' . Mg~ . 
3. Elongation step: Functional 70 .~ ril--osume (i nitiation 
1 
complex), aminoacyl-tRNAs specified hy codons, 
elongation factors (EF-Tu, EF-Ts, EF-G). pep1i<~1i iran~fe- I 
~ + 
rase, GTP, Mg"" ; I 
4. Termination step: 70S ribosom e, termination codons in 
mRNA (UAA.' UAG, UGA), polypeptide release factors I 
(RFI, RF2, RF3), ATP; 
5. Post-translational modifications: Specific enzymes and i 
cofactors for removal of initiating residues and signal se- ! 
quences; additional proteolytic processing: modification of j 
terminal residues; attachment of phosphate, methyl, carbox- I 
yl, carbohydrate, or prosthetic groups. I 
Activation of amino acid: 
1-PHI.:' 
NH, :(:~~ ? 0.JT4 
N._A, ~I\ ~ (( ii 1 R- Cll ~ 7 ~....--o 
N---.. ~ '--o .~ ~ + t-RNA 1
1 
- ~, 1ro,H,), l N r " ,...._,I o'l{°~ + NH,-T"-COOH .... 0-~Hi I --- I OH 
" I R fl - i:I' · AMP ,.,.__ 
O '1 v1 • PPI 'f=O 
OH OH Amino Acid ~~ R-Ctt-Nll, 
ATP Amlnoacyl-adenylate Aminoacyl-tRNA 
(Amlnoacyl-AMP) 
3 16 
186 
I 
I 
i ----- Initiation step 
1 
I mRNA 5' 
UA A AUG auu CC A C A A 
·~~~'W'~'-L-' W''L-..L1 L' L' ~'~' ~' -'-'' 1W1'--~---~ 3' I 
Sm•" ,;~'.'.'.-'.'.~','"'"°" \ 
\_ ' 5' _..J.....1...._....U....._....U.......U....:......l ........ _,__~ 3· 
)
l ltlaUon 
factors 
M~ '.:F•) 
187 
I. Large 11bosomal subunit DP+P1 
eIFs 
317 
Elongation step 
I Mtl Vi l 
'm"~ Ef1·an>' Eft'(l(f 
+P1 
( ~; ~ :JJ:W: ~Gi.ii;cH r , .. ,rr;, ., 1. i ,,. 
...... _::;;-
Elm1gation step~ 
1-3 repeated 
I. Binding of aminoacyl tRNA to the A site. 
2. Fonnation of a peptide bond. 
3. Translocation. 
The two steps in J occur simultaneously 
'--------------------- ------
_ 'j 
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G fl'-
·~+ 
Pept·~· 
i 
Termination step 
I/WA 
T•rm•netlon 
lnQr>Mnse! 
codon 
+ '+ 0111' + ,, 
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Vitamins 
i 
I 
' ! 
.~J 
Antivitamins are antagonistic to the action of vitamins I 
1. Antivitamins are a structural analogue of the vitamins and a 1 
competitive inhibitors of the vitamin's action, causing defi-
ciencies, e.g., dicumarol, 4 · -hydroxythiamine. 
2. Some antivitamins are enzymes, destroying vitamins, e.g., I 
thiaminase found in raw fish cleaves thiamine. j 
3. Some antivitamins form with vitamins strong inactive com-
1 
plexes, e.g., avidin combines tightly with biotin, preventing its I 
absorption. I 
4. Some antivitamins have ability to induce chemical modifica- : 
tion of vitamins. I 
I 
32 1 I 
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Exogenous causes of hypovitaminosis 
I. One-~ ided nutrition (insufficient intake). 
2. inadequate amounts of or absence of vitamins in food. 
3. Improper storage of food products and gross violations in 
preparing and cooking food, which result in the destruction 
C'f most of the \itamins. 
.- --·--·-
I 
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I Endogenous causes of hypovitaminosis 
I The need of the human organism for vitamins is greatly in-
1 
creased during severe physical stress, pregnancy, and breast 
feeding. 
I I. Increased Jcslruction of vitamins at febrile states. 
1
1 2. Diseases affecting the gastrointestinal tract - impaired ab-
sorpt ion of vitamins. 
3. Diseases affecting the liver, pancreas - impaired intake of 
lipid soluble vitamins. 
4. Drug therapy: 
•antibiotics, sulfanilamides administration suppress the in-
testinal microflora; 
•suppression of endogenous synthesis of vitamin K, biotin, 
vitamins of B group in the intestines; 
•tranquilizers suppress synthesis of coenzyme form of vita-· 
min B2; 
•aspirin suppresses utilization of folic acid; 
•nitrous oxide used in surgery inactivates 8 12; 
•some medicines are antivitamins. 
L 5. Administration of antivitam-in_s_. __________ __. 323 
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Features of lipid soluble vitamins 
I. Apolar hydrophobic molecules, wh ich are all isoprene de-
rivatives. 
2. Cannot be synthesized by the body and must be supplied 
by the diet. 
3. Require normal fat absorption in order to be absorbed. 
4. Must be transported in the blood in lipoproteins or specific 1 
binding proteins. i 
5. Can be stored in liver and adipose tissue. 
6. Excess consumption of these vitamins (particularly A and 
D) leads to their accumulation and to~ic effc:.: ts (hypervi-
taminosis). 
I 
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Provision rate of organism with vitamins 
I 
·-
-p;;,.-;;;neter j _ J2.iag,;~S~£.]!_alue _ ~ I ! Vitamin Rate 
Retinol In plasma >0.7 i Norma 1 I 
µmol/L 0.35-0.7 1 Moderate deficit 
<0.35 -1---· __ _E:xtreme deficit 
Calciferol In plasma >25 I Nonna 
nmol/L 12.5-25.0 Moderate deficit 
<12.5 I Extreme deficit 
·- --- - -----t--- ------
Tocopherol In plasma >2.22 j Nonna 
a-Tocopherol I <2.22 Deficit 
·I cholesterol I 
I µmot /mmol I 
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Vitamin A (retinol, antixerophthalmic vitamin) 
reduction 
R ~C-H~ 
~ - . ~- l CH20H 
Retina l Retinol 
I 
nxidntio11 
acy/CoA 
11 
' -ex 
0 
I II ~ C-OH 
Retinyl esters 
Rctinoic acid 
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Biological roie of vitamin A 
I. Retinol supports the normal function of the reproductive system in 
males and females. 
2. Retinol and Retinoic acid are involved in the control of the ex-
pression and transcription of certain genes. Thus they regulate the 
protein synthesis and are involved in the cell growth and differen-
tiation. 
3. 
4. 
5. 
6. 
7. 
8_ 
Vitamin A is essential to maintain epithelial tissue. This is due to 
the fact that retinol and retinoic acid are required to prevent keratin 
synthesis (responsible for horny surface). 
Retinoic acid is necessary for the synthesis of certain glycoprote-
ins, which are required for growth and mucus secretion. 
JJ-Ca1 otenc is an antioxidant and may play a role in trapping pe-
roxy free radicals in tissues at low partial pressures of oxygen. 
Vitamin A and JI-carotene antioxidant properties may well ac-
count for their possible anticancer activity. 
Vitamin A is essential for the maintenance of proper immune sys-
tem to tight against various infections. 
Retinal participates in the visual cycle. 
327 
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Visual cycle 
Rhodopeln L 1q11: 
(11-cls-retloal-o:fpsin} _ ...,........-(pr:::: :-:. ,, 
Nerve 
Impulse 
Op sin 
11·cl9'retinal 
NAD .. 
11 ·cis-retinol 
t 
I 
NADH ... H..:..I 
. NA0·1 ............ (.-·--
AU· tran.s-:-retinol (liver) 
The daily requirement 
1.5-2.5 mg of vitamin A (5.000-7.000 JU) 
or 2-5 mg of carotio. 
328 
! 
Sources: liver, kidney, egg yolk, milk. cheese, but- / 
ter, cod-liver oil. I 
Vegetable sources - P-carotenes (A provitamins) - 1 
carrots, spinach, tomato, pumpkins, mango, papaya etc. 
'----------------------·---~-! 
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l~~;ght-blindn"' ( nye1':::::::::::;;, y;,;on I ~- Dcyne" and det";orahoo ;o eonjunehvo ond eomoo of the eye (X<-
1 
rophthalmia). 
3. Keratinization of epithelial tissues of the eye, lungs, gastrointestinal, 
1 and genitourinary tracts. coupled with reduction in mucous secretion. 
I ·+. Destruction of the cornea (keratomalacia) causing total blindness 
i 5. Drying of skin and atrophy of sebaceous glands, appearance of pus-
' tuks around hai r follicles. 16. Deg<.:"neration of germinal epithelium, thus affecting reproduction. 
1 7. Defective fonnation of the enamel of teeth. 
' 8. Growth retardation due to impairment in skeletal formation. 
Hypervitaminosis A 
This is po.>sih le in children by ingestion of large dose of vitamin A. 
Manifestations are headache, lack of appetite, dermatitis (drying and red-
ness of skin), enlargement of liver and spleen, skeletal decalcification, 
I thickening of long bones . loss of weight, irritability, loss of hair, joint 
I pains etc. 
I rn I _____ _ _ 
Vitamin E 
(tocopherol, antisterile vitamin, 
vitamin of reproduction) 
195 
Biological role of vitamin E 
I. Vitamin E is essential for the membrane structure and integri-
ty of the cell. 
2. Vitamin E is a most potent fat soluble antioxidant: 
• Vitamin E prevents the peroxidation of polyunsaturated fatty 
acids contained in cellular and subcellular membrane phos-
pholipids of mitochondria, ER, and plasma membranes by 021; 
and free radicals such as 0 2·-, OH", Ho2• and H202. 
Toe-OH+ 0 2·- -+ Toc-0 + Ho2• 
• Vitamin E breaks free-radical chain readions as a result of it 
ability to transfer a phenolic hydrogen to a peroxyl free radi-
cal of a peroxidized polyunsaturated fatty acid. The phenoxy 
free radical formed then reacts with a further peroxyl free rad-
ical. 
Toe-OH + R --+ Toc-o· + RH 
Toc-0' + R' --+ Toc-0-R 
• Selenium as prosthetic group of glututhione peroxidase offers I 
protection against the peroxidation of membrane lipids. Sele- 1 
nium and vitamin E spare each other by cooperative function-
ing. 
ROOH + 2G-SH -+ ROH + G-S-S-G + H20 
3. Vitamin E prevents the oxidation of vitamin A and carotenes 
from oxidative destruction. 
4. Vitamin E is required for cellular respiration through electron 
transport chain (believed to stabilize cocnzyme Q). 
The daily requirement 
20-30 mg of vitamin E 
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Requirement of vitamin E increases with increased intake of po-
lyunsaturated fatty acids (PlJF A): I g of PUF A is corresponding to I mg of 
vitamin E. 
Sources: Wheat germ oil, cotton seed oil. sunflower seed 
oils, com, peanut and soya bean oil, grain crops. hips, salad, 
cabbage, eggs, meat, fish, liver, milk and butter. 
333 
196 
Hypovitaminosis E 
1. Severe symptoms of vitamin E deficiency are not 
seen in humans except increased fragility of erythro-
cytes. muscular weakness, creatinuria and minor neu-
rological symptoms. 
2. ln 11 ~~my animals like rabbit, rat, guinea pig, the defi-
cic:h'Y is associated with sterility, degenerative 
cha;iges in muscle, megaloblastic anemia and 
I changes in ~eutral nervous system. 
I 
I 
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Vitamin K ! ----(phylloquinone, antihemorrhagic vitamin) 
I 
I 
I 
I 
0 
0 
Phylloquinone (K1) 
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Biological role of vitamin K 
1. The functions of vitamin K are concerned with blood clotting 
process. It brings about the posttranslational modification of 
clotting factors II (prothrombin), VII, IX and X, synthesized 
as inactive precursors in the liver. For their modification into I 
the active forms they require vitamin K as coenzyme for the 
y-glutamate carboxylase enzyme that forms y-carboxy glu- j 
tamate from glutamate residues present in the proteins. y- , 
carboxy glutamate residues are high affinity calc imr chela- ! 
~n. I 
- AA - Glu - AA- - AA - Glu -- AA · I' 
CH "tK CH2 ~~~H VI -~ c6~~'! ) ' 001 l 1 
inactive clotting factor active ciutting factor ,. 
2. Vitamin K is also required for the carboxylation of glutamate 
residues of osteocalcin, a calcium binding protein present in , 
~~~- I 
3. Vitamin K as a cofactor in oxidative phosphorylation being 
associated with mitochondrial lipids. 336 I 
I 
The daily requirement 
0.2-0.3 mg of vitamin K 
I 
Sources: Vitamin K can be adequately synthesized in the I 
gut by the microflora, cabbage, cauliflower, tomatoes, alfa alfa, 
spinach, egg yolk, meat, liver, cheese and dairy products. I 
Vitamin K is widely distributed in plant and animal tissues 
used as food, and production of the vitamin in the intestine en- I 
sures that dietary deficiency does not occur in adults. 
337 
198 
Hypovitaminosis K 
1. Vitamin K deficiency can be caused by fat malabsorption, 
which may be associated with pancreatic dysfunction, bi-
liaf) disease, atrophy of the intestinal mucosa, or any cause 
of steatorrhea. In addition, sterilization of the large intestine 
by antibiotics can result in deficiency when dietary intake is 
lim ited. 
2. At vitamin K deficiency blood coagulation is adversely af-
fected. The individual bleeds profusely even for minor inju-
ries. The blood clotting time is increased. 
3. Vitamin K deficiency leads to bleeding and hemorrhage of 
the ne~bom. 
L ____ ___ ___ _ 
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Vitamin D ( cholecalciferol, calciol, 
antirachitic vitamin) 
CH 
338 
LI OHD"" Cholecalciferol (vitamin D3) 339 
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Biological role of calcitriol (or 1,25-
dihydroxycolecalciferol) 
1. Action of calcitriol on the intestine. 
• Calcitriol stimulate the intestinal reabsorption of Ca 
and phosphate by increasing the synthesis of the cal-
cium-binding protein which increases the Ca upt1ke 
by the intestine. 
2. Action of calcitriol on the bone. 
• Promotes bone formation by stimulating osteoblast I 
differentiation. In the osteoblasts calcitriol stimu-
lates Ca uptake for deposition as calcium phosphate 
thereby influencing the mineralization of young 
bone tissues. 
• Increases blood Ca levels through increased Ca and 1 
phosphate mobilization from old bone. ! 
3. Action of calcitriol on the kidney. 
• Calcitriol is involved in minimizing the excretion of 
Ca and phosphate by decreasing their excretion and 
enhancing reabsorption by inducing transporters. I 
Thus calcitriol causes elevation in the plasma Ca and I 
phosphate levels. -.io 
200 
Metabolism of vitamin D 
341 
The daily requirement 
12-25 µg (500-1000 JU) of vitamin D 
Sources: fish liver oils, liver, butter, milk, fatty fish, egg 
yolk etc. 
Vitamin D can be provided to the bodv in three ways: 
J. Exposure of skin to sunlight for synthesis of vitamin D; 
2. Consumption of natural foods; 
3. By irradiating foods (like yeast) that contain precursors of 
vitamin D and fortification of foods (milk, butter etc.). 
342 
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Hypovitaminosis D 
Deficiency of vitamin D causes rickets in children and osteo-
malacia in adults. 
1. Rickets is characterized by defective ossification leading to 
soft and pliable bones, bow-legs, knock-knees, bead-like 
swellings at the rib junctions (rachitic rosary), enlargement 1 
of the epiphyses and contracted pelvis. 
2. In case of osteomalacia (adult rickets) demineralization of 
the bones occurs (bones become softer). increasing their 
susceptibility to fractures. The ionic serum calcium is 
reduced to low levels resulting in neuro-muscular 
irritability and tetany. 
Hypervitaminosis D 
1. Excess of vitamin D causes demineralization of bone (re-
sorption) and increased calcium absorption from the intes-
tine, leading to elevated calcium in plasma (hypercalce-
mia). 
2. Prolonged hypercalcemia is associated with metastatic cal-
cification of soft tissues such as kidney and arteries, calculi 
formation. 
3. High consumption of vitamin D is associated with loss of 
appetite, nausea, increased thirst, loss of weight, digestive 
disturbances etc. 
343 j 
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Vitamin C 
(ascorbic acid, anti-scorbutic vitamin) 
O=C1 HO-C 
II 0 
HO-~J 
o-c 
I 
HO-C-H 
I 
COOH 
I 
o=c 
I 
+ n20 o=c 
~I 
H-C-OH 
I 
HO-C-H 
I 
C~20H CH20H 
Ascorbic acid 
li ±2H 
0=~1 
o=C 
10 
2,3-diketogulonic 
acid 
O = ~ J Debydroascorbic acid 
H-C 
I 
HO-C-H 
I 
CH20H 
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Oxalic acid 
COOH 
I 
COOH 
+ 
COOH 
I 
H-C-OH 
II 
HO-C-H 
I 
CH20H 
Tbreonate 
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Biological role of vitamin C 
Vitamin C participates in several types of reactions: 
I-st type of reactions: Ascorbic acid + NADP --> Dehydroascorbic 
acid + NADPH2 ; NADPH2 is used in hydroxylation reactions: 
Examples: 
I . Vitamin C as coenzyme of lysyl hydroxylase and prolyl hydrox-
ylase in hydroxylation of proline to hydroxy proline and lysine to 
hydroxy lysine. Thus vitamin C is involved in collagen synthesis. 
2. Hydroxylation of tryptophan (enzyme hydroxylase) to hydroxy-
tryptophan in the synthesis of serotonin. 
3. Synthesis of norepinephrine from dopamine. 
4. Neutralization of toxic substances by microsomal oxidation. 
5. Role in the production of the steroid hormones from cholesterol, 
by activating certain enzyme systems involved in the process in 
the gonads and adrenal cortex. 
6. Oxidation of p-hydroxyphenylpyruvate (enzyme hydroxylase) to 
homogentisate in tyrosine metabolism. The subsequent step is 
catalyzed by homogentisate dioxygenase, which also requires as-
corbic acid. 
7. The bile acid formation at the initial 7a-lzydro.'1.ylase step. 
11-nd type of reactions: reactions of reduction: 
l. Ascorbic acid is involved in the redox mechanisms. 
2. Iron absorption by conversion of the ferric form (Fe3-) to the ferr-
ous form (Fe2+). 
3. Reconversion of methemoglobin to hemoglobin by conversion of 
the ferric form (Fe3+) to the ferrous form (Fe2·). 
4. The degradation of hemoglobin to bile pigments. 
5. Formation of deoxyribose from ribose. 
6. Formation of tetrahydrofolate from folic acid (enzyme folic acid 
reductase). Thus vitamin C is involved in the maturation of eryt-
hrocytes. 
111-d type of reactions: as antioxidant: 
I. Sparing of vitamins A and E from oxidation and may inhibit the 
formation of nitrosamines during digestion. Act as a general wa-
ter-soluble antioxidant. 
2. Synthesis of immunoglobulins (antibodies) and increasing of the 
phagocytic action of leucocytes. lmmunologic1.1l fimction of vita-
min C. 
345 
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Eventual effects of vitamin C 
I . Increasing of organism resistance to the action of adverse 
factors. Participation of vitamin C in I type of reactions, 
(examples 2-5) and in III type of reactions. 
2. Maintenance of normal connective tissue - synthesis of 
collagen. 
3. Participation in hernatopoiesis (II type of reactions). 
346 L_ 
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1------Hypovitaminosis C 
•The deficiency of ascorbic acid results in scurvy. This disease 
is characterized by spongy and sore gums, loose teeth, anemia, 
pains at the swollen joints, decreased immunocompetence, de-
layed wound healing, union of fractures, sluggish hormonal 
function of adrenal cortex and gonads, reduction in the amount 
of inter-cellular substance and weakens the endothelial wall of 
the capillaries, fragile blood vessels, hemorrhages inside the 
muscles, from the mucous membranes of the mouth and gastro-
intestinal tract and under the skin (petechial hemorrhages), os-
teoporosis, swelling and bleeding of gums with ulceration and 
even gangrene, etc. Subcutaneous bleeding results in the for-
mation of red patches under the skin. 
•Most of these symptoms are related to impairment in the syn-
thesis of collagen and/or the antioxidant property of vitamin C. 
347 
205 
Medicines of vitamin C 
Ca ascorbate Treatment of diabetes, cardiac in-
sufficiency 
Fe ascorbate Treatment of anemia, antiulcerant, 
tonic effects 
- -----·-
Mg ascorbate Treatment of psychical disorders, 
asthenia, physical and mental re-
tardation 
------·------ -
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Provisio: rate~forganis-;,,-:;-h vita:;: C I 
Rate Parameter i _piag11ostj_<;_'l!_~Ue I ! 
In plasma I > 17.0 _I ______ N2rma __ 1 
µmole /L t'-- 6.0 - 17.0 ti_ Moderate deficit 1 
< 6.0 Extreme deficit 
- ------- --- · - - - _ J 
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The daily requirement 
70-120 mg of vitamin C 
Sources: Citrus fruits, gooseberry, guava/ green vegetables 
(cabbage, spinach), tomatoes, potatoes (particularly skin), green 
peppers, hips, currant, sorrel. High content of vitamin C is found 
in adrenal gland and gonads. 
350 
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I Vitamin P (vitamin of permeability) 
I 
The colouring pigments in plants like rutin and hesperidin arc 
referred to as vitamin P. They are bioflavonoids. 
Ru tin L ___ _ 351 
1-------Biological role of vitamin P 
I l. Bioflavonoids act as antioxidants. 
2. Bioflavonoids protect vitamin C from being destroyed. 
3. Biotlavonoid's antioxidant property responsible for main-
tenance of capillary penneability for correct the vascular 
abnormality. 
The daily requirement 
30-50 mg of vitamin P 
I 
Sources: Tea, peels and pulp of citrus fruits (oranges, lem-1 
ons), tobacco leaves, hips, currants, sorrel and many vegetables. I 
152 
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Vitamin B1 (thiamine, anti-beri-beri vitamin, 
antineuritic vitamin) 
NH2 j e r/tt-cu2-~-IT-CH3 
~ / BC., / C-CH2-CH2-0H 
H3C N s I 
Thiamine 
Active fonn is coenzyme, Thiamine diphosphate (TDP).1 
The pyrophosphate moiety is donated b) ATP and the reaction is 
catalyzed by the thiamine pyrophosphate trans/erase mainly in 
brain and liver. 
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Biological role of vitamin B1 
Enzymes are dependent on TOP: 
1. Pyruvate dehydrogenase catalyses oxidative decarboxyla-
tion of pyruvate to acetylCoA. I 
2. a-Ketoglutarate dehydrogenase catalyses oxidative decar-
boxylation of a-ketoglutarate to succinyl CoA (citric acid I' 
cycle). 
3. a-Keto acid dehydrogenase (decarboxylase) catalyses the I 
oxidative decarboxylation of the a-ketoanalogs of Leu, Ile, 
and Val. 
4. Transketolase (pentose phosphate pathway of glucose me-
tabolism). 
5. TOP is required for acetylcholine synthesis by inhibition of 
choline es/erase. 
6. Pyruvate decarboxylase catalyses decarboxylation of py-
ruvate to acetaldehyde (alcoholic fermentation). 
Thus B1 is involved in carbohydrate '.11etabolis~  
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The daily requirement 
2-3 mg of vitamin B1 
Sources: Whole grains, rice bran, wheat bran, cereals (oat, 
buckwheat, millet), meal, pulses, oil seeds nuts, hazelnut, wal-
nut, yeast, liver, eggs, fish, pork, heart, kidney, milk etc. I 
~ 
Hypovitaminosis B1 
The deficiency of vitamin B1 results in a condition called 
beri-beri. rhe early S) mptoms of Beri-beri are loss of appetite I 
(anorexia), weakness, constipation, nausea, mental depression, i 
peripheral ncuropathy, irritability, fatigue, headache, insomnia, · 
gastro-intestinal disorders and tachycardia etc. Numbness in the 
legs complaints of "pins and needles sensations" is reported. 
Manifestations of hypovitaminosis B1 
in European countries 
1. Wemicke's encephalopathy - neurological disorder caused by j 
thiamine deficiency, typically from chronic alcoholism or 
persistent vomiting, and marked by mental confusion, abnor-
mal eye movements, and unsteady gait. 
2. Wemicke-Korsakoff syndrome - disorder mostly seen in 
chronic alcoholics. It is characterized by loss of memory; apa-
thy and a rhythmical to and fro motion of the eye balls. 
356 
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Vitamin B:z (riboflavin, growth factor) 
Riboflavin 
Flavin mononucleotide (FMN) and Oavin adenine di-
nucleotide (FAD) are the two coenzyme forms of riboflavin. 
357 
Synthesis of FAD from FMN 
The daily requirement 
2-4 mg of vitamin B2 
Sources: It is synthesized by intestinal microflora, milk 
and milk products, meat, liver, kidney, heart, eggs, yeast, ee-l reals, fruits. vegetables, fish, roots, grain, seeds. 
L_ 359 
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' Hiological role of vitamin B2 
I Enzymes that use tlavin coenzymes (FMN or FAD) are called 
flavoprotei11s anJ participate in redox reactions responsible for 
energy production. The functional unit of FMN or FAD is isoal-
loxazine ring whkh serves as an acceptor of two hydrogen form-
ing FMNH 1 or FADH2. FAD and FMN are associated with en-
zymes involved in various metabolisms: 
I). Cellular respiration, where FAD and FMN act as components 
of the respiratory chain (RC): 
I. FMN is a component of the complete RC (FMN-linked-
dehydrogenase or NADH dehydrogenase). 
2. FAD is a component of the incomplete RC: 
• Succinate dehydrogenase - citric acid cycle, 
• Acy/ CoA dehydrogenase - P-oxidation of fatty acids). 
2). FAD is a prosthetic group of pyruvate and a-ketoglutarate 
dehydrogenase complexes (oxidative decarboxylation). 
3). FAD is the prosthetic group of: 
• D-amino acid oxidase (amino acid deamination), 
• Xanthinc oxidase (purine degradation), 
• Aldehyde dehydrogenase (degradation of aldehydes). 
4). FMN is a prosthetic group of L-amino acid oxidase (amino 
acid deamination). 
360 
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Hypovitaminosis of vitamin B2 
Riboflavin deficiency symptoms include: 
1. Cheilosis (fissures at the angles of the mouth or angular 
stomatitis). 
2. Glossitis (tongue smooth and purplish). 
3. Dermatitis. 
4. Inflammation of cornea, blood-shot c~es. dimness of vi-
sion, photophobia, burning and dryness of eyes and r.:dness 
of the conjunctiva. 
5. Itching. 
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Vitamin PP (niacin, pellagra-preventing factor, Bs) I 
(JcooH /;0 [ (lrc-NH2 ~ )J I 
.N N I 
Nicotinic acid or niacin Nicotinamide or niacinamide 
Niacin in the form of niacinamide is a part of the coen-
zymes nicotinamide adenine dinucleotide {NAD+) and nicoti-
namide adenine dinucleotide phosphate (NADP+). 
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Biological role of vitamin PP 
The NAD+ and NADP+ coenzymes of oxidoreductases are in-
volved in a variety of oxidation-reduction reactions. They accept 
hydride ion and undergo reduction in the pyridine ring. 
I. NAO+ is concerned with cellular respiration as a component 
of the complete respiratory chain (NAD-linked dehydrogenase).11 
NAOH produced is oxidized in the electron transport chain to 
generate ATP. 
• Ma/ate dehydrogenase, isocitrate dehydrogenase - CAC, 
• Lactate dehydrogenase, glyceraldehyde-3-phosphate 
dehydrogenase - anaerobic glycolysis, 
• /3-Hydroxyacyl CoA dehydrogenase - P-oxidation of fatty ac-
ids, 
• Alcohol dehydrogenase - oxidation of alcohol, I 
• Glutamate dehydrogenase-deamination of Glu . 
2. NAO is a coenzyme of pyruvatc and a-ketoglutarate dehydro- 1· 
genase complexes (oxidative decarboxylation) . 
3. NAOPH is a component of microsomal oxidation for neutrali- ' 
zation of xenobiotics. 
4. NADPH takes part in biosynthesis of fatty acids, cholesterol, 
bile acids, steroid hormones, vitamin D. 
5. NAOP"'" is a coenzyme of glucose-6-phosphate dehydrogenase 
and 6-phosphogluconate dehydrogowst! - pentose phosphate 
1
. 
pathway. 364 
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I The daily requirement 15-25 mg of vitamin PP 
Sources: Liver, kidney, heart, meat, fish, yeast, beans and 
peanuts, wheat and rice bran, whole grains, cereals, eggs, wge-
tables, milk. Tryptophan can be converted to niacin in the liver. 
1 g of a protein containing 60 mg of tryptophan is equivalent to 
1 mg of niacin. 
365 
214 
I 
I 
Hypovitaminosis PP 
Niacin deficiency results in a condition called pellagra 
(rough skin). This disease involves skin, gastrointestinal tract 
and central nervous system. 
The _<;ymptorn~ .Jf pellagra are referred to as 3 "D"s: 
Dermatitis liHtlamrnation of skin) is found in the areas of 
1 h..: :,kin t x poseLl t~' sunlight (neck. dorsal part of feet, an-
kle ad parts of fa-:.-..:'.-J Stages are erythema, desquamation, 
pigrnt>ntal ion, 
.., Diarrhea may he in the form of loose stools, often with 
blood and mucus . Prolonged diarrhea leads to weight loss; 
3. Dementia i~ associated with degeneration of nervous tis-
1
- sue. The symptoms of dementia include delusion, halluci-
nations, anxiety, irritability, poor memory, insomnia 
(sleeplessness) etc. 
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r 
I Provisi on rate of organism with ! 
vitamin PP 
I Rate I 
r:
------- --r-
1 in urine N- methyl-
1 nicotinamide I crea-
tinine, mlmole/L 
i 
I 
Parameter 
I .3-3.9 
0.4-1.3 
<0.4 
215 
Diagnostic value 
Norma 
Moderate deficit 
Extreme deficit 
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Vitamin B6 (pyridoxine, anti-dermatitis vitamin) 
Pyridoxine Pyridoxal Pyridoxamine 
The active forms of vitamin B6 are the coe1:zymes, pyri-
doxal phosphate and pyridoxamine phosphate. 
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....._-------------------·· ·---~ 
Coenzymes of vitamin B6 
Pyridoxal phosphate Pyridoxamine phosphate 
369 
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Biological role of vitamin B6 
Pyridoxal phosphate as coenzyme is used for certain en-
zymes: 
1. Aminotra~ferase -- transamination reactions (synthesis of 
nonessential amino acids, indirect deamination). 
2. Decarhoxylase - decarboxylation of certain amino acids 
(synthesis of biogenic amines). 
3. Kynureninase -- biosynthesis ofNAD and NADP from Trp. 
4. Cystathionine synthase - transsulfuration reactions in Cys 
metabolism. 
5. Dehydratases - deamination of Ser and Thr. 
6. Hydroxymethyltransferase -- Ser biosynthesis from Gly. 
7. Amino levulinic acid synthase - biosynthesis of o-amino 
levulinic acid (precursor for heme synthesis) from succinyl 
CoA and Gly. 
8. G~vcogen phosphorylase (glycogen degradation). 
Thus 136 is closely associated with the metabolism of amino 
acids. 
'~------------------------37_0__, 
,----- -
1 
The daily requirement 
2-3 mg, pregnant 6-7 mg 
Sources: synthesized by intestinal microflora, yeast, liver, 
heart kidney, meat, egg yolk, fish, milk, whole grains, wheat, 
legumes, peas, crude molasses, green pepper, cabbage, roots and 
tubers. 
371 
217 
Hypovitaminosis B6 
• Pyridoxine deficiency is associated with neurological symp-
toms such as depression, irritability, lethargy, nervousness 
and mental confusion. Convulsions, peripheral neuropathy, 
vomiting, diarrhoea and decrease in hemoglobin levels, as-
sociated with hypochromic microcytic anemia l re observed J 
in deficiency. 
• In children, B6 deficiency results in convulsions I epilepsy). I 
• Vitamin B6 more than 200 mg/day may cause neurological 
damage. I 
I 
17? I 
-- -------~ 
Vitamin B3 (pantothenic acid, chick J 
anti-dermatitis factor or filtrate factor) I 
CH3 I 
HOCH2---C---CH-CO-NH-CH2-CH2-COOH 
I I Beta-alanine 
CH,OH 
Pantoic acid part 
Pantotbenic acid 
Coenzyme forms of pantothenic acid : 
1. 4'-pbospbopantetbeine - non-protein group of Acy! car-
rier protein in the enzyme fatty acid synthase; 
2. Depbospbo-CoA - coenzyme of citrate (vase (fatty acid 
synthesis) and N-acetyltramferase (am mo acid 
metabolism); 
3. HSCoA. 
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I 
Biological role of vitamin B3 
I. Acyl carrier protein containing pantothenic acid moiety -
4' -phosphopantetheine and has an important role in the 
biosynthesis of fatty acids. 
II. Reaction:. invol\'ing Coenzyme A (HSCoA): 
I . Metaboli<;m r•f carbohydrates - oxidative decarboxylation 
of pyruvate to acclyl CoA and a-ketoglutarate to succinyl 
Coi\. S t il cinyl C0i\ is required for the synthesis of por-
ph:, rino; . 
2. Mt:·Lai.1oltsrn of lip ids - acylCoA and acetylCoA during the 
oxidation of fatty acids are produced. 
3. Acct;. i Cor\ is required for the synthesis of acetyl choline, 
cholesterol, skroid hormones, fatty acids, ketone bodies. 
4. Acety l CoA is a central molecule involved in all the meta-
bolisms (carbohydrates, lipids and proteins). 
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Hypovitaminosis B3 
Manifistations of pantothenic acid deficiency are: 
1. Dermatitis. 
2. U leers of the mucous of gastrointestinal tract. 
3. Burning feet syndrome (pain and numbness in the toes, 
sleeplessness, and fatigue). 
l~D:igmcntatio_n_. ---------------37_5__. 
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The daily requirement 
0-15 mg of vitamin B3 
Sources: liver, kidney, eggs, beef, milk, yeast, cabbage, 
cauliflower, potatoes, peanuts and peas. ------ -
376 
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Vitamin H (biotin, antiseborrheic vitamin, 
anti-egg white injury factor, vitamin B7) 
BiOtin Carboxybiotin 
.______ ___ mj 
220 
Biological role of vitamin H 
Biotin functions as cofactor of the multi-subunit enzymes which 
are involved in carboxylation reactions: 
I. Pyruvate carboxylase (gluconeogenesis). 
?"' ~':a" 
C=O +C02 +ATP I 
t ooH 'f82 
Pyruvat< ADP + Pi COOH OUl<>Acetate 
I 2. Acety!CoA carboxylase (synthesis of fatty acids). 
0 
o 11 
II + r o , + ATP coou-cu,-c-scoA 
CH,- ( - SCoA 
Aoetyl CoA A DP+ Pi l\folon~1 Co..\ 
i 3. PropionylCoA carboxylase (oxidation of fatty acids with odd 
I 
numbers of carbon atoms). 
CJ~ +lrnCoA+ATP ~H3 +C~+ATP ~H3 
I 
tH, ... ~MP-ffi"7 ~B? -ADP-Pi H-~-COOH-> 
1 • C=o PropionylCoA C:o 
' COOH l carboxylase f 
Propionate 
CH3 
- I 
---71100<> c-H 
I F=o 
SCoA 
SCoA <>Co A 
PropionylCoA 
coon 
I 
Cfl2 I 
CH2 
I C=o I 
SCoA 
CAC 
L-Methyhnalonyl CoA Succinyl C'oA 
4. fJ-A1ethylcrotony!CoA carboxylase (catabolism of leucine and 
certain isoprenoid compounds). 
fl-MethylcrotonylCoA --- fl-MethylglutaconylCoA 
5. Methylmalonyl-oxaloacetate transcarboxylase (reaction of 
transcarboxylation). 
:\fethylmalonylCoA + Pyruvate -if>ropionylCoA + oxaloacetate 
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Hypovitaminosis H 
• The symptoms of biotin deficiency include seborrhea, 
alopecia, paralysis, anemia, loss of appetite, nausea, 
dermatitis, glossitis, depression, hallucinations, muscle I 
pain, scaly desquamation of skin, lethargy. 
• Children develop dermatitis, alopecia. and loss of 
muscular control, and have retarded grovvth. ; 
The deficiency may be associated with two causes: I 
1. Destruction of intestinal flora due to prolonged use of I 
drugs such as antibiotics, sulfonamides. 1 
2. High consumption of raw eggs containing avidin. 
which tightly combines with biotin and hampers its 
absorption from the intestine. 
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The daily requirement 
120-200 µg of vitamin H 
Sources: supplied by intestinal bacteria, liver, kid-
ney, heart, milk, yeast, egg yolk, tomatoes, grains, brans, 
beans, soya beans, cauliflower. 
380 
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222 
Folic acid (folacin, vitamin B9, pteroyl glutamic acid, 
growth factor, B0 antianemic vitamin) 
OH 
' t JO ' ~rCH - 1-NH~CO"-NH-CH-CH -CH -COOH Ii ' 1 2 I ~j i I 2 2 
J-:::::. "'8 .J. I I COOH 
H2N N N I I 
I 
Pteruiit1c Para-aminobenzoic acid, L- Glutamate 
PAB(A) 
Folic acid 
Coennme 
i (THFA). . 
form or Folic acid 1s Tetrabydrofolic acid 
L ____ _ _ 
,-----
Synthesis of tetrahydrofolic acid 
N ~,Ny,?' 
1 • II Ny ' 
OH 
223 
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Biological role of folic acid 
The THF A acts as the one-carbon acceptor and 
forms derivatives: 
1. Ns(N10)-Formyl (-CHO), 
2. NS-Hydroxy methyl (-CH20H), 
3. NS-Formate (HCoo·), 
4. N5-Fom1imino (-HC = NH), 
5. N5,N10-Methylene (-CHr), 
6. N5,N10-Methenyl (-CH=), 
7. N5 -Methyl (-CH3). 
1. Folic acid plays biochemical role in the metabolism of 
glycine, serine, glutamic acid, histidine, ethanolamine, l 
betaine and choline. I 
2. N5,N10-methenyl-THFA and N10-formyl-THFA are / 
involved in the incorporation of formyl carbon into the I 
purine skeleton (carbon 2, 8) which is incorporated in- I 
to DNA and RNA. , 
3. N5,N10-methylene-THFA is involved for the synthesis 
of pyrimidine nucleotide - deoxythymidine ( dTMP) 
involved in the synthesis of DNA. 
4. N5-methyl-THFA (the major form of folate deriva-
tive) is required for the formation of methionine. 
383 
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Hypovitaminosis folic acid 
The deficiency of vitamin results in a macrocytic 
anemia that may be attributed to the decreased formation 
of new red blood cells due to interference with purine and 
thymine synthesis. Due to synthesis, the maturation block 
in DNA erythrocytes is slowed down leading to macro-
cytic red blood cells. 
Manifestations of macrocytic anemia: 
1. Low hemoglobin levels. 
2. Decreased number of erythrocytes. 
3. Presence ofmegaloblasts. 
4. Leukopenia. 
Treatment 
200 of folic acid per os or 10-20 mg intravenously 
The daily requirement 
50-200 µg of folic acid 
Sources: synthesized by intestinal microflora, green 
leafy vegetables, cauliflower, cabbage, salad, carrots, to-
1 matoes, onion, whole grains, cereals, liver, kidney, yeast, 
1 
eggs milk. 
385 
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Vitamin B12 ( cobalamin, antianemic vitamin, 
anti-pernicious anemia vitamin) 
::cr:CH, O-P---0 ( 
.II I . CH3 ....... 
0 H ~H 5. 6, dimethyl 
.Ao H H Benzimidazole part 
Of,OH T 
ribose 
Cyanocobalamin 
1. The structure of vitamin B 12 consists of a corrin ring having 
4 pyrrole rings with a central cobalt atom. 
2. Cobalt also holds dimethylbenzimidazole containing ribose-5-
phosphate and aminoisopropanol. 
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There are two coenzyme forms of vitamin B12 
l. Deoxyadenosyl cobalamin - cyanide is replaced by 5' 
deoxyadenosine. 
2. Methylcobalamin - cyanide is replaced by methyl groupj 
387 
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Absorption of vitamin 8 12 
I. Cobalamin binding proteins, known as 'R-proteins', are secreted by 
the salivary glands and the stomach and bind the 8 12• 
2. In the stomach 'R-proteins under action ofHCL are released. 
3. Cobalamins bind to the intrinsic factor of Castle. This binding protects 
8 12 against its uptake and use by bacteria. 
Intrinsic f actor'?( Castle is secreted by the parietal cells of the gastric 
mucosa of the Cardi a and the fundus of the stomach. It is resistant to 
proteolytic digestive' n i=ymes. 
4. The complex crosses the ilea mucosa. 
5. In the mucosa ! cells, intri nsic factor is released and B 12 is converted to 
methyk ob:'l lamin. 
6. Methylcobalamin is then transported in the circulation in a bound 
form to a plasma transport protein, transcobalamin II. 
7. Methylcobalamin is taken up by the liver, converted to deoxyadenosyl 
8, 2 and stored in this form in a bound form to a protein, transcobala-
min I. 
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Biological role of vitamin 8 12 
There are only two reactions that are dependent on vitamin B12. 
1. Conversion of methyl malonyl CoA to succinyl CoA in the 
mitochondria (see biotin above). The enzyme is L-methyl-
malonyl CoA-mutase and the coenzyme is 5'-deoxyadenosyl 
cobalamin. 
2. Synthesis of methionine from homocysteine in the cytosol. 
B12 converts N5-methyl-THFA to THFA. The enzyme is ho-
mocysteine me thy/trans/erase (or methionine synthase) and 
I 
the coenzyme is methylcobalamin. 
NS·Msthyt TliF Tl-IF 
L ~ Metlwtoooal111111n _/ ~eill& H I Metllionincl 389 
- --
227 
Hypovitaminosis 8 12 
The disease associated with vitamin B12 deficiency is per-
nicious (malignant) anemia. 
Manifestations of pernicious anemia are: 
1. Macrocytic megaloblastic anemia (see folic acid above): 
folate is trapped as N5-methyl THFA (Folate-trap) results 
in decreased folate coenzymes that lead to reduced nucleo-
tide and DNA synthesis. 
2. Neurological manifestations (neuronal degeneration of the 
cord and demyelination of nerYous sysrem) due to the I 
accumulation of methylmalonyl CoA and ddiciency of I 
methionine that interferes in myelin sheath fomiation. The 
symptoms include paresthesia (numbness and tingling) of 
fingers and toes, confusion, loss of memory and psychosis. 
3. Loss of appetite and failure of gro\.\th. I 
The deficiency of vitamin B 12 may be associated with fol-
lowing causes: 
I. Autoimmune destruction of gastric parietal cells, partial or 
total gastrectomy - intrinsic factor of Castle deficient. 
2. Hereditary malabsorption of vitamin B12. ____ _:j 
The daily requirement 
2-5 µg of vitamin B12 
Sources: 
1. Vitamin B12 synthesized by only microorganisms and not 
by animals and plants. 
2. Liver can store about 4-5 mg of vitamin B 12• 
3. Vitamin B12 is abundant in liver, meat, eggs, and milk, but 
not in plant products. 
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Hormones 
Hormone hierarchy 
Tropin 
Stalin e 
(inhlbitin11 
hormone) 
larget cell 
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Major mechanisms of hormones 
on metabolic regulation l 
I. Regulation of alterations in enzyme activity (hydrophil ic 
with cell-surface receptors). 
hormones j 
2. Regulation of amounts of enzymes :n the cell (lipophilic hormones 
with intracellular receptors). 
3. Regulation of membrane permeability (insulin). 
194 ! 
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Classification of hormones according to 
chemical structurt: 
1. Peptides or proteins (insulin, calcitonin, ACTH. ADH, glucagon). 
2. Amino acid derivatives (epinephrine, norepinephrine, th ~ rox me (T4). 
triiodothyronine (T3)). 
3. Steroids (sex hormones, glucocorticoids, mineralocorticoids) . 
Lipophilic 
honnones 
with intra-
cellular 
receptors 
Steroid-
thyroid 
mechanism 
Gluco- and 
mineralo-
Classification of hormones according to 
mechanism of action 
HydriE!i iiic hom1~nes ~vith ceU-s~rfa~r~ccpt0rs-- 1 
G p-r~ein-Iink~~ecc;:ptors___ TE~~~~~:-! 
I ! receptors 
- -·-- y,:-;-;---- I -
Adenylate Guanylate Ca "'"/phospho- j Kinase 
cyclase ; cyclase ' tidylinositol I mecha-
mechanism 1 mechanism mechanism ~-·ni~m . _ 
ai- and P- 1 Atrionatri- u ,-adrenergic Insulin, i 
adrenergic ca- uretic fac- catechol- GH, PRL ··. I 
! c~~~~~~-s, 1 ~;!~~;~: tor (ANF). ,
1
. ~:iinTn:RsAH~x~-~ ,r. Ill 
I 
mones, T3 ADH., gluca-
and T4, cal- gon, calcitonin, 
citriol TSH :==========:===--~~~~~~~~~~~~~~~~~~~-~~~~===----_ - 395 I 
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Mechanisms of hormone action 
Ca2• /phosphatidylinositol mechanism 
Gaknodulin 
(~J (C:.M} !--- c.,>+x; .... -Le. .. 
Prol•111 luruuu< 
Cn>°"ICaM 
'"""""' Pro._,-~-·----P~-
• 
-.. 
--· 
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Mechanism of hormone action 
Steroid-thyroid mechanism 
~-----------------~~ 
Hypothalamic and pituitary 
hormones 
232 
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I Hypothalamic hormones I 
I 
I 
Hypothalamic hormone Structure Anterior pituitary 
hormone affected 
--
I Corticotropin releasing 41 amino Adrenocorticotropic hormone I I hormone (CRH or corti- acids (ACTH or corticotropin) I coliberin) 
; I Thyrotropin releasing tripeptide Thyroid stimulating hormone 
I ~nnon' (TRH octhym- (TSH or thyrotropin) 
liberin) 
Gonadotropin releasing decapep- 1. Luteinizing hormone (LH 
hormone (GnRH or gona- tide or lutropin); 
doliberin) 2. Follicle-stimulating hor-
mone (FSH or follitropin) 
' 1-------
I Grow1h hormone- 1 44 amino Growth hormone (GH or 
· releasing hormone (GRH acids somatotropin) 
or somatatropin-releasing 
honnone, somatoliberin) 
- -·-·--
Growth hormone-release- 14 amino 
inhibiting hormone acids -
(GRIH or somatostatin) 
- ----
Prolactin releasing hor- tripeptide Prolactin (PRL or mamma-
mone (PRH or prolactoli- tropin, lactotropin) 
berin) 
---
-
Prolactin release- dopamine I inhibiting hormone and/or 
(PRlH or prolactostatm) peptide -
I 
I Molonotropin relming 
(56 amino 
acids) 
hexapep- Melanocyte stimulating hor-
hormone (MRH or mela- tide mone (MSH or melanotropin) 
noliberin) 
1----
Melanotropin release- tripeptide 
inhibiting hormone -
(MRIH or melanostatin) 
399 
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Pituitary hormones 
Anterior Structure Target Hormone Patlwphysiology 
pituitary tissue affected 
hormone 
--·-
ACTH Polypep- Adrenal Adrenal Excessive produc-
tide (39 cortex cortisol, tion: Cushing's 
amino aldoste- 1 syndrome -
acids) rone I hyperpigmen-
I 
tation, increased 
production of 
adrcnocortico-
I steroids, negative 
, nitro5en b<>lance, I impaired glucose 
I 
1 •olomnre, hyp«-
tension, edema. 
I 
muscle atrophy I 
TSH Dimer (ap) Thyroid rTJ,14 I 
Glycopro- gland I --
tein (Mm 
I I 30.000) 
--- ----
LH Glycopro- Corpus Estradiol, ' Desensitization 
tein (Mm luteum progeste-
25.000) cells, rone, 
Leydig testoste-
cells in the rone ! testis 
FSH Glycopro- Follicular Testoste-
tein (Mm cells in the rone, 
25.000) ovary, estradiol -
Sertoli 
cells in the 
testis 
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Pituitary hormones (continuation) 
Anterior Structure Target Hormone Pathophysiology 
pituitary tissue affected 
hormone 
I-
GH 191 amino Muscle, Insulin Deficiency: in the 
acids (Mm liver, like growing age caus-
22.000) adipose growth es dwarfism. Ex-
tissue, factor I cessive produc-
bone, (ICF-1 or tion: gigantism in 
mamma- soma to- children and aero-
ry glands medin C) megaly in adults. 
I and Insu- Gigantism is cha-
I I 
lin like racterized by in-
growth creased growth of 
factor II long bones. Aero-
(ICF-11 or megaly is charac-
somato- terized by increase 
medin A. in the size of 
I hands, facial 
I 
changes enlarged 
nose, protruding 
jaw), excessive 
hair, thickening of 
skin etc 
PRL Protein Mam ma- Progeste- Amenorrhea, ga-
(Mm ry gland rone lactorrhea in worn-
23.000) en; in men gyne-
comastia, impo-
tence 
MSH Polypep- Melano- Hyperpigmenta-
tide cytes in - ti on 
the skin 
Endor- Peptides Central 
phins and nervous - -
enkepha- system 
I ins 
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Anterior pituitary hormones. lliologi""I role ;i 
ACTH Promotes the conversion of cholesterol to pregnenolone, en-
hances RNA and protein synthesis, adrenocortical growth, in-
I creases lipolysis by activating lipase of adipose tissae. 
TSH Promotes the uptake of iodide (iodide pump) by thyroid gland. 
Enhances the conversion of r to t. Increases the prcteol) sis of 
I thyroglobulin to ~ecrete T3 and T4. Incre \Ses the synthesis 0f 
proteins, nucleic acids and phosp:iolipids in thyroid gland. 
LH Stimulates the ripe foliicle to ovulate, leaving the residual fol-
licle, which forms the corpus lutcum. Causes ovulation. 
FSH In females, stimulates ovulation, maturation of the ovi;m, sti-
mulates follicular growth. and increase~ the weight of the ova-
ries. In males, stimulates spermatogencsis. grov.th of semini-
ferous tubule. 
GH Promotes the uptake of amino acids into the tissues and in-
creases the proteii· synthesis, positive nitrogen balance, hypt:r-
glycemia. increases heµatic gluconeogenesis, hepatic gl: 'cogen 
synthesis, decreases peripherrl gluco: e utilization. impairs 
glycolysis in muscle and reduces the ti..;sue uptake of gluc1>sc. 
Promotes lipolysis in the adipose tissue and increases the le-
vels of free fatty acids and their oxidation in the liver, increas-
es ketogenesis. Promotes bone mineralization and its growth, 
cell growth, synthesis of RNA and DNA, positive Ca, Mg, 
Po/· balance, the retention of Na\ K+, and Cl", lactogenesis. 
PRL Grov.th of mammary gland, initiation and maintenance of lac-
tation. Synthesis of milk proteins (caseia, lacta!bumin), lactose 
during lactation. Increa~es the levels ::>f several enzymes in-
volved in carbohydrate and lipid metabolism. Promotes HMP 
shunt, increases lipid biosynthesis. Promotes the growth of 
corpus luteum. 
MSH Promotes the synthesis of skin pigment melanin (melanogcne-
sis) and disperses melanin granules that ultimately lead to dar-
kening of the skin. In humans, MSH docs not appear to play 
any role in melanin synthesis. 
Endorphins Produce analges;c opiate-like effects. hence they are also 
and enke- known as opioid-peptide:;. They bind to the receptors and con-
phalins trol the endogenous pain p~rception. 
___J 
402 
?36 
Pituitary hormones (continuation) 
l 
r 
Posterior 1 ---- Vasopressin- -
pituitary j (antidiuretic hormone, Oxytocin 
lrormones ~ ADH) 
Site of .\'._Vn- I ~~~raoptic nucleus of hy- 1 Paraventricular nucleus 
tlresis pothalamus of hypothalamus 
l Stimulus of Increased osmolarity of Stimulation of the nip-
1 
secretion plasma, hypovolemia, pies, vaginal and uterine 
· hypotension, emotional distention 
r _ ____  J and physical stress, pain 
Target tis- I Distal convoluted and , Mammary gland, uterus 
sue collecting tubules of the 
-~--~~idn~-----------1------------l 
Structure _ ,___ Nanopeptide __ -+-----=N--=-an=o:.r>oe:.=.c:o-=·ti=d-=-e __ -J 
Patlroplry- Deficiency: Diabetes in-
siology sipidus: excretion of large 
volumes of dilute urine 
_ ____ _ (polyuria) 
Process af- Acts on renal collecting Contraction of pregnant 
fected 1 ducts via V2 receptors- · uterus (smooth muscles) 
aquaporins to increase and induces labor. Con-
water reabsorption, which traction of myoepithelial 
leads to decreased urine cells (look like smooth 
'
i bfo
10
nn
0
dation. This increases 
volume, cardiac 
output and arterial pres-
sure. Binding to VI re-
ceptors on vascular 
smooth muscle cause va-
soconstriction, which in-
muscle cells) of breast. 
This causes milk ejec-
tion. Oxytocin synthe-
sized in the ovary ap-
pears to inhibit steroido-
genesis 
____ __._!_c_re_a_ses arterial pre~_su_r_e __ _,__ __ _____ __, 
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Hormones of the adrenal cortex 
404 
Glucocorticoids 
Corti ol Corticosterone 
405 
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I 
I 
I 
I 
I 
I 
I 
Regulation of cortisol secretion 
Emotion, stress, trauma and 
influence of circadian rhythm 
[ 
Corticotmpin releasing factor 
8 (CRF) 
: ~ 
c: 
.E 
• 
.,. 
J 
1 ~ Adrenocortlcotropic hormone 
;IL (ACTH) 
L _____________ Co_ rti_·ao __ , _________ 4_0_6___. 
r-- Transport of cortisol 
I • The main plasma binding protein is a a-globulin called tran-
scortin or corticosteroid-binding globulin. 
• Much smaller amounts of cortisol are bound to albumin. 
• The unbound, or free, fraction constitutes about 8% of the to-
tal plasma cortisol and represents the biologically active frac-
tion. 
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Biochemical functions of glucocorticoids 
I. Effects on intermediary metabolism 
l ). Effects on carbohydrate metabolism is to increase blood glucose 
concentration. Increase glucose production in liver by: 
• increasing the delivery of amino acids from peripheral tissues 
(amino acids are released from proteins of muscle, lymphoid and 
connective tissue). 
• increasing the rate of gluconeogenesis by inducing synthesis and 
activity of the enzyme phosphoenolpyruvate carboxykinase. Glu-
cose produced is stored as glycogen in the liver by the activation 
of glycogen synthase. 
2). Effects on lipid metabolism is to increase the circulating free fatty 
acids by two mechanisms: 
• increasing the breakdown oftriacylglycerol (lipolysis) in adipose I 
tissue but can cause lipogenesis in other sites (face and trunk). 
• reducing utilization of plasma free fatty acids for the synthesis of 
triacylglycerols. 
3). Effects on protein and nucleic acid metabolism: 
• anabolic effects in liver - promote transcription and synthesis of 
proteins by the stimulation of specific genes. I 
• catabolic effects (particularly at high concentration) in extrahe-
patic tissues (e.g., muscle, adipose tissue, bone, lymphoid and 
connective tissue) - promote degradation of proteins. 
II. Effects on host defense mechanisms 
1). Suppress the immune response by: 
• species- and cell-type-specific lysis of lymphocy1es. 
• impainnent of antibody synthesis. 
2). Suppress the inflammatory response by: 
• decreasing the number of circulating leukocy1es and the migra-
tion of tissue leukocytes. 
• inhibiting fibroblast proliferation. 
• inducing the synthesis of lipocortins, which, by inhibiting phos-
pholipase A2, blunt the production of the inflammatory prostag-
landins, thromboxanes and leukotrienes. 
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Ill. Other effects of glucocorticoids 
I ) Necessary for maintenance of normal blood pressure and 
cardiac output. 
2) Required for maintenance of normal water and electrolyte 
balance. 
3) Necessary in allowing the organism to respond to stress. 
Stimulate the fight and flight response (to face sudden 
emergencies) of catecholamines. 
4) Increase the production of gastric HCI and pepsinogen. 
I 5) Inhibit the bone formation, hence the subjects are at a risk L __ for osteoporosis . 
409 
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1 Disorders of glucocorticoid hormone deficiency 
1 I ) Primary adrenal illsufficiency (Addison's disease) results 
I 
I 
I 
I 
I 
I 
I 
m: 
• decreased blood glucose level (hypoglycemia), extreme 
sensitivity to insulin . 
• increased susceptibility to stress. 
• loss of appetite (anorexia), weight loss, nausea. 
• muscle weakness. 
• low blood pressure. 
• decreased ability to excrete a water load. 
• impaired cardiac function. 
• decreased Na~ and increased Ki level in serum. 
'J) Secondary adrenal insufficiency is due to a deficiency of 
CTH resulting from tumor, infarction, or infection. 
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Disorders of glucocorticoid hormone excess 
Cusbing's syndrome is due to long tenn pharmacological 
use of steroids, tumor of adrenal cortex or tumor of pituitary. 
------Emotional disturbance 
----Enlarged sella turcica 
------ Moon tacies 
------Osteoporosis 
------ Cardiac hypertrophy 
(hypertension) 
-----Buffalo hump 
--------Obesity 
...__----Adrenal tumor or 
hyperplasia 
·-Thin, wrinkled skin 
·--- - -Abdominal striae 
I 
~-----------------------4~ 
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Mineralocorticoids 
I 
I Aldosterone 
I I Aldosterone does not have a specific plasma transport pro-
! tein, but it forms a very weak association with albumin. 
412 I 
---------------------------~ 
Regulation of aldosterone production 
The Renin-Angiotensin System: 
Blood pressure!. blood volume l. [Na+] 1 ~ Angiotensinogen -I Liver I 
[Kidney Renln -! 
Anglotensin I 
Angl~tensin II - Blood I 
t pressure 
Aldosterone --j Adrenal co~ 
' f [Na+] -[Hypothalamus ~ ADH 
i 
t Blood volume -- Reabsorptlon of water 
I Aldosterone secretion is sensitive to changes in plasma potas-
sium (K) levd: 
• increased level ofK stimulates production of aldosterone. 
• decreased level of K reduces production of aldosterone. 
413 
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Biochemical functions of mineralocorticoids 
1). Aldosterone acts in the kidney to stimulate active Na' trans-
port by the distal convoluted and collecting tubules, the net re-
sult being Na+ reabsorption. 
• Aldosterone causes the production of proteins in eel Is of the 
kidney. Permease produced allows Na' to enter cells from 
the lumen. i 
I 
• Aldosterone inc~e~ses the ~umber of apic~l ml..!mbranl! Na ' I 
channels, and this mcreases mtracellular Na ·. i 
• Aldosterone also increases the activity of several mitochon-
drial enzymes. Citrate synthase is induced, which stimulates 
citric acid cycle activity and results in the generation of ATP. 
Energy is thus provided to drive the Na !K ATPase, which 
also may be induced. 
2). Aldosterone promotes the excretion of K+, H+ and NH4' in 
the kidney. 
IJlntll Ptiqiai QI of~ lb.le 6llod 
~Nat 
Na' 
IC' 
K+ /<lilly 
H' 
(11111191 ~ (Acld-basti IC' ' 
3). Aldosterone affects ion transport in other epithelial tissues 
including sweat glands, intestinal mucosa, and salivary glands. 
414 
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Disorders of mineralocorticoid hormone 
deficiency 
• A deficiency of aldosterone secretion is accompanied by a 
reduction in the secretion of other adrenal steroid hormones 
I 
as well. The loss of adrenocortical steroids is known as Ad-
dison's disease (see disorders of glucocorticoid hormone de-
i .ficiency). 
I • The mineralocorticoid deficiency leads to a net loss of Na ... and water into the urine with a reciprocal retention of K+ I j (hyperkalemia) and H (mild metabolic acidosis). The subse-
quent contraction of the effective plasma volume may lead to 
I a reduction in blood pressure. 
I 415 
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Disorders of mineralocorticoid hormone excess 
• Adenomas of the glomerulosa cells result in primary a/doste-
ronism (Conn's syndrome), the manifestations of which in-
clude hypertension, hypokalemia, hypernatremia, and alkalo-
I • 
sis, low levels of renin and angiotensin II. 
Renal artery stenosis, with the decrease in perfusion pressure, 
can lead to hyperplasia and hyperfunction of the juxtaglome: 
rular cells and cause elevated levels of renin and angiotensin 
II. This action results in secondary a/dosteronism. 
I 
L 416 -------~ 
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Hormones of the 
adrenal medulla 
4 17 
I 
Catecholamine hormones 
H H 
I I ~C-C-NH 
l.._JI I 2 
Ho'I H H 
OH 
Dopamine Noreplnephrine 
OH H CH 
Yb-t-N/ 
3 
I I " HO/ H H H 
OH 
Epinephrine 
• Synthesis of catecholamine hormon£'s see in metabolism of 
phenylalanine and tyrosine. 
• Catecholamines circulate in plasma in a loose association 
with albumin. 
• Catecholamines have short biologic half-life (I 0-30 seconds). 
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I 
I 
I 
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I 
Regulation of catecholamine hormones production 
• Catecholamines are produced in response to stress (fight, 
fright and flight). These include the emergencies like shock, 
cold, fatigue, emotional conditions like anger, etc. 
• Response involves many processes in the organs vital to the 
resoonse (brain, muscles, cardiopulmonary system, and liver) 
at the expense of other organs that are less immediatelv in-
volved (skin, gastrointestinal system, lymphoid tissue). 
419 
Biochemical functions of catecholamines 
I). Effects on carbohydrate metabolism is to elevate blood glu-
cose level: 
I . Increase the degradation of glycogen and decrease glycogen 
formation in the liver and muscles. 
2. Increase the hepatic gluconeogenesis. 
3. Inhibit insulin secretion. 
2). Effects on lipid metabolism is to increase the free fatty acids 
in the circulation by enhance the breakdown of triacylglycerols 
(lipolysis) in adipose tissue. 
3). Effects on physiological functions: 
I. Increase cardiac function (myocardial contraction) and oxy-
gen consumption, constrict the blood vessels and thereby in-
crease blood pressure. They cause smooth muscle relaxation in 
bronchi, gastro-intestinal tract, genitourinary tract and the blood 
vessels supplying skeletal muscle. 
2. On the other hand, catecholamines stimulate smooth muscle 
contraction of the blood vessels supplying skin and kidney. 
420 
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Hormones of the pancreas 
4'.!I J 
- --------
Insulin l 
I 
•Insulin is a polypeptide hormone (MW=5. 73) containing 51 1
1
• 
amino acids, arranged in two polypeptide chains A and B. 
"'""' ... I 
" 
• Insulin has no plasma carrier protein. 
• Plasma half-life is less than 3-5 minutes under normal con-
ditions. 
422 
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Regulation of insulin secretion 
• Increase in plasma glucose concentration is the most impor-
tant regulator of insulin secretion. 
• The threshold concentration for secretion is the fasting plas-
ma glucose level (80-100 mg/di), and the maximal response 
is obtained at glucose levels between 300 and 500 mg/di. 
• a-Adrenergic agonists, epinephrine inhibit insulin release. 
• P-Adrenergic agonists, growth hormone, cortisol, placental 
lactogen, estrogens, and progestins stimulate insulin release. 
423 
Biosynthesis of insulin 
• Insulin is produced by the P-cells of pancreatic islets of Lan-
gerhans. 
• It is synthesized as a preprohormone with I 08 amino acids 
(MW 11.500) which undergoes proteolytic processing to give 
proinsulin with 86 amino acids (MW 9.000). The arrange-
ment of proinsulin is B chain-connecting (C) peptide-A 
chain. The proinsulin molecule undergoes cleavages that re-
sult in the formation of mature insulin and C- peptide. 
• C-peptide has no biological activity; however its estimation 
in the plasma serves as a useful index for the endogenous 
production of insulin. 
• In the P-cells, insulin (and also proinsulin) combines with 
zinc to form complexes. In this form, insulin is stored in the 
granules of the cytosol which is released by exocytosis. 
424 
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Biochemical functions of i~sulin--f 
1) Effects on carbohydrate metabolism is to decrease the blood glucose I 
level: 
I. Enhances the glycolysis in muscle and liver by increasing the activity 
and the quantities of key enzymes glucokinase (or hexokinase). phospho-
fructokinase, and pyruvate kinase. 
2. Enhances the glycogen synthesis by activation of glycogen symhetase 
whereas glycogen degradation is decreased by inhibition of phosphory-
lase. 
3. Inhibits the gluconeogenesis by suppressing the key enzymes pyruvate j 
carboxylase, phosphoenolpyrumte carhoxykinase and glucose-6- I 
phosphatase. I 
4. Enhances the pentose phosphate pathway by increasing the activity of 
key enzyme glucose-6-phosphate dehydrogenase to provide ~ADPH re-
quired for fatty acid synthesis. 
5. Enhances the uptake of glucose by muscle (skeletal. cardi<tc and 
smooth) and adipose tissue by increasing the quantities ofGLUT-4. 
2) Effects on lipid metabolism is to reduce the release of fa tty acids from 
the stored fat: 
l. Stimulates the synthesis of triacylglycerols (lipogenesis) and fatty acid 
synthesis by: 
•increasing the uptake of glucose by adipose tissue antl pro. iding gly-
cerol-3-phosphate from glycolysis . 
• increasing the activity of key enzyme of pentose phosphate pathway to 
provide NADPH required for fatty acid synthesis. 
• increasing the activity of a key enzyme acetyl CoA carhoxylase of fat-
ty acid synthesis. 
2. Inhibits lipolysis in liver and adipose tissue by decreasing the activity 
of hormone-sensitive lipase. 
3. Decreases circulating free fatty acids and mohilization of fatty acids 
from liver. 
4. Inhibits ketogenesis by decreasing the activity of HMG CoA reductase. 
5. Insulin affects the formation or clearance ofVLDL and LDL. 
3) Effects on protein metabolism and cell replication: 
1. Stimulates the entry of amino acids into the cells, including muscle, 
liver, bone and lymphocytes, enhances protein synthesis and reduces pro-
tein degradation. 
2. Promotes cell growth and replication. 
42s I 
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Comparison of two types of diabetes mellitus 
-------~·-----------~ Character Insulin-dependent diabetes mellitus _ ___ Type I diabt;_l!S evalence I 0-20% of diabetic __ _ -1 p~ulation __ Body weig~- l _ ___!Jo~3l or l~~-
-
1 Genetic I tvlild or moderate 
L red is _.'.::! li·:n J __ _ .... _____ _ 
Defect Insulin deficiency due 
tu destruction of P-cel 
I Pla~!_'.~_~.i_n~_!:d i;i ~ Decreased 01~absent Acute Ketoacidosis 
I com11lications ~ 
~Adm i nistration - ' - . .\ fu'ays-;.e-cluired I ~f jt~~ulin __ 
ls 
·-
' Non-insulin dependent 
diabetes mellitus 
Tvoe 2 diabetes 
80-90% of diabetic popula-
ti on 
Obese 
Very strong 
impairment in the produc-
ti on of insulin by P-cells 
and/or resistance of target 
cells to insulin 
Normal or increased 
Hyperosmolar coma 
Usually not necessary 
---
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Major metabolic alterations in diabetes mellitus 
... 
nYPERGl YCEMIA 
251 
KETOACIDOSl5 HYPERTRIGL Y· 
CERIDEMIA 
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Glucagon 
• Glucagon is secreted by a-cells of the pancreas. 
• Glucagon is a polypeptide hormone composed of 29 amino I 
acids in a single chain (MW=3.500). 1 
• G lucagon is actually synthesized as proglucagon ( l\IW= I 
9.000). 
• Glucagon has no plasma carrier protein. 
• Plasma half-life is less than 5-10 minutes. 
428 
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Regulation of glucagon secretion 
• The secretion of glucagon is stimulated by low blood glucose 
concentration, amino acids derived from dietary protein and 
low levels of epinephrine. 
• Increased blood glucose level markedly inhibits glucagon se-
cretion. 
429 
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Biochemical functions of glucagon 
I). Effects on carbohydrate metabolism is to enhance the blood 
glucose level: 
1 
• Acts on liver to cause increased gluconeogenesis by activa-
tion of gene transcription of phosphoenolpyruvate carboxyki-
11ase and activation of Jructose-1,6-bisphosphatase. 
I • Enhances glycogen degradation in liver. 
I The actions of glucagon are mediated through cyclic AMP. 
i 2). Effects on lipid metabolism: 
I I • Stimulates lipolysis in adipose tissue by increasing the activi-
ty of hormone-sensitive lipase. 
• Promotes fatty acid oxidation resulting in energy production 
for muscle and myocardium. 
• Enhances ketone body synthesis (ketogenesis). 
3 ). Effects on protein metabolism: 
1 
• Enhances protein degradation and reduces protein synthesis. 
I • Increases the amino acid uptake by liver which, in tum, pro-! motes gluconeogenesis. Thus glucagon lowers plasma amino 
I acids. 
,_ 
r----- - - -
1 
l 
Hormones that regulate calcium 
metabolism 
I 
I L_ 
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Calcium metabolism l 
I 
Ca2+ regulates following processes: 
I. Neuromuscular excitability. 
2. Blood coagulation. 
3. Activation of muscle phosphorylase. 
4. Secretory processes. 
5. Membrane integrity and plasma membrane transport . 
6. Enzyme reactions. 
7. The release of hormones and neurotransmitters. 
8. The intracellular action of honnones. 
9. Bone mineralization. I 
I 
m l 
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Parathyroid hormone (PTH) 
• Parathyroid hormone is secreted by parathyroid glands. 
• PTH is a single chain polypeptide (MW= 95.000), containing 
84 amino acids. 
• PTH is synthesized as preproPTH which is degraded to 
proPTH and, finally, to active PTH. 
• Low plasma calcium enhances the production of PTH. 
• Phosphate has no effect on PTH secretion. 
433 .._ __________________________  
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Biochemical functions of parathyroid hormone 
1. Action on the bone: 
PTH binds to osteobla'5ts, the cells responsible for creat-
ing bone. Binding stimulates osteoblasts to release cyto-
kines. Jn turn, the cyiokines stimulate the development 
of mature osteoclasts. This is brought out by PTH stimu-
lated increased activity of the enzymes pyrophosphatase 
and collagenase. These enzymes result in bone 
resorption Dernin,::rali?ation ( decalcification) leads to 
an increase the blood Ca level. PTH also promotes 
phosph.ite mobilization from bone. 
2. Action on the kidney: 
PTH increases the Ca active reabsorption or reduces Ca 
excretion from kidney distal tubules and the thick as-
cending I imh hy promoting the production of calcitriol. 
PTH reduces the re-absorption of phosphate from the 
proximal tubule of rhe kidney which means phosphate is 
excreted through the urine. 
3. Action on the intestine: 
The action of PTH on the intestine is indirect. It increas-
es the intestinal absorption of Ca by stimulating the bio-
synthesis of calcitriol in the kidney. PTH activates 1,a-
hydroxylase, the enzyme responsible for hydroxylation 
of 25-hydroxy vitamin D ( calcidiol) to 1,25-dihydroxy 
vitamin D ( calcitriol). 
Thus the net effect of PTH is to elevate calcium and de-
crease the phosphate concentrations in the blood. 
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Hypoparathyroidism 
• A low level of PTH in the blood is known as hypopa-
rathyroidism. The usual cause of hypoparathyroidism 
is accidental removal or damage of the glands during 
neck surgery (secondary hypoparathyroidism), but the 
disorder occasionally results from autoimmune de-
struction of the glands and inborn errors of metabolism 
(primary hypoparathyroidism). I 
• The biochemical hallmarks are decreased serum io-
nized calcium (hypocalcemia) and elevated serum 
phosphate levels. Symptoms include neuromuscular ir-
ritability, spasms and convulsions which, when mild, 
cause muscle cramps and tetany. I 
• Severe, acute hypocalcemia results in tetanic paralysis 
of the respiratory muscles, laryngospasm, severe con-
vulsions, and death. I 
I 
• Long standing hypocalcemia results in cutaneous j 
changes, cataracts, and calcification of the basal gan-
glia of the brain. 
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Hyperparathyroidism 
A high level of PTH in the blood is known as hyperpara-
1 thyroidism. If the cause is in the parathyroid gland it is called i primary hyperparathyroidism due to the parathyroid adenoma, 
I parathyroid hyperplasia or to ectopic production of PTH in a ma-
1 
lignant tumor. If the cause is outside the gland, it is known as 
secondary hyperparathyroidism. This can occur in chronic renal 
I 
failure. 
The biochemical hallmarks are elevated serum ionized cal-
cium and PTH and depressed serum phosphate levels (due to in-
creased renal losses) and increase in alkaline phosphatase activi-
ty. Elevation in the urinary excretion of Ca and P, often resulting 
in the formation of urinary calculi. 
Parathyroid adenoma 
__...- or hyperplasia 
Hypercalcemia 
Pancrea@s 
The symptoms include lethargy, loss of appetite, constipa-
tion, nausea, increased myocardial contractility and susceptibili-co fracrures 
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Calcitriol 
• Calcitriol or 1,25-dihydroxycholecalciferol is the physiologically ac-
tive form of vitamin D3 and is a steroid hormone. 
• The synthesis of calcitriol, biochemical actions, hypo- and hypervita-
minosises are described under vitamins. 
I 
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Cakitonin I 
• Calcitonin is secreted by the parafollicular C cells of thL human th) TO- I 
id. I 
• Calcitonin is a 32-amino-acid peptide cleaved from a larger prohor-
moo~ 1 
• Elevated blood Ca levels strongly stimulate secre1 ioa, and secretion is I 
suppressed when Ca concentration fa lls below nonr.a l. I 
-- --~~I 
Biochemical functions of calcitooin ·--, 
1. Action on bone: 
Calcitonin suppresses resorption of bone by inhibiting the activity of os-
teoclasts therefore directly reduces the amount of Ca and phosphate re-
leased into the blood. However, this inhibition has been shown to be 
short-lived. Calcitonin also prevents Ca release from bone hy inhibiting 
the release of cytokines by osteoblasts. At th~ same time, it promotes the 
development of osteoblasts. 
2. Action on kidney: 
Calcitonin inhibits tubular reabsorption of Ca and phosphate. leading to 
increased rates of their excretion in urine. 
Thus the net effect of calcitonin on bone and kidney is to decrease the 
calcium and the phosphate concentrations in the blooJ. 
-------~ 
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Thyroid hormones 
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Thyroid hormones 
I I 
~ j j\\ HO~O~CH2TH-COOH 
I I NH2 
3.5,J',5'· Tetraiodothyronine (thyroxine (T 4 1) 
I I 
HO\~o-0-ctt,?H-COOH 
- I- NH2 
3,5,3' -Triiodothyronine {T 3 1 
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Regulation of thyroid hormones 
secretion 
Excess Iodide intake, 
stress, somatostatin, 
glucocorticoids and 
dopamine 
Leptin and 
a-melanocyte t 
stimulating J 
hormone 
c Thyrotropic releasing hormone ! {TRH) 
.s::. 
E 
Thyroid stimulating hormone 
(TSH) 
Thyroid hormones 
(T3 /TJ 
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Transport of thyroid hormones 
• T4 and T3 circulate in bound form, ie, bound to 2 specific 
binding proteins, thyroxine-binding globulin and tbyroxine-
binding prcalbumin. 
• The small, unbound fraction is responsible for the biologic 
activity. 
1. T4 has a half-life of 4-7 days while T3 has about one day. 
I 443 L_ _ _ _ _ _ 
~ Synthesis of thyroid hormones 
T4 and T3 are synthesized from the tyrosine residues of the 
glycoprotein thyroglobulin and activated iodine. 
1. The uptake of iodide by the thyroid gland is linked to the 
Na '!K ATPasc. 
2. The conversion of iodide (r) to active iodine (t), concen-
trated in the follicular cells, is catalyzed by the enzyme thyro-
peroxidase. 
3. The follicular cells of the thyroid gland produce the protein 
thyroglobulin, which is secreted into the colloid. Iodination 
of tyrosine residues (organification) in thyroglobulin produc-
es monoiodotyrosine (MIT) and diiodotyrosine (DIT) (inac-
tive precursors). 
4. The coupling of two DIT molecules to form T4 or of MIT and 
DIT to form T3. 
1 5. Thyroglobulin is digested by lysosomal proteolytic enzymes 
in the thyroid gland to release the free hormones, T3 and T4 .. 
6. T4 (90%) and T3 (10%) are released into the blood, a process 
stimulated by TSH. 
Thyroglobulin containing T4 and T3 can be stored for 1-3 
months in the thyroid gland. 
444 
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Biochemical functions of thyroid hormones I 
T3 is about four times more active in its biological functions 
1
1 
than T4. 
1 
I. Influence on the basal metabolic rate by regulating mitochon-
drial ATP synthesis: 
•Stimulate the metabolic activities and increases the oxygen I 
consumption via oxidative phosphorylation in most of the tis-
sues of the body (exception-brain, lungs, testes and retina) . 
•Enhance the function of the Na IK 4.TPase pump with ATP j 
utilization by increasing the number of pump units. I 
2. Effect on protein synthesis: 
•Enhance protein synthesis and cause positive nitrogen bal- , 
ance; while very high concentrations of T3 inhibit protein ,, 
synthesis and cause negative nitrogen balance. 
• T3 and glucocorticoids enhance transcription of the growth ' 
hormone gene, so that more GH is produced. 
• Promote embryonic development. 
•Regulate gene expression, tissue differentiation, growth . gen-
eral development and maintenance of aimost all tissues of the j 
body. I 
3. Effect on carbohydrate metabolism is 10 enhance hlood glu-
cose level: 
•Promote intestinal absorption of glucose and its uti lization. 
•Increase gluconeogenesis and glycogen degradation. 
4. Effect on lipid metabolism: 
•Stimulate lipolysis in adipose tissue by increasing the activity 
of hormone-sensitive lipase . 
I 
I 
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Hypothyroidism 
• Hypothyroidism is due to impairment in the function of thyroid gland 
that causes decreased levels of T3 and T4. Disorders of pituitary or 
hypothalamus also contribute to hypothyroidism. Women are more 
susceptible than men. 
• Hypothyroidism is characterized by reduced basal metabolic rate, slow 
I heart rate, weight gain, sluggish behavior, constipation sensitivity to 
I
, cold, dry skin etc. 
• Hypothyroidism in adu lt causes myxedema. 
~klscle "'Elakness 
I 
I I 
C:)arse. bri111e hair 
I Loss of lateral eyebrow / , "Myxeclema" madness 
I 
I 
Menormagla 
(anoYUlatofy 
cycle$) 
Peripheral eclema 
!hands. teat, ate.) 
• Intrauterine or neonatal hypoth)Toidism in children is associated with 
physical multiple congenital defects and severe, irreversible mental re-
tardation, collectively known as cretinism. 
• Hypothyroidism later in childhood results in short stature but no men-
L""d"~=- -- 446 
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Simple endemic goiter 
• Any enlargement of the thyroid is referred to as a goiter. 
• Enlargement of thyroid gland is mostly to compensate the decreased 
synthesis of thyroid hormones and is associated with elevated TSH. 
• Endemic goiter is due to iodine deficiency in the diet. It is mostly 
found in the geographical regions away from sea coast where the water . 
and soil are low in iodine content. I 
• Consumption of iodized salt is advocated to overcome the prol,lcm of 
endemic goiter. j 
- --=42__J 
Hyperthyroidism -, 
Hyperthyroidism is caused by Grave's disease. It is also known as I 
thyrotoxicosis and causes a diffuse enlargement of the thyroid and exces-
sive, uncontrolled production ofT3 and T4. 
Muscle wasting 
V5;1Ut---f~~-Tacll)'Caldl~ 
lllgtl OUlpUt !allure 
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Hormones of the gonads 
449 
. 
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Androgens (male sex hormones) 
OH 
I 
I 
Testosterone I 
• Androgens are produced by the leydig cells of the testes and I 
to a minor extent by the adrenal glands in both the sexes. 
Ovaries also produce small amounts of af'drogens. 
• Testosterone binds with plasma B-globulin which is called 
sex hormone-binding globulin (SHBG or testosterone-
estrogen-binding globulin). Since SHBG and albumin bind 
97-99% of testosterone, only a small fraction of the hon none 
is in the free (biologically active) form. I 
• The production of androgens is under the contr0I of LH and 
FSH. 
451 
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Metabolic pathways of testosterone 
Testosterone 
1-s•:./,2"/ \ ..  
Estradiol Androstanediol Oihydrotestosterone (DHT) 
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Physiological and biochemical functions of androgens 
1). Sex-related physiological functions: 
•growth, development and maintenance of male reproductive 
organs. 
•sexual differentiation. 
• spermatogcnesis . 
•male nattern of aggressive behavior. 
• development l) f secondary sexual organs and ornamental 
strnctures (1m;sclt:s, hair, etc.). 
2). Biochemical functions: i 1. Effrcts on protein metabolism: 
I •promote Rl\1 i\ synthesis (transcription) and protein synthesis. 
1 •cause positive nitrogen balance. 
I •increase the muscle mass. 
1
2. Effects on carbohydrate and fat metabolisms: 
. •increase glycolysis . 
j • incr~ase fatty acid synthesis. 
I •increase citric acid cycle. 
3. Effects on mir.eral metabolism: 
• prom •.)te mineral deposition. 
I •promote bone growth before the closure of epiphyseal carti-1 
L:·_·__ 453 . 
The pathophysiology of the male reproductive system 
• The Jack of testosterone synthesis is called hypogonadism. If this oc-
curs before puberty, secondary sex characteristics fail to develop, and 
if it occurs in adults, many of these features regress. 
• Primary hypogonadi.sm is due to processes that affect the testes di-
rectly and cause testicular failure. 
• Secondary hypogonadism is due to defective secretion of the gonado-
tropins . 
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Estrogens (female sex hormones) 
! 
l 7p-estradiol (E2) Progesterone j 
• Estrogens are systhesized by the follicles and corpus lut~um of ovary, ,. 
progesterone - by corpus luteum and placenta. 
• Emogem ore bound to '" hormone-binding globulin •nd pcog"-1 
tins to cortisol-binding globulin. 
• The synthesis of estrogens is under the control ofLH and FSH. 
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Physiological and biochemical functio~s of estrogens I 
1). Sex-related physiological functions: I 
• Growth, development and maintenance of female reproduc- I 
tive organs. I 
• Maintenance of menstrual cycles. 
• Development of female sexual characteristics. 
2). Biochemical functions: 
1. Lipogenic effect: Estrogens increase lipogenesis in adipose 
tissue. 
2. Hypocholesterolemic effect: Estrogens lower the plasma total 
cholesterol. The LDL fraction of lipoproteins is decreased 
while the HDL fraction is increased. 
3. Anabolic effect: Estrogens promote the synthesis of many 
proteins in liver. 
4. Effect on bone growth: Estrogens promote calcification and 
bone growth. 
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Biochemical functions of progesterone 
1. Progesterone is essentially required for the implanta-
tion of fertilized ovum and maintenance of pregnancy. 
2. Progesterone promotes the growth of glandular tissue 
in uterus and mammary gland. 
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,- Hormonal pattern during mestrual cycle 
I 
I 
9 4 
Menstruation 
8 12 14 18 20 24 J. --+Dllya 
OYuldon 
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Biochemistry of muscle 
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Structure of muscle 
Tnad 
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Structure of myosin along with its digested products 
by trypsin and papain 
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A diagrammatic representation of the thin filament 
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Mechanism of muscle contraction 
1. During the relaxation phase 
of muscle contraction, the S-1 
head of myosin hydrolyses the 
bound ATP to ADP and Pi. 
This resulL in the formation 
high energy ADP-Pi-myosin 
complex. 
2. On contraction, when action potential reaches the end of motor neuron 
(nerve terminal) in the neuromuscular junction. The neurotransmitter re-
leased and will elicit action potential in muscle fiber . Action potential 
spread all muscle cell membrane and cause release of Ca2• from sarcop-
lasmic reticulum in cytosol to contractile myosin and actin. Cai+ binds 
Troponin C and will result in conformational changes in Troponin mole-
cule that result in pulling of Tropomyosin away from active sites of actin 
(myosin binding sites on actin). When active site of actin is exposed, it 
will react with active site of myosin and they will attach to each other to 
finally form actin-myosin-ADP-Pi complex. 
3. Myosin releases the ADP and Pi and ATP energy released [by hydro-
lyzed ATP to ADP and Pi] will make the cross bridges of myosin bend 
forward, toward the center of sarcomere, by this, driving movement of ac-
tin filaments over myosin filaments. This movement of cross bridges, pull-
ing actin filaments and movement of the head of myosin that caused by 
energy released from hydrolyzed ATP is called (power stroke). The actin-
myosin complex is in a low energy state. 
4. Up to now movement is achieved (shortening), second ATP will bind 
to myosin head (ATP site), to form actin-myosin-ATP complex. This 
binding will result in detachment of cross bridge from actin active site and 
cross bridge will return back to its position, facing another actin active 
site. 
5. Actin is released, as myosin-ATP has low affinity for actin. 
A fresh cycle of muscle contraction and relaxation now commences with 
the hydrolysis of ATP and the formation of ADP-Pi-myosin complex. 
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An overview of muscle contraction 
. 
·~ 
I. The troponin- tropomyosin complex is blocking the myosin-binding 
sites on the actin. The myosin head is already energized to power a con-
traction. 2. After Ca binding to troponin, a conformational change in the 
troponin molecule pulls the troponin away from the binding site. 
3. Once the binding sites on the actin are exposed, the myosin head 
binds to it. 4. After cross-bridge attachment, the energy stored in the 
myosin head is released, and the myosin head pivots toward the center of 
the sarcomere (power stroke). Now the ADP and phosphate bound to the 
myosin head are released. 5. Now a molecule of ATP binds to the myo-
sin head with simultaneous detachment of the myosin head from the 
binding site on the act in molecule. 6. The A TPase activity of the myosin 
head hydrolyzes the ATP into ADP and phosphate. The energy released 
from the hydrolysis of this high-energy bond is used to re-energize the 
myosin head, and the entire cycle can be repeated as long as calcium is 
present and there are sufficient ATP reserves. 
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Cycle of the structured conversions of the actin-myosin com-
plex, leading to the movement of the myosin along the actin 
® 
® I 
® CD r ATP 
ATP I 
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Actin-myosin orientation 
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The scheme of the myosin movement along the actin 
4nm 
a~~---
b 
w...j.--- 36 nm ---~ 
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Characteristics of white and red 
fibers of skeletal muscle 
White (fast) Red (slow) mus- : 
muscle 1bers cle 1bers I i------------+--- -------' 
Color 
M o lobin 
Myosin A TPase 
Ener utilization ~· Hig~ ___ _  t _____ 1=ow --
Contraction rate _L __ _ _ f~J_ . _ _ [ ___ Slo~ __ 
Duration -~-- ~Qr:!__ _ _ ! ___ Prolo~ed _ ___: 
Mitochondria __ l _____ _lew _r __ M~~r __ _ _J 
There are 3 ATP- dependent mechanisms 
in the muscles: 
1. Na.+/JC ATP-ase pump in the cellular membrane. 
2. Intracellular calcium pump. 
3. Actin-myosin interaction (contraction - relaxation). 
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The multiple sources of ATP in muscle 
ADP 
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Biochemistry of connective tissue 
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An overview of connective tissue extracellular matrix 
c 
0 
nt 
nj 
es 
Ca 
tu 
ie 
y 
e 
/Epithefial 
· cell layer 
. -Basal 
~ \~'- lamina ~ ~ 'Si~ CoHagen 
}::' /-;;;-~ ""-4, E);•stic 
"' JI'' l ffe t::5 ,1,:iers 
~---*~~ 
- Proteogiycan 
472 
Interactions between the cell membrane and the com-
ponents of the extracellular matrix 
473 
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Steps in the formation of mature collagen fibrils 
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Plasmatic membrane of the eukaryotic cell 
•GlcNAc 
•Man 
aGalNAc 
oGal 
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Structure of proteoglycan 
Protein core Glycoa1mlne polymers 
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Hyaluronic acid - proteoglycan complex 
Proteoglycen aggregate 
/ Chondroltln •ullate 
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Biochemistry of nervous system 
478 
Structure of synapse l 
Synaptic vesicles ,--
r----- Neuronal axon ~ptic I j ' Neurotransmitter 
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Acetylcholine receptor 
Acetylcholine..,, 
480 
Compounds effecting synaptic transmission 
Cholinergic synapses 
!:----~-------Protem of rod-shaped bacterium Clostndtum botulinwn. Blocks 
ulinum , neuromuscular transmission through preventing vesicles from anc- I 
: toxin 1 boring to the membrane to reicase acetylchohne and causes poison- , 
1\ mg by growmg in badly handled or prepared meat products I 
~ A""1o>d <oo>amod io '"""'•· A<• ~ • oi<ohoK =>rkbolmo ~ 
Nicotine ceptor agonist Blocks the action of autonomic nerve and skeletal 
muscle cells. 
' Alkaloid contained in the bnght red fly aganc mushroom. Acts as a 
I Muscarine muscarmtc acetylcholine receptor agomst Muscarine bound at the 
receptor is not broken down and therefore causes permanent stimu- 1 
lation of muscle. 
Alkaloid, active ingredient of curare, an extract from the bark and 
stems of the South American vine (Chondodendron tomentoswn). 
Tubocurarin I Blocks acetylcholine receptor sites at neuromuscular junctions, 
I causing relaxation (neuromuscular relaxant) and paralysis of mus-I cles, including res~iratorv organs and the heart. 1.---! Alkaloid poisonous compound found in deadly nightshade and re-
Atropine I lated plants. Blocks muscarinic receptors. It is used in medicine as a 
. muscle relaxant. e.g., in dilating the pupil of the eve. -----~lkaloid which is the active ingredient of the Calabar bean and is 
lhysostigmine , used medicinally in eye drops (treatment of glaucoma) on account 
_ _ ___ I of its anticholinesterase activity. 
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I __ Adrenergic synapses 
ll Dihydroergo- f Derivative of ergot ergotamine. It is a-adrenergic receptors 
II tamine blocker and is used mainly in the treatment ofmigrain_~-­
Synthetic compound which acts as a P-adrenergic receptors 
Propranolol blocker and is used mainly in the treatment of cardiac arr- . 
hythmia, stenocardia. ______ . _ _ - - ·-·· ------- .. ·- · ________ ___; 
Moderate to strong reuptake inhibition of catecholam ines. I 
Synthetic compound. amidepressant is mainly used in the I 
treatment of major depression such as depr•:ssior, associatt:d 
lmipramine with agitation or anxiety and enuresis. lmipr:•m ine has a sig-
nificant analgesic effect and, thus. is v·~1) usdul in some pain 
conditions. 
-- , Alkaloid obtainedfroffilndiai1-snakt:root l ra~wollia). Depktes 
Reserpine 
catecholamines in the synapses from peripheral sympathetic ;J 
nerve endings. As drug is used in the treatrrh:nt of hyperten-11 
sion and as antidepressant for the rdief of psychotil" symp-
e------~t_o_m __ s_(~s_ch_i_z_op~h_r_enia). __ _ _ _ __ __ I 
'--------------------- -- 482 J 
Strychnine 
- ---i 
Glycine synapses I 
Highly poisonous compound alkaloid obtained from-tE~ 11 
seeds of the nux vomica and related plants. Acts as a blocker , 
or antagonist at the inhibitory or strychnine-sensitive glycine i I 
receptor. It is used as a stimulant in small doses. __ j 
,,__A __ p_a_m_i_n_-+1-A_p_am~-i~-is_an_ element in bee venom. Effectlssi~nilar-to J 
1 . strychmne. _____ _ 
Morphine 
1 Naloxone 
Peptide synapses 
It acts as an enkephalin receptor ag~nist-Analgesic and nar::l
1 cotic drug obtained from opium and used medicinally to re-
lieve pain. __ __ __! 
Synthetic drug, similar to morphine. Blocks opiate receptors 
in the nervous system. It is used to cmmter the effects of 
opiate overdose, for example heroin or morphine overdose 
and to counteract life-threatening depression of the central 
nervous system and respiratory system. 
----~J 
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Biochemistry of blood 
Iron intake 
·-<!Onig'day 
-0.35mmot'da)· 
Iron balance 
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The major functions of the blood 
1. Respiration - transport of oxygen from the lungs to the tis-
sues and of C02 from the tissues to the lungs. 
2. Nutrition - transport of absorbed food materials. 
3. Excretion - transport of metabolic waste to the kidneys, 
lungs, skin, and intestines for removal. 
4. Maintenance of normal acid-base balance in the body. 
5. Regulation of water balance through the effects of blood 
on the exchange of water between the circulating fluid and 
the tissue fluid. 
6. Regulation of body temperature by the distribution of 
body heat. 
7. Defense against infection by the white blood cells and cir-
culating antibodies. 
8. Transport of hormones and regulation of metabolism. 
9. Transport of metabolites. 
10. Coagulation. 
486 
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Albumin 
1. Albumin is the major protein of human plasma (35-52 g/l), 
has a MW of approximately 69.000, and comprises some 
60% of the total plasma protein. 
2. Some 40% of albumin is present in the plasma, and the 
other 60% is present in the extracellular space. 
3. The liver produces about l2g of albumin per day, 
representing about 25% of total hepatic protein synthesis 
and half of all of its secreted protein . 
4. Their half life is 17-20 days. 
5. Albumins are soluble in pure water. 487 
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Functions of albumin 
1. Oncotic function - albumin is responsible for 75-80% of 
the oncotic pressure of human plasma (25 mm Hg) because 
of its relatively low MW and high concentration. 
Decrease in plasma albumin level results in a fall in osmot-
ic pressure, leading to enhanced fluid retention in tissue 
spaces, causing edema. 
2. Tmmport function - albumin binds various biochemically 
important compounds and transports them in the circula-
tion (free fatty acids, Ca, Zn, I, 10% of the plasma Cu, ste-
roid hormones, vitamin D, bilirubin, variety of drugs - sul-
fonamides, penicillin, dicoumarol, aspirin). 
3. Nutritive function - albumin serves as a source of amino 
acids for tissue prote in synthesis to a limited extent, partic-
1 ularly in nutritional deprivation of amino acids. 
L
I 4 Buffering function - albumin has the maximum buffering 
capacity among the plasma proteins. 
488 
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Globulins 
1. Concentration of globulins in blood - 20-30 g/L. 
2. Globul ins dissolve in the presence of salts. 
3. Globulins constitute several proteins that are separated 
into 4 distinct bands (a I, a2, ~and y) on electrophoresis. 
l_:_alobulins have a MW of approximately 75.000. 
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Functions of globulins 
1. Oncotic function - globulins are bigger in size molecules 
when compared with albumin. Hence, the contribution of 
globulins to oncotic pressure is less than that of albumin. 
2. Transport/unction (globulins as specific transpo1ters): 
• Lipoproteins transfer lipids; 
• Cortisol-binding globulin transfers steroid hormones; 
• Testosterone-estradiol-binding globulin transfers sex 
honnones; 
• Transcobalamin transfers vitamin B12; 
• Thyroxine-binding globulin transfers thyroid hormones; 
• Transferrin transfers Fe; 
• Ceruloplasmin transfers Cu. 
3. Maintenance of PH. 
4. Protective/unction - immunoglobulins. 
5. Coagulation - fibrinogen. 
Almost all globulins are synthesized by the liver, y-globulins 
are synthesized by reticuloendothelial cells. 
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Acute phase proteins 
! C-reactive Protein (CRP) is a major component of acute 
i phase proteins. It is produced in the liver and is present in the 
I circulation m minute concentration. C-reactive protein (C 
strands for carbohydrate to which it binds on the capsule of 
pneumococi) is involved in the promotion of immune system 
through the activation of complement cascade. Estimation of 
I 
CRP in serum is important for the evaluation of acute phase re-
sponse and to make a diagnosis of inflammatory and oncological 
I diseases. 
I 
al-Antitrypsin is a protease inhibitor with a normal con-
centration of about 200 mg/di. It inhibits trypsin, elastase, and 
I 
certain other proteases by forming complexes with them. It is 
synthesized in the liver. A deficiency of this protein has a role in 
certain cases (approximately 5%) of emphysema and in one type 
of cirrhosis. 
Haptoglobin (Hp) plasma concentration is increased in 
several inflammatory conditions. The levels of Hp in human 
plasma vary and are of some diagnostic use. Low levels of Hp 
are found in patients with hemolytic anemias. Haptoglobin binds 
with the free hemoglobin that spills into the plasma due to he-
molysis. The haptoglobin-hemoglobin complex cannot pass 
through glomeruli of kidney. Haptoglobin, therefore, prevents 
I the loss of free Hb into urine. 
I 
l_____~~~~~~~~~~~~~~~~~~~~-4-9-1~ 
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Xenobiotics. 
Biochemistry of liver 
Cross section of liver lobule 
bile duct 
sinusoid 
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bile dud 
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Functions of the liver 
1. Biosynthesis of endogenous substances (plasma proteins) 
and storage (glycogen, lipid-soluble vitamins, B6, B12, Cu 
and Fe). 
2. Transformation and degradation of endogenous sub-
stances to excretable molecules (metabolism). 
3. 5)•11thesis, storage, interconversion, and degradation of 
metc1bolite~ (metabolism). 
4. Regulated .mpply of energy-rich intermediates and 
building blocks for biosynthctic reactions. 
5. Detoxification of xenobiotics by biotransformation. 
6. bxcretion of bile pigments, bile salts and cholesterol in the 
bile into intestine. 
7. Protective junctions (Kupffer cells perform phagocytosis 
to el iminate foreign compounds). 
494 
Hemoglobin degradation 
1. Enzyme heme oxygenase cleaves the methenyl bridges be-
tween the two pyrrole rings (A and B) of porphyrin to form 
verdoglobin (green pigment). Simultaneously, ferrous iron 
(Fe1) is oxidized to ferric form (Fe3+). 
2. Iron and globin are released. Porphyrin is unwound to 
chain to form biliverdin (green-yellow pigment). 
3. Biliverdin's methenyl bridges (between the pyrrole rings C 
and D) are reduced to methylene group to form bilirubin 
t_yellow pigment). 
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Bilirubin metabolism and excretion 
Akorplio11 
Portal 
System 
' 
Hemoelobin (Rdiculoeadodlelial mis) 
• Unconjugated (indirect) bilirubin 
• Blood-stttam 
Liver 8 .1 
• le 
Conjuited (dired) bilirubin 
lntestin~ 
Mao ilinogen 
.; .._ Colo11 
Blood-stram Sterc:obilinoeea 
(stercobilin) 
(Fttes) 
Hitocytes 
D penols 
(BU~) 
Urobiu!O&ftl 
(uro6Uin) 
(Vri~) 
Blood 
Bile 
Feces 
Urine 
Distribution of bile pigments 
Total bilirubin I 3.2-20.52 µmoll / 
Indirect bilirubin ! 1.7-17.1 µmoll / i 
1 
~ 
-- -
Direct bilirubin I 2.2-5 . l µmoll/ l 
=J 
Direct bilirubin 
Stercobilinogen (stercobilin) 
----
Urobilinogen (urobilin) I Traces 
·- - - - - · 
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I 
I 
I 
I 
Hemolytic (choluric) jaundice 
Blood t Total bilimbin at the expense of t Indirect bilirubin 
Feces t Stercobilinogen, dark color 
Urine Bilirubin (-), t Urobilinogen 
Hepatocellular (parenchymal) jaundice 
Blood t Total bilirubin at the expense of t Indirect and Direct bilirubin 
Feces .J, Stercobilinogen 
Urine I Bilirubin (+), t Urobilinogen 
Obstructive (cholestatic) jaundice 
t Total bilirubin at the expense of tt Di-
Blood rect and t Indirect bilirubin, t alkaline 
phasphatase activity, skin itch (t bile acids) 
Feces J.. J.. Stercobilinogen (light-colored feces) 
Urine Bilirubin (+), Urobilinogen (-) 
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Serum-biochemical hepatic syndromes 
1. Syndrome of bepatocyte integrity impairment (cytolytic syndrome, 
syndrome of byperpermeability): 
I. Increased activity of serum hepaticospecific enzymes: alanine 
transaminase (ALT), decreased de Ritis coefficient - AST/ ALT, al-
dolase, isoforms of lactate dehydrogenase LDH4 and LDH5, gluta-
mate dehydrogenase, ornithine carbamoyl tramferase, fructose-1-
phosphate aldolase and so on; 
2. Hyperbilirubinemia (mainly at the expense of din:ct bilirubin); 
3. Increased serum vitamin B1i. iron. 
2. Cbolestasis syndrome (excretory-biliary syndrome): 
I. Increased activity of serum y-glutamyltranspeptidase; 
2. Increased activity of serum alkaline phosphatase; 
3. Hyperbilirubinemia; 
4. Hypercholesterolemia, increased serum LDL and decreased serum 
HDL. 
3. Hepatocellular insufficiency syndrome: 
I. Decreased activity of serum choline esterase; 
2. Hypoproteinemia and disproteinemia with decreased albumins; 
3. Decreased serum prothrombin and another clotting factors, im-
paired coagulation; 
4. Hypocholesterolemia, decreased cholesterol esterification ratio; 
5. Hyperbilirubinemia. 
4. Hepatic reticuloendotbelium stimulation syndrome («inflammato-
ry» syndrome): I 
I. Increased serum globulins (sometimes with hyperproteinemia); I 
2. Alteration of protein- sedimentary tests (corrosive sublimate test, 
thymol test, zinc - sulfate test, heparin test). 
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absorption 
--y 
-
Sites of Drug 
= Metabolism: 
----
--
-----
(intestinal 
wall), liver. 
(organs) 
Sites of Drug 
Elimination: 
kidnevs (polar 
compounds), 
bile, feces 
(lipophilic 
analogs), lung 
Factors affecting drug metabolism 
I. Physiological conditions: 
• age (drug metabolism slows down with old age). 
• diet (level of albumins, presence of cofactors). 
• hormone balance. 
• pregnancy. 
502 
2. Pathological conditions (impaired liver or kidney function: 
hepatitis, cirrhosis, hepatic cancer, nephritis, etc., general de-
crease with acute or chronic liver disease). 
3. Genetic factors (gender, ethnic polymorphism, individual 
differences). 
4. Drug-drug interactions (enzyme induction > more metabolism 
> larger k of elimination; enzyme inhibition > less metabolism > 
smaller k of elimination). 
5. Chemistry of drug. 
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Purpose of phase I and phase II 
drug metabolism 
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Functions of the kidney 
1. Maintenance of homeostasis (regulation of water, electrolyte, 
acid-base balance). 
2. Excretion of metabolic waste products (urea, creatinine, crea-
tine, uric acid, sulfate and phosphate), water soluble toxic sub-
stances and drugs. 
3. Retention of substances vital to body (reabsorption of several 
substances, e.g. glucose, amino acids). 
4. Endocrine/unctions (synthesis of hormones): 
• Erythropoietin - peptide hormone, stimulating hemoglobin 
synthesis and formation of erythrocytes. 
• 1,25-Dihydroxycholecalciferol ( calcitriol) - the biochemical-
ly active form of vitamin D, regulating calcium absorption 
from the gut. 
• Renin - proteolytic enzyme, stimulating the formation of an-
giotensin II which leads to aldosterone production for the 
regulation of electrolyte balance. 507 
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Kidneys metabolism 
1. Concentrating urine and transporting it through membranes 
are processes that require large amounts of energy. The kid-
neys therefore have very high energy demands. Although the 
kidneys only represents about 0.5% of the body's mass, it 
consumes around I 0% of the oxygen. ATP needed is ob-
tained from oxidative metabolism of glucose, fatty acids, ke-
tone bodies, and several amino acids, lactate, glycerol, and 
citric acid. 
2. Transport of substances through the apical membrane of kid-
ney epithelial cells at urine formation depends on the cellular 
Na" gradient, which is maintained by the Na · K -ATPase in 
secondary active transport. 
3. Kidneys are capable of glucose synthesis from amino acids 
and lactate (gluconeogenesis) but a major precursor, in aci-
dotic conditions, is glutamine. 
4. The kidney takes up glutamine, and by the action of renal 
glutaminase, initially release NH3 and glutamate. NH3 
formed is released into the tubules to buffer protons that are 
secreted into the glomerular filtrate by the kidney, to reduce 
the hydrogen ion concentration in the blood. This helps to 
maintain the normal pH of the blood. 
5. In the kidneys from the glutamate formed, a second molecule 
of NH3 can be obtained by oxidative deamination with the 
help of glutamate dehydrogenase. The resulting a-
ketoglutarate is further metabolized in the citric acid cycle. 
Several other amino acids - alanine in particular, as well as 
serine, ?lycine, and aspartate - can also serve as suppliers of I 
ammonia. 
508 I 
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The formation of urine 
Urine is formed as a result of a three phase process - glomerular fil-
tration, selective (active) and passive reabsorption, secretion. 
Glomerular filtration. This is a passive process that results in the 
formation of ultrafiltrate of blood. Filtration takes place through the 
semipermeable walls of the glomerular capillaries. About 20% of renal 
plasma flow is filtered each minute (-125 ml/min). All the (unbound) 
constituents of plasma, with a molecular weight less than about 70.000, 
are passed into the filtrate. Therefore, the glomerular filtrate (primary 
urine) (- 150L) is almost similar in composition to plasma. The driving 
hydrostatic pressure is provided by arterial pressure. 
Selective (active) and passive reabsorption. In the proximal and 
distal tubule, the glomerular filtrate becomes highly concentrated as the 
result of the removal of water. The renal tubules retain water and most of 
the soluble constituents of the glomerular filtrate by reabsorption. This 
may occur either by passive or active process. 
Proximal tubule. Many low molecular weight constituents are 
rebsorbed by active transport - proteins, peptide, amino acid, uric acid, 
glucose, Na-, K', Ca~·, Mg2+, phosphate and sulphate; by passive 
transport - water, HC03-, er, urea. Reabsorbs 60% of all solute (100% of 
glucose and amino acids, 90% of bicarbonate, 80-90% of inorganic phos-
phate and water. Parathormone stimulates the absorption of calcium and 
inhibits the resorption of phosphate. 
loop of Henle. Next reabsorption of NaCl. In descending loop of 
Henle: resorption of water by osmosis and increasing of osmolarity; in 
ascending loop of Henle: active transport of NaCl out of the tubule and 
decreasing of osmolarity. 
Distal tubule and collecting ducts. Reabsorption of Na-, Ca2·, 
Mg~+ by active transport and by passive transport - water, chlorides and 
urea. Aldosterone promotes Na+ ions and water reabsorption and 
excretion of H+ ions. Antidiuretic increases the water permeability thus 
increasing the concentration of urine. The tubule cells absorb C02 from 
the blood and then hydrate it to carbonic acid (enzyme carbonate 
dehydratase). Carbonic acid then dissociates to HC03- and H+. H- is 
exported to the urine by an ATP-driven transport system, while HCOi-
returns to the blood. 
I Secretion. Some of the substances are released into urine by active 
transport - W and i.,: • ions, urea, creatinine and drugs (antibiotics); by 
passive transport - ammonia. 
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Substances according to their entering into urine may 
be divided into the following groups: 
I. Substances filtered by the glomerulus (inulin, creatinine, 
urea). 
2. Substances, concentration of which in urine is determined by 
ratio between the processes of secretion and reabsorption in 
the tubules (electrolytes). 
1 3. Substances mainly secreted from plasma into lumen of [ 
proximal tubules (organic acids and basis) . j' 
4. Substances, which are practically absent in plasma and enter 
into urine from the renal tubules (NH3, some enzymt!s). : 
5. Substances reabsorbed in the proximal tubule and do not ap- I 
pear in urine until the plasma level reaches a certain concen- I 
tration known as the renal threshold (glucose, amino acids, 
ketone bodies, Na+, Ca2+, Cr, HC03-, HPO/, SO/). 
Substances whose excretion in urine is dependent on their 
concentration are referred to as renal threshold substances. At I 
the normal concentration in the blood, they are completely reab- 1 
sorbed by the kidneys, with a result that their excretion in urine 
is almost negligible. While calculating the renal threshold of a 
particular compound, it is assumed that both the kidneys are op-
timally functioning, without any abnormality. But this is not al-
ways true-in which case the renal threshold is altered. For in-
stance, renal glycosuria is associated with reduced threshold for 
glucose due to its diminished tubular reabsorption . The renal 
threshold for glucose is I 0 mmol/J or 180 mg/di. 
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Functions of the kidney in the acid-base balance 
Renal regulation of the acid-base balance which occurs by the 
following mechanisms: 
I) Reabsorption of bicarbonate HC03-; 
2) Regeneration of HC03-; 
3) H• secretion. 
1. Reabsorption of bicarbonate HC03-. This mechanism 
is primarily responsible to conserve the blood HC03-, with a si-
multaneous excretion of H ~ ions. The normal urine is almost free 
from HC03-. Bicarbonate freely diffuses from the plasma into 
the tubular lumen. Here HC03- combines with H+, secreted by 
tubular cells, to form H2C03. H2C03 is then cleaved by carbonic 
anhydrase (of tubular cell membrane) to form C02 and H20. As 
the C02 concentration builds up in the lumen, it diffuses into the 
proximal tubular cells along the concentration gradient. In the 
tubular cell, C02 again combines with H20 to form H2C03 
which then dissociates into H+ and HC03-. The HT is secreted in-
to the tubular lumen in exchange for Na+. The HC03- is reab-
sorbed into plasma in association with Na ... _ 
Carbonic anhydrase 
:u+ + HC03- -== H2COJ = CQz + H20 
Carbonic anhydrase 
C~ + H20= H2C03 = :u+ + HCOf 
2. Regeneration of HC03-. 
C02 diffuses from the urine into the cells of the distal tu-
bules and forms H2C03. H2C03 dissociates into H+ and HC03-. 
The H+ is secreted into the urine and HC03- is reabsorbed into 
plasma. 
3. Ir secretion. 
H ... ions are secreted into the urine in the free form, in the form 
of H2P04- and NH4T. 
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Disturbances of urine formation 
• Urine formation depends on glomerular filtration rate 
(GFR). Decrease in GFR leads to oliguria, uremia, metabolic 
acidosis, hyperkalemia and delay of the urea and other final 
products of the metabolism of the nitrogen substances in or-
ganism, decrease in bicarbonate level in plasma. Low GFR is 
due to damaged kidneys, and due to decreased hydrostatic 
pressure between capillaries of renal corpuscle and contents 
of tubules. This is usually related to renal blood flow insuffi-
ciency or can be caused by obstruction for urine outflow. I 
• Polyuria, low level of bicarbonate in plasma and metabolic i 
acidosis, hypokalemia, hypophosphatem ia, hypouricaemia I 
are due to damaged tubules. 
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Renal failure (or renal insufficiency) 
Renal failure is caused by impaired processes of renal 
blood flow, glomerular filtration, renal tubular reabsorption and 
secretion. 
Causes of renal failure: 
I. Decreased volume of extracellular space due to cardiovascu-
lar insufficiency, shock, and decrease in arterial pressure. 
This leads to decrease in renal blood flow and as result to de-
crease in renal filtration. 
2. Decreased volume of functional renal parenchyma at nephri-
tis, neoplasms, intoxications, traumatic loss of kidneys. 
3. Obstruction in the urinary tract below the kidneys. This can 
occur from urinary tract stones, tumors, and anatomic ob-
struction due to benign prostatic hypertrophy that lead to the 
increase in renal pressure and decrease in glomerular filtra-
tion. 
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Signs of renal failure 
I. Azotemia - waste accumulates in the blood and the body, 
when kidneys fail to filter properly. 
2. Proteinuria, hypo- and proteinemia as a result of increased 
catabolism of proteins, secondary hyperlipidemia of IV type; 
decrease in urine concentration; metabolic acidosis. 
3. Anemia a decreased red blood cell count, because lower le-
vels of erythropoietin produced by failing kidneys. It's also 
important that degree hemolysis is increased, which shortens 
erythrocytes life duration. 
4. Qualitative changes of thrombocytes (thrombocylopathy). It 
appears as bleeding duration increase. 
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Kidney stones 
Kidney stones are produced whenever the body exceeds its 
normal levels of minerals such as oxalate, uric acid and calcium. 
When these minerals exceed normal quantities, they crystallize 
among the tissues of the kidney along with the other elements 
that comprise urine. Sometimes, these kinds of kidney stones are 
small enough to be excreted along with normal urine, but often, 
they are too big and remain inside the kidney indefinitely. 
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Causes of kidney stones 
I. Supersaturation. The urine carries salts, including calcium oxalate, uric 
acid, cystine, or xanthine. These salts can become extremely concen-
trated if there is not enough urine, or if unusually high amounts of 
crystal-forming salts are present. When salt concentration levels reach 
the point at which they no longer dissolve, these salts form crystals. 
2. Changes in the acidity of the urine. 
3. Congestion of urine due to impairment of urination. 
4. Low levels of stone-blocking compounds. Normally. urine contains j 
substances that may protect against stone formation, incluJir,g mlgne- I 
sium, citrate, pyrophosphate, enzymes. J 
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Kinds of kidney stones I 
I. Calcium stones, which comprise 70-90% of all kinds of kidney 1 
stones, are made of calcium, usually combined with oxalate, or oxalic 
acid. About 6% of calcium stones are made of calcium phosphate. 
Calcium phosphate increases in alkaline urine. Hypercalciuria is re-
sponsible for as much as 70% of calcium-containing stones. The fol-
lowing can lead to hypercalciuria and calcium stones: I) too much cal-
cium absorption in the intestines; 2) excessive chloride; 3) renal cal-
cium leak; 4) excessive sodium. Hyperoxaluria is responsible for up to 
60% of calcium stones and is usually caused by too much dietary oxa-
lates (found in a number of common vegetables, fruits, and grains) or 
by hypervitaminosis C. 
2. Uric acid stones. Excess uric acid is responsible for close to 10% of 
kidney_ stones. It is the breakdown product of purines, found in certain 
foods (dried beans, peas, and liver). Uric acid mainly forms in acidic 
urine. 
3. Cystine stones are caused by a rare congenital defect that can cause 
stones composed of the amino acid cystine to form in the kidney called 
cystinuria. 
4. Xanthine stones are composed of xanthine. These stones are extreme-
ly uncommon and usually occur as a result of a rare genetic disorder. 
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Components of urine and change of its composition 
• Rate of urine formation, volume and composition of urine are 
subject to wide variation and depend on diuresis, food intake, 
digestion, body weight, age, sex, and living conditions such 
as temperature, humidity, physical activity, health status, and 
many other factors. It is rather thereby to analyze a daily por-
tion of urine. 
• As there is a marked circadian rhythm in urine excretion, the 
amount of urine and its composition are usually given rela-
tive to a 24-hour period. The urine volume varies from 600 to 
2500 ml for 24 hand depends mainly on amount of the liquid 
absorbed. 
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Color of urine 
Urine is a transparent solution that can range from color-
less to amber but is usually a pale yellow. In the urine of a 
healthy individual, the color comes primarily from the presence 
of urobilinogen which is related to the bile pigments produced 
by hemoglobin degradation. If urine is left to stand Jong enough, 
oxidation of the urobilinogen may lead to a darkening in color. 
Unusual dark color is the excess presence of bilirubin, urobilin, 
porphyrins and homogentisate. Many things affect urine color, 
including fluid balance, diet, medicines, and diseases. 
5 19 
305 
Precipitates of urine 
Precipitates of urine are formed due to urine standing and 
are the following: 
l) Flaky precipitates formed from nucleoproteins or muco-
proteins and epithelial cells of genitourinary tract. 
2) Precipitates formed from the mixture of calcium phosphate 
and ammonium phosphate, if urine is alkaline. I 
3) Precipitates formed from oxalates and urates, dissolving , 
during acidification. :_J 
4) Precipitates formed from uric acid, if urine is acid. 
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Specific gravity and PH of urine 
Specific gravity checks the concentration of solutes in the 
urine and ranges between 1.008 and 1.012. The specific gravity 
varies depending on the time of day, amount of food and liquids 
consumed, and the amount of recent exercise. 
The pH of urine is close to neutral (7) but can normally 
vary between 4.6 and 8. Acidity of urine is due to presence of 
phosphoric acid as the product of breakdown of tissue, foods 
rich in phosphoproteins, phospholipids and nucleoproteins. A 
diet high in citrus, vegetables or dairy can increase urine pH 
(more basic). A diet high in meat can decrease urine pH (more 
acidic). Acidity of urine increased in acidosis, fevers, and diet 
with excess proteins; alkaline - increased in chronic cystitis and 
urine retention due to decomposition of urine in bladder. 
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Protein in urine 
Protein is normally not found in the urine. Quantities of 
protein (0,03g/24 h) may be present in urine which cannot be de-
tectable by chemical methods. When chemically detectable 
quantities of proteins are present in urine, the condition is called 
as proteinuria. Proteins are filtered through glomeruli in kidney 
diseases due to altered glomerular permeability. Fever, hard ex-
ercise, pregnancy may also cause protein to be in the urine. 
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Reasons of proteinuria: 
1. Proteinuria due to hyperproteinemia: 
a) normal proteins 
- hemoglobin (hemolysis). 
- myoglobin (rhabdomyolysis). 
b) abnormal proteins 
- fragments of immunoglobulin (Bence Jones protein). 
2. Proteinuria due to glomeru/ar impairment: 
a) renal haemodynamics failure 
- orthostatic proteinuria, physical activities. 
b) increased permeability of glomerules 
3. Tubular proteinuria - the presence of proteins normally fil-
tered, which are not reabsorbed in tubules: 
a) tubular impairment 
- heavy metal and medicine intoxication. 
b) interstitial diseases 
- nephritis, pyelonephritis. 
4. Secreted proteinuria: 
a) Tamm-Horsfall proteinuria 
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The classification of proteinuria 
e.g. Benoe-Jones e.g. albuminurla e.g. II, or a, 
protalnurla mlcrcglohUl:mma 
e.g. 11 
Tamm-Hors!ali 
proteinuria 524 _J 
Nonprotein nitrogen-containing compounds excretion 
1. Urea is the product of protein metabolism and constitutes about 80'%-
90% total nitrogen excretion. About 15-30 g of urea (7-15 g nitrogen) or 
333-583 mmol/24h is excreted in urine per day. This is associated with in-
creased protein breakdown, leading to a negative nitrogen balance, as ob-
served during starvation, burns, traumas, after major surgery, prolonged 
fever, diabetic coma, thyrotoxicosis etc. Urea excretion is decreased in pre 
renal (diabetes mellitus, dehydration, cardiac failure, bums, high fever 
etc.), renal (kidney diseases) and post renal (prostate enlargement etc.) 
conditions. 
2. Uric acid is the end product of purine metabolism. The daily excretion 
of uric acid is about 500-700 mg. Elevation in the serum uric acid concen-
tration is associated with increased uric acid excretion (uricosuria). 
Hyperuricaemia may be caused by an increased rate of purine synthesis, 
an increased rate of turnover of nucleic acids, as in malignancies, tissue 
damage or starvation, a reduced renal excretion. High uric acid is excreted 
in gout and leukaemia. Lesch-Nyhan syndrome and some cases of glyco- I 
gen storage disease are associated with uricosuria. Salicylates in doses oj 
less than 2-3 g/d may produce renal retention of uric acid. 
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~-------------------------- - --. 
Non protein nitrogen-containing compounds excr:etic•n 
3. Creatinine is the anhydride of creatine as a product from metabolism ir 
the muscle tissue~. Normal urinary excrP-tion C'f crt>atinir.~ ;, l 5 to :: .0 !! 
per 24 hours. Exc,·etion rate decreases in all k.ill(i~ of renal a1seases .ll'C 
post renal condition~ . Cr~atinine bP'ffS a ~ :rt::• r("19 i ' •('> t"' a ,mscle mass 
of the individua; e,<pn:~ sed as creatinine codoc1c1. (ar11ou 11c ...,f t n::a;in i ·" 
in mg excreted in 24 hours per kg of bodv "'"';!!i ' ~' ,., !;t adult 1;;ale 1 
coefficient is 18-32; female is 14-22. Dec.rt.ust: vC11t."' 11.uicates 1u 5cl · 1 
wasting due to prolonged negative nitrogen balance; seen in starvatior, <l -
abetes, muscle dystrophy. 
4. Creatine is mostly found in the muscle as creatine phosphate, a h:gl · 
energy compound. Normally, small amounts of creatine are excreted ir1 th< 
urine. Increased output of creatine in urine is referred to as creatin.Jri ri 
Elevated in states of elevated catabolism, in muscular dystrophies such as 
progressive muscular dystrophy, myotonia atrophica, and myasthenia gr;:-
vis; muscle wasting, as in acute poliomyelitis, amyotrophic lateral sclero- j 
sis, and myositis manifested by muscle wasting; starvation and cacher. tic , 
states; hyperthyroidism; and febrile diseases, diabetes mellitus. Decrei srn J 
in hypothyroidism, amyotonia congenita, and renal insufficiency. 
5. Amino acids are normally excreted in 0.29-5.35 mmol per 24 hours (ni- 1 
trogen of amino acids). Glycine, histidine and alanine are the most abur -
dant amino acids excreted into urine. They may be pr<.!sent in Jria<.! L1 ' ·. 
cessive amount due to defect in protein targeting, defective rePal re 1:w>1 P · 
tion, increased catabolism of proteins, because the p1ru.m<> .;,mc.c.1u.t i...,i, 
exceeds the renal threshold, or because there is specific failure of nonna; 
tubular reabsorptive mechanisms, such as :r. , 1e ; .. ht 1: teJ • lif , "; !: : · >-
order, cystinuria or more commonly beca1 : ~- ~ 0f ' cnu:•"' -J r-:r 1J ~ l-11 ' · 
damage. i 
6. Ammonium salts are normally excreted in 3Ci-t.i" mn.ol 124 h li..11m0nia ; 
of ammonium salts). Increased in acidosis, dt.ci.. :. -'-' · . :'l ! · -~ · . 
to damage of distal tubules, where ammonium s=-lt0 ~- ""1:"' ·: ; - '· • • · c. 
7. Hippuric acid is excreted into urine in amounts thrit are pro 1or i, ,., ,. ro ! 
the amounts of the taken food. Usually excretion is abuut :>,.) mnu1 1'..i.'1· l ~ I 
8. Indican presents in urine in trace amounts ,_1d derived 1i om iPdo 1~ · 
which in tum arises from the action of putrefyiPg 1-~<;t ·=- - · t ' - · ' 
!~creased in lavish meat products or due to putrefactive processes in .n .cs · I 
tme. 
9. Nitrogen pigments, in particular urobilinogen, and also ghwurnnidfis uf ! 
bile acids, bilirubin are excreted into urine in small amounts. 
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Nonnitrogen-containing com pounds excretion 
1. Glucose is normally not present in urine. Small amount of glucose (2-20 
mg or 0.3-1.1 mmol) may be present in fasting urine which can not be de-
tectable by chemical methods. When glucose is present, the condition is 
called glucosuria. It results from either: diabetes mellitus or diabetes insi-
pidus; a reduction in the "renal threshold (renal glycosuria); hormonal dis-
orders, liver disease, medications, pregnancy, hyperthyroidism and peptic 
ulcer (alimentary glycosuria). 
2. Lactate and pyruvate nonnal urinary excretion are 1.1 to 0.11 mmol/24 
h. Large amounts may be present during intensiYe muscular exercises or 
hypoxia, and at pathologic conditions such as diabetes mellitus, starvation; 
3. Ketone bodies are not normally found in the urine. Small amount of ke-
tone bodies (20-50 mg/24 h) may be present in urine which can not be de-
tectable by chemical methods. Large amounts of keto ;1cs in the urine (ke-
tonuria) may mean a diabetes mellitus is present. A diet low in carbohy-
drates, starvation or high-protein diets also cause kctones to be in the urine. 
4. Mineral salts: 
• Urine sodium (Na) excretion per 24 hours is 174-222 and urine potas-
sium (K) excretion per 24 hours is 69-71. Potassium and chloride excretion 
of potassium in urine is found in fever, acidosis. In Addison's disease, po-
tassium is retained and sodium chloride is excreted. In Cushing's syn-
drome, sodium chloride is retained and potassium is excreted. Sodium 
chloride is excessively lost in salt losing nephritis; 
• Urine calcium (Ca) excretion per 24 hours is 4.02-4.99. Excretion of 
calcium in urine is low in rickets. It is high in hyperparathyroidism and 
hyper thyroidism. In multiple myeloma, it is high. It is frequent in renal 
stones, 
• Urine inorganic phosphorous (P) average value excreted in 24 hours 
urine is 33 mmol. Excretion is increased in hyperparathyroidism. Excretion 
is decreased in hypoparathyroidism and rickets. 
310 
repa ir / 
enzymes 
Normal 
DNA 
( 
Biochemistry of 
carcinogenesis 
Normal Normal tissue 
daughter cells ~ grow1h 
) damage 
/ 
528 
Damaged Celi ~"Cle Abnormal impaired Abnormal tisSue 
DNA A..,, daughter cells - growth 
! ~--- - --~otOSIS , Cell ~eath -·- ·· - -- --.:: p53 
Role of p53 as a tumour suppressor gene. p53 induces a cell with 
damaged DNA either to initiate apoptosis, or arrest the cell cycle, to 
give time for damaged DNA to be repaired. Damage can be, for ex-
ample, a mutation, DNA strand breakage or chromosomal rear-
rangement. 
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r Proto-oncogene •• : Mutations t ......... ·:.> .' (somatic o<lnhe<;led) 
( I ~ ( Tumour suppressor ·1 Oncogene ·• gene , 
. ... ~? --
Pro life ration 
A diagram representing a simplified account of bow oncogenes and 
tumour suppressor genes affect progrssioo through the cell cycle and 
the possible effects of mutations. Ao oncogene increases progression 
through the cell cycle (+) and a tumoursuppressor gene decreases or 
arrests progression (-). The dotted line from mutations to the conver-
sion of a proto-oocogene to an oncogene indicates activation of the 
process, whereas that to the tumour suppressor gene indicates inacti-
vation of the gene. 
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Summary of events in the carcinogenic process 
Pro ca1cinogens Direet ~g carcinogens 
:: I 
Ulllmale carcioogJ{. 
(r~ alectfoptliles) 
Scavenging I 
Adducts wltn non· I 
oritteal nucioophiles 'ii 
CQvalent +binding to 
ONA (ONA adducts) 
_._._ :- ! 
Cell raplicstion & flxettan 
of genoli<: JeSiQ<ns 
Genetie altlf'alioi ol oricogenes 
1umOur·supprBMOr gel189 
(a~on. tnmlllocallon. polnl 
mulSltoo, rearrangement. oeii.llon) 
i 
INITIATED CELLS 
~de*h • i (Immunological ddenoe} 
i 
i 
MAUGNANT NEOPLASM 
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PROMOTION 
CONVERSION 
l"ROGRESSION 
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lllS 
. 
© 
' 
' raf (~PKKK) 
' A 
MAPKK MAPKK~ 
. 
' A 
fv\6.PK MA~~ 
' A 
Transcrjptlon TF-® 
factor • © 
' Gene 1-
mR NA Nuci&otlcr~ 
n 
Protein Amino J acids 
Protlferanon 
The mitogen-activated protein kinase cascade (MAP kinase cascade). 
The active protein Ras activates Raf by promoting its recruitment to 
a cell membrane. Through a series of phospborylations MAP kinase 
is activated as follows: MAP kinase kinase kinase (Rat) pbospbory-
lates MAP kinase kinase which, in turn, phospborylates MAP kinase, 
the final target enzyme. MAP kinase phospborylates transcription 
factors for genes that express proteins involved in proliferation. 
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IU"P GEF ADP 
~ 
Ras GDP Ras GTP 
Inactive Active 
GAP Pr 
GEF ADP 
·-•.. GTPue •• / 
~ · 
............... --
... 
a b 
a - contrul of the acti\.ity of Ras by a balance of the activities of gua-
nine nucleotide exchange factor and GTPase. GAP is the abbrevia-
tion for GTPase-activating factor and GEF for guanine nucleotide 
exchange fac tor Ras oncogenes are present in about 30% of all hu-
man tumours. 
b - mamtenance of Ras in the activated from by loss of GTPase activi-
ty. A point mutation in the Ras protooncogene leads to a very low ac-
tivity of the GTPase so that Ras protein remains in the active form. 
The broken line indicates low activity ofGTPase. 
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Pathways in the process of apoptosis 
Stimulus 
Growth factor depri\lation 
Steroids 
L Apof - ''"'"""' "'°'""' oo;.,ting "'''°' 
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-7~'.:-· 
Apa! Caspase 9 
\. ' .. Apoplosome 
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Selected tumor markers and associated cancers 
Tumor marker Associated cancer(s) 
Oncofetal antigens 
a-Fetoprotein (AFP) Cancer of liver and germ 
cells of testis 
- ·-
Carcinoembryonic antigen Cancers of colon, stomach, 
(CEA) lung, pancreas and breast 
·-
Cancer antigen-125 Ovarian cancer 
(CA-125) 
Hormones 
Human chorionic Choriocarcinoma 
gonadotropin (hCG) 
Calcitonin Carcinoma of medullary 
thyroid 
Catecholamines and their Pheochromocytoma and 
metabolites (mainly vanillyl neuroblastoma 
mandelic acid) 
Enzymes 
Prostatic acid phosphatase Prostate cancer 
Neuron specific enolase Neuroblastoma 
Specific protein 
Prostate specific antigen Prostate cancer 
(PSA) 
Immunoglobulins Multiple myeloma 
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Etiology of common tumors 
;;te I i--- - ---~ancer Major hypothesized cause I Smoking, asbestos, chemical substances, uv 
, radiation, radon gas and occupation ~;~int 
j and rectum 
Skin 
~stine j Familial predisposition, high fat and low fi-
, ber intake, intestinal flora, smoking 
I Endogenous hormones, solar radiation, light 
) --titin, coal pitch, creosote, arsenic, radium 
. igh fat intake, alcohol, vinyl chloride, ni-
~-~melanom~ 
l Liver 
Pancreas 
Lymphatic 
system 
rBlood--
--- -
rus 
1 K1dne) ~j;dder ~yofute 
j trosoamines, chlorinated hydrocarbons 
I Age, smoking, high fat intake, smoking and 
1 occupation 
· Slackening of immunity, herbicides, sol-
vents, vinyl chloride, viruses, benzene, and 
irradiation 
I Genetic disturbances, 10mze radiation, 
chemical substances, viruses 
Smoking, alcohol abuse, nutrition 
Smoking, heavy metals, dyes, drugs 
, Smoking, heavy metals, dyes, drugs 
Reproductive history, early sexual life, , 
smoking, no pregnancy 
I Age, familial predisposition, genetic distur-
*ces, no pregnancy 
ast ge, familial predisposition, no pregnancy, 
i early menarche, late menopause, late first 
I Ovary 
I 
Female bre 
I birth, high fat intake, viruses 
- - I Age, familial predisposition, high fat intake, 
occupation, and smoking 
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Agents causing cancer (carcinogens) 
I. Compounds and the products made and used by the indus-
try. Natural carcinogens. 
I. Asbestos and similar fi-
bers 
2. Aflatoxins (B, G, G2) 
3. Benzidine 
Benzene 
8. Polycyclic hydrocarbons 
in soot, tar, oil and resul-
tant fumes and products of 
I combustion 
4. 
5. 
I 9. Arsenic and its com-
pounds Beryllium and its com- i 
pounds IO.Nickel and its compounds 
I I.Chromium (VI) 6. Vinyl chloride 
7. Cadmium and its com-
pounds 
II. Therapeutic drugs 
1. Phenacetin 
2. Azathioprine 
3. Melphalan 
4. Methoxsalen 
5. Mileran 
6. Thiophosphamide 
7. Treosulfan 
8. Chlorambucil 
9. Ciclosporin 
I 0. Cyclophosphamide 
11. Steroid estrogens (es-
tradiol -I 7 and its ethers, 
estriol, estrone, ethinyl es-
tradiol, mestranol, estro-
gens conjugated) 
12. Nonsteroid estrog~ns 
(diethylstilbestrol. diene-
strol, hcxestrol) 
13. Oral contracepti" es 
ill. Household and natural factors 
I. Alcohol 
2. Radon gas 
3. Ultraviolet radiation from the sun 
4. Tobacco 
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Selected oncoproteins, protooncogenes 
and associated cancers 
~ Oncoproteins Protoonco- i Associated human f!enes 1 cancers -------i Growth factors sis Osteosarcoma 
Platelet derived ~ 
growth factor 
(PDGF) F 
Epidermal growth hst-1 - 1 Cancers of sto-
factor (EGF) , mach, breast~d · 
: bladder 
Growth factor re- erb-Bl I Lung cancer 
ceptors erb-B2 Stomach cancer , 
erb-B3 
Signal- ras 
: transducing pro-
teins 
OTP-binding pro-
teins 
Non-receptor tyro- abl 
sine kinase 
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I 
Breast cancer 
--- - -
Leukemia, cancers 
of lung, pancreas 
and colon 
Leukemia 
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Biochemistry of tooth tissues 
and saliva 
Tooth is a complex system of specialized tissues I 
Crown 
Root 
Sone 
540J 
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Biochemistry of teeth 
Pi.que 
'- Bacterium 
I 
Anaerobic .;...,. Acids I 
met.lbolism , i..ctlcadd ]' 
La..~ .c.~-...;i~ Proc>k>nlc acid i 
Bacterium Acellc acid 
~"~OCCl/S ::: ackj .,' r. ·:-,:,_ 
.. it. . lutlon \ . 
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Biochemical composition of teeth tissues 
- - - I ~Compounds I Pulp, Dentin, Enamel, Cement, I % % % % 
Water 30-40 13 2,5 IO 
Organic compounds ! 40 17 4 20 
Inorganic compounds 20-30 70 96 70 
Ca 30 i 35 36 35.5 
~ Mg 0.8 1.2 0.5 0.9 Na 0.2 ! 1,2 0.2 I. I K 0.1 0.1 0.3 0.1 p i 17.0 17.4 17.3 17.l F 0.02 ' 0.02 0.02 0.02 [ ____ Citrate I - 1.0 0.3 -
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Macromolecules associated with calcification 
Cartila e Bone Dentine Enamel 
+ + + -
GLA Proteins + + 1 
(y-carboxyglutamate) I 
1 
-
( osteocalcin, 
osteopontin, 1 I J 
osteonectin, osteo enin -~-±-' ---+---
Glycoproteins + ~ + · "- I 
Phos hoproteins + + · + 1 -~ 
Proteo lycans + + _.:::._~ND _I 
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Components of calcified oral tissues 
Inorganic Protein , - Other 
1------+-'c~o~m~'P~·o~n~e~n~t~s+-__ c_o__._mo_,o_n_en_t_s __ --+~-co_mponen'!___ 
Tissue 
Cement 45 % , 33 % (protein Water 22 % 
mainly collagen 
type I and III) 
Dentin 70% 20 % (collagen I, b- 10 % (glyco-
FGF, osteocalcin, proteins, pro-
osteonectin, osteo- teoglycans), 
-95% 
genin, osteopontin I' phospholipids, 
phosphoproteins, water 
dentin specific :=J 
proteins) ' 
5% (ameloblastin, I < l % --
amelogenin, ename-
lins, tuftelins) i 
Enamel 
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'llme 
Loss of proteins and increase in mineral content with time during 
enamel formation 
Maj~r salivary compo!lents 
H~~tinsT""~----t-~~-;~~~+-~~--t 
Sta~erins't"".....,~=t-,--~~1--~~--+-~~---1 
Lysozyme 
Prollne-rich proteins Garbonicanhydrasell~~ Amylases Per xidases . 
Lactoferrin 
Mucln 2 (MG2) 
slgA 
Mucin 1 (MG1 
1 10 100 1000 10000 
Size (kDa) 
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The most important functions of saliva related to the each 
salivary component 
Functions ::I_ Co"'P!!"ents in'""""- ~ 
Protection of teeth and oral, pbaryn_g_eal and oes_~~ageal mucosa 
Mechanical cleansing of teeth ! Water 
and mucosa i , 
Lubrication of teeth and mu- Water, mucins 
cos a : 
Keep oral mucosa intact, soft j Water, mucins, salts, cpidc1mal growth i 
and moistened j factor, fibroblast growth factor, ncn e · 
growth factor 
Prevent tooth demineralization Proline-rich proteins. ~;tatherir.s cysta-
tins, histatins, calcium and phosphate 
! Buffer capacity Bicarb~!_l~le ,_ pl!_<?~hate and prokin _ __ . 
Antimicrobial activities _________ ___ ______ ___ _j 
Antibacterial functions : Amylases, cystatins. histatins, mucins, I 
peroxidase, lysozyme, iactoferrin, cal-
protectin, immunoglobulins, chromo- , 
" Fungicidal functions 
granin A. I 
Histatins, immunoglobulins, chromo- , 
granin A 
Antiviral functions _____ I Cystatins, mucins, immunoglobu~i_!_!~ 
Die:estive properties 
Formation of food bolus 
Facilitation of mastication and 
swallowing 
Initial digestion 
Water, mucins 
Water, mucins 
Dissolution 
oounds 
of taste 
a-amylases, lipases, ribonucleases, 
1 
proteases, water, mucins I 
com- Gustin (carbonanhydrase), zinc, water i 
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The most important inorganic and organic 
components of saliva 
___E'!!!!/!onents_ I _ ___ ~_c_o~_o_n_e_n_ts___,_ _ ___ _ _ __. Inorganic Content Organic Content I 
Water _ 1 ___ 98 ".i _ __ -+ _ Proteins 0.95-2.32 g/L 
1
- -- pH *~5-7-l__ + Glucose 0.05 mM/L ' 
HC03 5-10 mM/L Lac~---t---J.:03-0.05 g/L j 
.----p - . 1.9-7.7 mM/L I Pyru~,A}-45.4 µMIL 
L Na _ ~1-5 mM/L. Cholesterol 
1
. 0.065-0.233 mM/L I 
I Cl __J_ __ 5 mM/L . Urea . 1.83 mM/L ~ K--- - 15 mM/L:=t Uric acid 0.088 m~~ 
L _ Ca 1.5-5 mM/L _NH3 I 1.2-1.6 µ~ 
Chemical composition of dental plaque 
and dental calculus 
Organic 60 % 13-25 % 
548 
F , Dental plaquet Dental calculus 
components Glycosaminoglycans, 
1 
Amino acids, monosaccharides 
I 
<_ W_a_te:::t ,--80 % 4-10 % 
glycoproteins, poly- (glucose, galactose, galactosa-
1 
Jsacchar.ides, hetero- mine, glucuronic acid), phos-' polysaccharides pholipids, cholesterol, di- and , triacylglycerols, fatty acids, en-,_____ _ ___ _ __ __ 1~' ~mes, bacterias, leukocytes lnorgan 40 % 72-82 % components I P, Na, K, Ca, F, Zn, Fe Ca, P, Mg, Na, Si, Zn, Pb, Cd 
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Stages in the development of caries 
I. The enamel becomes decalcified. 
2. A small white spot appear. 
3. Discoloration becomes pronounced. 
4 . The tooth surface softens and decay penetrates through the 
enamel into the dentine. 
5. Caries spreads laterally and in depth. 
6. Cavitation occurs. 
7. The lesion deepens, and pulp becomes affected, first react-
ing to stimuli (e.g. sweets, temp.), then damaged and dead. 
8. Bacteria travel down the root canal, out through the apex 
causing abscesses. 
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Factors determining the inci~cnc~ of~ 
I. Microorganisms: Acid producing bacteria, especially if I 
they produce extracellular polysaccharides, \viii increase 
risk. 
2. Host factors: 
a. Decreased saliva secretion increase incidence. 
b. Buffering power of saliva to raise pH decrease incidence. I 
c. The morphology of the teeth: well spaced teeth d~crease 
incidence, while fissures & pits increase it. 
d. The composition of the teeth: certain trace elements de-
crease incidence (e.g. F, Mb and B), while others (e.g. Cu / 
& Mn) increase it. 
3. Time: frequency of consumption of carbohydrates and 
length of time in the mouth are related to incidence. Good 
oral hygiene can counter act this. 
4. Substrates for acid production provided in diet. 
551 
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Factors in unrermed food lead to decreased 
incidence of caries 
1. Substances that decrease solubility of calcium phosphate. 
2. More phytate and/or calcium. 
3. Antibacterial substances. 
4. Substances that inhibit aggregation of bacteria: decrease 
plaque formation. 
5. Absence of free sugar (most important). 
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